Author index to Volume 7

Aakhus, S. (Abst) 774
Abbadi, A.A. (Abst) 713
Abbott, F. 997, (Abst) 556
Abbott, S. (Abst) 1160
Abboud, O.I. (Letter) 1162
Abdelhamid, S. 844
Abdelmaged, A. (Abst) 667
Abraham, C. (Abst) 748
Abramow, M. (Abst) 972, 974
Abramowicz, D. (Abst) 970
Abu-Romech, S.H. (Abst) 713
Abud, O. (Abst) 1056
Aby, M.A. (Abst) 772
Achard, F. (Abst) 736
Achard, J.M. (Abst) 731
Ackrill, P. 1030
Adams, J.E. (Abst) 759, 1144
Adamson, A.S. 855
Addassi, A. (Abst) 713
Adida, C. 288
Adorno, D. (Abst) 785
Adu, D. 397, 967, 1077, (Abst) 676, 745, 1142, 1145, 1149
Afanasiev, B.A. (Abst) 753
Agar, J.W.M. 472
ağlar, Ş. 704
ağlar, Ü. 704
Agorreta, J.A. (Abst) 1064
Agostini, M.M. (Abst) 699
Agroyannis, B. (Letter) 365, 1071
Aguado, S. (Abst) 776
Aguardo, M.J. (Abst) 1058
Agud, J.L. 246
Ahlstrand, C (Abst) 691
Ahmad, R. 125
Ahmed, E. (Abst) 460
Ahonen, J. (Abst) 786
Airaghi, C. 896, (Abst) 665
Ajzen, H. (Abst) 755
Akaydin, M. (Abst) 782
Akcahuseyin, E. 29
Akhan, G. (Abst) 764
Akiba, T. (Abst) 765
Akollu, E. 422
Akpolat, T. (Abst) 704
Al Khursany, I. 251
Al-Kutoubi, A. (Abst) 552
Al-Wali, W. 133
Alamartine, E. (Abst) 779
Alameddine, F.M. (Abst) 758
Alamillo, C. (Abst) 1056
Alati, G. (Abst) 724, 735
Albarracin, C. (Abst) 691, 710
Albert, C. (Abst) 708, 730, 765
Albertazzi, A. (Abst) 710, 714, 767
Alberti, D. (Abst) 712
Albouze, G. (Abst) 698
Alcalde, P. (Abst) 753
Aldridge, C. (Abst) 1142, 1159
Alexopoulos, E. (Abst) 668
Alfurayh, O. 327, 939
Algaba, E. (Abst) 1067
Algrim, C. (Abst) 743
Ali, A.A. 1230
Aljama, P. (Abst) 729, 1055
Allan, P.L. 613
Allaria, P. 412
Allen, A.C. (Abst) 548
Allendorf-Ostwald, N. (Abst) 715
Allison, M.E.M. (Letter) 883
Allouache, M. (Abst) 746
Alm de Francisco, J.A. (Abst) 761
Alm de Francisco, M. (Abst) 753
Almirall, J. (Abst) 779, 781
Almond, M.K. 829
Alonso, J. (Abst) 676
Alonso, N. (Abst) 766
Alpers, C.E. (Abst) 662
Alpsten, M. (Abst) 727
Alsina, J. (Abst) 1065
Altieri, P. S1/85
Altman, J.J. (Letter) 1258
Altmann, H. (Abst) 728
Altmann, P. 360
Alvarez Grande, J. (Abst) 776
Alvarez Lipe, R. (Abst) 1058
Alvarez, J. (Abst) 778
Alvarez, M.A. (Abst) 1055
Alvarez, R. (Abst) 1063
Alvarez, V. (Abst) 674
Amado, J.C. (Abst) 753
Amado, M. (Abst) 761
Amato, M. (Abst) 738
Ambrosecchia, R. 1007
Ambroso, G.C. (Abst) 722
Amemiya, K. (Abst) 675
Amend, W. (Abst) 786
Amiel, C. (Abst) 659
Amoedo, M.L. (Abst) 758
Amore, A. (Abst) 668, 670
Amoroso, A. 587
Amoroso, L. (Abst) 710, 714
Anaya, F. (Abst) 668, 774, 785
Andériz, B. (Abst) 1064
Andersen, C.B. 147
Anderson, J.J. (Abst) 684
Anderton, J.L. (Letter) 653, (Abst) 459
Ando, Y. (Abst) 730, 738
Andrassy, K. (Abst) 667
Andres, A. (Abst) 778
Andrés, E. (Abst) 1055, 1057
Andreu, J. (Abst) 779, 781, 785
Andreucci, V.E. (Abst) 701, 751
Andricopoulos, N. (Abst) 680
Ang, K.S. (Abst) 711
Angelini, D. (Abst) 669, 716
Angielski, S. (Abst) 681
Angos, J.A. (Abst) 1058
Ansell, J.D. (Abst) 677
Antao, A.J.O. (Abst) 1156
Antivalle, M. (Abst) 721
Antonelli, A. (Abst) 669, 716
Antoniadis, A. (Letter) 273
Antoniou, S. (Abst) 705
Antonopoulou, S. (Abst) 680
Aoyagi, K. (Abst) 708
Aparicio, A. (Abst) 766
Aparicio, M. 158, (Abst) 670, 706, 756
Aparicio, S. (Abst) 673
Apostolou, Th. (Abst) 761
Apperloo, A.J. (Abst) 165
Aracil, J. (Abst) 770
Arakawa, M. (Abst) 750, 751
Ardaillou, R. (Abst) 777, 779
Argent, N.B. 155
Argilés, A. 1106, (Letter) 453, 881, (Abst) 660, 747, 748
Arias, H.U. (Abst) 753
Arias, M. (Abst) 761
Arik, N. (Abst) 704
Arinsoy, T. (Abst) 704
Arisz, L. (Abst) 165, 168, 169, 171, 657, 743
Armelloni, S. (Abst) 672, 676
Arnadottir, M. (Abst) 775
Arnaud, J. (Abst) 724
Arnold, M. (Abst) 731
Arribas, I. (Abst) 711
Arrieta, J. (Abst) 1066
Arrigo, G. (Abst) 703
Arrobas, M. (Abst) 766
Artero, M. (Abst) 775
Asano, Y. (Abst) 730, 738
Ashcroft, T. 362, 1043
Ashraf Ali, M. 327
Asmus, G. (Abst) 752
Assounga, A. 924
Ataman, R. (Abst) 719
Aterini, S. (Abst) 738
Atkins, R.C. (Abst) 660, 747, 748
Atti, M. (Abst) 738
Attman, P.-O. (Abst) 727
Attroun, L. (Abst) 770
Aubia, J. (Abst) 756

Aubia, J. (Abst) 1060, 1061, 1065
Augeri, C. (Abst) 762
Aumont, J. (Abst) 736
Aurell, M. 400
Austin, M. 1199
Aventaggiato, L. (Abst) 675
Axelsen, R.A. (Abst) 687
Ayala, J.A. (Abst) 724
Ayaz, M. (Abst) 719
Aymard, B. (Abst) 687
Azadian, B.S. 848
Azikawa, T. (Abst) 727
Aziz, Q. 1047
Aznar, R. 924
Azofra, J.A. 161
Azuara, M. (Abst) 1058
Azuma, N. (Abst) 752
Azzadin, A. (Letter) 882, 980, (Abst) 770

Baamonde, E. (Abst) 763
Bacchini, G. (Letter) 274, 1164
Badalamenti, S. (Abst) 725
Baelde, J.J. (Abst) 661
Baeva, L.B. (Abst) 753, 762
Bagnato, C. 1007
Baguet, J.C. (Letter) 367
Bahner, U. (Abst) 679
Baillod, R.A. 133, 443
Baines, A.D. (Abst) 657
Bajardi, P. (Abst) 740
Bajo, M.A. (Abst) 742
Baker, F. (Abst) 550, 659, 1147
Baker, L.R.I. (Abst) 758
Bakir, N. (Letter) 173
Bakkaloğlu, A. (Abst) 682
Bala Subramanian, V. (Abst) 459, 549
Balakrishnan, V.S. (Abst) 1152
Balcke, P. (Abst) 780
Baldamenti, S. (Abst) 720
Baldamus, C.A. (Abst) 678
Balducci, F. 1092
Baleva, M. (Letter) 1256
Ballardie, F.W. (Abst) 658, 661, 684
Ballarin, J. (Abst) 1063
Ballerini, L. (Abst) 723
Balletta, M. (Abst) 688
Bancale, E. (Abst) 695
Banfi, G. (Abst) 694
Bangsgaard-Petersen, F. 902
Bar-Khayim, Y. (Abst) 705
Bar-Ziv, J. 956
Barany, P. (Abst) 765
Barbier, Y. (Letter) 559
Barceló, P. (Abst) 1059, 1063
Bard, J.B.L. 563
Barenbrock, M. (Abst) 775
Bargagna, R. (Abst) 729
Bariéty, J. (Abst) 736
Barker, J.N.W.N. (Abst) 551
Barna, I. (Abst) 680
Barone, M.T. (Abst) 721
Barosi, G. 438, (Letter) 1254
Barrán, J. (Abst) 1061
Barrau, J. (Abst) 1056
Barrett, N. (Abst) 684
Barri, Y. 327, 939
Barrientos, A. (Abst) 726
Barril, G. (Abst) 1056, 1058, 1060, 1061, 1064, 1066
Barrois, E. (Abst) 720
Barthelemy, C. 300
Bartnicki, P. (Abst) 669
Bartoli, E. (Abst) 685, 686, 766, 767
Bartoli, J.M. (Letter) 366
Bartoli, R. (Abst) 723
Bartolomé, J. (Abst) 739
Barton, I.K. (Letter) 1162
Basolo, B. (Abst) 696
Bassa, P. (Abst) 781
Basta-Jovanović, G. (Abst) 785
Bataille, R. (Letter) 881
Batista, J.E. (Abst) 1056
Batlle, D.C. (Abst) 1066
Battaglia, G. (Abst) 683
Baumelou, A. 57, (Abst) 737
Bax, C. (Abst) 1160
Baz, M. (Letter) 366, (Abst) 722
Bazzato, G. (Abst) 710
Beaman, M. 1030
Beaufils, H. (Abst) 702
Beauwens, R. (Abst) 972
Becaus, I. 931, (Abst) 703, 974
Beccari, M. (Abst) 669, 720
Becker, A. (Abst) 711
Becker, H. (Abst) 744
Beer, J.C. 63, 829, (Abst) 753, 781
Beer, M. (Letter) 1073
Beermann, E.M. 1213
Belardi, P. (Abst) 734
Belch, J.J.F. 235, (Abst) 461, 554, 773, 1158
Belgiojoso, G.B. (Abst) 721
Belitsky, P. 143
Bell, G.M. 125, (Abst) 698, 704, 1146, 1157
Bellinghieri, G. 1022
Bellini, M.E. (Abst) 740
Bellizzi, V. (Abst) 705
Bellon, B. (Abst) 671
Belovezhdov, N. (Abst) 683
Bembridge, J.L. 110
Ben Maïz, H. (Abst) 702
Ben Moussa, F. (Abst) 702
Ben-Chitrit, S. (Abst) 720
Ben-Dahan, J. 79
Benazzi, E. (Abst) 723
Bending, M.R. (Abst) 1150, 1158, 1160
Benhamou, P.-Y. 1092
Benhmida, M. 300, (Abst) 699
Bennett, S.E. (Abst) 550
Bennis, D. (Letter) 1258
Benziane, A. (Abst) 711
Berden, J.H.M. (Abst) 671
Berg, K.J. 256
Berg, U. 487
Bergamaschi, C.M. (Abst) 710
Berger, J. (Abst) 689
Bergia, R. (Abst) 740
Bergijk, E.C. (Abst) 661
Bergmann, P. 311, (Abst) 166
Bergomaschi, C.T. (Abst) 754
Bergström, J. (Abst) 681
Berland, U. (Abst) 722
Berland, Y. (Letter) 366, (Abst) 754
Bermejo, M. (Abst) 717, 718
Bernal, C. (Abst) 1060
Bernard, A.M. 225
Bernard, D.B. (Abst) 684, 748
Bernardo, L. (Abst) 1065
Bernasconi, P. (Abst) 676
Bernheim, J. 79, 541, (Letter) 271, (Abst) 660, 682, 720
Bernis, C. (Abst) 1056, 1060, 1061, 1064, 1066
Bernis, G. (Abst) 1058
Berthelot, J.M. (Abst) 731
Berthoux, F. (Abst) 683, 693, 779
Berthoux, P. (Abst) 683, 779
Berto, I.M. (Abst) 713, 740
Bertoli, S. (Abst) 721
Bertotti, A. (Abst) 685
Besbas, N. (Abst) 666, 682, 1146
Better, O.S. 260
Betuel, H. (Abst) 683
Bevan, J.S. 1238
Bevington, A. (Abst) 550, 659, 1147, 1149
Bhatnagar, D. S1/109
Bhoola, K.D. 516
Biagini, M. (Abst) 729
Biagioli, M. (Abst) 699
Bialkowska, A. (Letter) 882
Bianchi, A.M. (Abst) 754
Bianchi, C. (Abst) 700
Bianco, L. 438
Biesenbach, G. 105
Billiouw, J.M. (Abst) 703, 974
Billip-Tomecka, Z. (Letter) 1165
Billis, A. (Abst) 761
Binda, P.L. 587
Binswanger, U. 1002, (Abst) 768
Biran, M. (Abst) 706
Bircks, W. (Abst) 688
Birnbaum, J. (Abst) 786
Biro, A. (Abst) 748
Bishop, A.J. (Abst) 697
Bismuth, A. 944
Bizon, D. (Abst) 681
Björck, S. 400
Blaehr, H. 147
Bláha, J. (Letter) 1072
Blake, D.R. (Abst) 551, 709, 1148, 1160
Blanc, P. (Abst) 667
Blethyn, J. (Abst) 553
Bloemena, E. 530, (Abst) 171
Blohmé, I. 1116
Bloom, S.R. 1019
Blum, G. (Abst) 674
Blum, M. (Abst) 701
Blum, W. (Abst) 780
Blundell, G. (Abst) 693
Bobrie, G. 647
Böcker, G. 917, (Abst) 167
Boelaert, J.R. 931
Boer, P. 991
Boero, R. (Abst) 686, 713
Boeschoten, E.W. (Abst) 165, 169
Bogdanovska, S. (Abst) 719
Bogner, C. (Abst) 707
Böhler, J. 875, (Abst) 711, 721
Boim, M.A. (Abst) 710, 754
Boje Rasmussen, H. 902
Bolaños, L. (Abst) 1062, 1063
Boletis, J. (Abst) 664, 678, 693
Bolino, A. (Abst) 757
Bombi, J.A. (Abst) 749
Bonal, G. (Abst) 705
Bonal, J. (Abst) 749
Bone, J.M. (Abst) 660, 1153
Bonello, F. (Abst) 734, 735, 736
Boner, G. (Abst) 708, 731
Bonet, A. (Abst) 778
Bonet, D. (Abst) 1066
Bonnardeaux, A. 40, (Abst) 765
Bonnet, J. (Abst) 670
Bonomelli, D. 587
Bonssen, K. (Abst) 702
Bonvalet, J.P. (Abst) 716
Borca, M. (Abst) 736
Borelli, I. 587
Borgatti, P.P. (Abst) 751
Borgel, F. 1092
Borrego, F. (Abst) 742
Bortel, L.V. (Abst) 167
Bosaeus, I. (Abst) 727
Bosch, J. (Abst) 680, 756
Bosch, R.J. (Abst) 545

Bosque, E. (Abst) 742, 743
Bossinakou, I. (Abst) 728
Bosteels, V. 479
Botella, J. (Abst) 763
Botey, A. (Abst) 680
Bouchet, J.L. (Abst) 756
Bougatsos, G. (Letter) 1071
Boulton Jones, J.M. 191, (Abst) 697
Boulton, H.F. 1219, (Abst) 759, 1143, 1144
Bourbouze, R. (Abst) 702
Bourgeon, B. (Abst) 762
Bourquelot, P. (Abst) 733
Bover, J. (Abst) 1062
Bovi, G. (Abst) 705
Bovio, G. 438
Bovyn, G. (Abst) 711
Bowser, M. (Abst) 1142
Bozhkov, B. (Letter) 1256
Bradbury, M.G. (Abst) 1144
Bradley, R.D. (Letter) 1162
Brahm, M. (Abst) 754
Brancaccio, D. (Abst) 750
Brandi, L. (Abst) 755
Brändle, E. (Abst) 657
Brando, B. (Abst) 669
Branger, B. (Abst) 721
Braun, M. (Abst) 684
Breathnach, A. (Letter) 455
Brekke, P. (Abst) 732
Brenchley, P.E.C. S1/21, S1/32, (Abst) 674, 1146
Brezis, M. (Abst) 660
Bricknell, S. 817
Bridoux, F. 100
Briggs, J.D. (Abst) 459, 462, 701
Brillet, G. (Abst) 702
Brink, H.S. (Abst) 165
Brivet, F. (Abst) 699
Brock, J.H. (Abst) 460
Brockhaus, M. (Abst) 705
Brocklebank, J.T. (Abst) 1144
Brodahl, U. 256
Brodersen, H.-P. (Letter) 653
Bromley, M.J.K. (Abst) 1156
Bronsoms, J.M. (Abst) 778, 1062, 1065, 1066, 1067
Brooks, C.J. (Abst) 1145
Brouard, R. 57
Brown, A.L. 362
Brown, C.B. 379, (Abst) 1161
Brown, E.A. 636, 848, 1226, (Letter) 270, (Abst) 684, 709
Brown, I. (Abst) 462, 701
Brown, J. (Abst) 689
Brown, J.H. 447, (Letter) 173, (Abst) 705, 1156
Brown, P.W. (Abst) 1149
Brown, R. (Abst) 1156
Brown, Z. (Abst) 666, 1148
Broyer, M. 279, 573, 579
Broyet, C. (Abst) 779
Bruijn, J.A. 507, (Abst) 661
Brumfitt, W. 133
Brummer-Korvenkontio, M. (Abst) 703
Brunaccini, A. (Abst) 662
Brunati, C. (Abst) 723
Brunet, P. (Abst) 722
Brunkhorst, R. 87, (Abst) 742
Brunkhorst, U. 87
Brunner, F.P. 279, 573, 579, 1171
Brussee, H. (Abst) 767
Bryan, J. (Abst) 1142
Brynger, H. 279, 573, 579
Buali, A.R. 327
Buccianti, G. (Letter) 1068, (Abst) 712
Bucciarelli, S. (Abst) 767
Buczko, W. (Letter) 882, 980, (Abst) 770
Buhler, R. (Abst) 550, 554
Buisson, C. (Abst) 732
Buisson, Y. 323
Burbea, Z. (Abst) 755
Burchert, W. (Abst) 752
Burden, R.P. 467, 642, (Abst) 458, 673, 726, 1159
Burdiel, L.G. (Abst) 1055
Bürger, A. (Abst) 783
Burkhardt, K. (Abst) 783
Burrichter, H. (Abst) 678

Cabili, S. (Abst) 701
Cacace, G. (Abst) 668, 677
Cachera, C. 1026
Caglioti, A. (Abst) 671
Cahen, R. (Letter) 559
Caillette, A. (Abst) 667, 690
Caimi, F. 1035
Calabrese, G. (Letter) 1070
Calderazzi, A. (Abst) 700
Calemard, E. (Abst) 714, 722
Calero, F. (Abst) 1059
Callard, P. (Abst) 692
Calpe, J. (Abst) 1057, 1058
Calvo, M. (Abst) 1063
Cam, G. (Abst) 711
Cambier, P. 479
Cambras, T. (Abst) 1065, 1066
Cambridge, G. (Abst) 547, 1147
Cameron, H. (Abst) 462
Cameron, J.S. 627, S1/72, (Abst) 554, 675, 676, 1145
Campbell, H. (Abst) 701
Campistol, J.M. (Abst) 684, 748, 749, 779, 785
Campo, C. (Abst) 778
Campos, A. (Abst) 695
Campos, C. (Abst) 742, 743
Canale, L. 587
Canaud, B. 924, (Letter) 453, (Abst) 723
Canavese, C. (Abst) 679, 696, 755
Canioni, P. (Abst) 706
Cannata, J.B. (Abst) 460, 763
Cannella, G. (Abst) 762
Cano, N. (Letter) 1069
Cantalamessa, L. (Letter) 1068
Cantarell, C. (Abst) 705
Cantón, C.G. (Abst) 1060
Cantù, P. (Abst) 745
Cao Huu, T. (Abst) 687, 750
Capasso, G. (Abst) 657
Capdevila, J. (Abst) 739
Capdevila, L. (Abst) 705
Capece, R. (Abst) 729
Capuano, A. (Abst) 705
Caralps, A. (Abst) 705, 749
Caramello, E. (Abst) 740
Caramelo, C. 674, (Abst) 700
Carasusán, J. (Abst) 1064
Caravaca, F. (Abst) 766
Carayon, A. 300
Carazo, E. (Abst) 1056, 1061
Cardona, M. (Abst) 1056
Carel, R. (Abst) 720
Carey, F.A. 1136
Caringella, A. (Abst) 670
Carlini, A. (Abst) 669
Carlsohn, H. (Abst) 739
Carozzi, S. (Abst) 766
Carpinteri, G. (Abst) 682
Carquin, J. (Abst) 782
Carr, S.J. (Abst) 1149
Carrera, F. 913
Carreras, J. (Abst) 1055, 1057
Carreras, L. (Abst) 1065
Carreras, M. (Abst) 1055
Carretero, P. (Abst) 781
Carrillo, T. (Abst) 673
Carrió, J. (Abst) 1056, 1058
Carvalho, A.B. (Abst) 755, 758
Carvounis, C.P. (Abst) 682
Casado, S. (Abst) 674, 700
Casal, C. (Abst) 1058
Casals, M. (Abst) 1055, 1066
Casanova, J.M. (Letter) 1166
Casati, S. (Abst) 722
Casciani, C.U. (Abst) 785
Cases, A (Abst) 680
Casino, F.G. 1007
Cassar, J. (Abst) 684
Castedo, M. (Abst) 714
Castelao, A.M. (Abst) 1055
Castellano, G. (Abst) 778
Castellote, E. (Abst) 705
Castelnovo, C. (Abst) 720
Castiglione, A. 412, (Abst) 669, 720
Castillo, D. (Abst) 729
Castro, F. (Abst) 1056
Catalano, C. 181
Cattell, V. (Abst) 661, 663
Cattell, W.R. (Abst) 548, 550, 554, 744, 1153, 1160
Catterall, A.P. 1226
Catto, G.R.D. (Abst) 458, 462
Cattran, D.C. S1/48
Catucci, G. (Abst) 767
Caudwell, V. (Abst) 749
Cavaillon, J.M. (Abst) 735
Cavaliere, G. (Abst) 669, 720
Cavallo, F. (Abst) 668
Cavallo, T. (Abst) 675
Cebollada, J. (Abst) 1058, 1063
Cecchin, E. (Abst) 685, 766, 767
Cecillon, S. (Abst) 683
Celibala, R. (Abst) 714
Cendoroglo Neto, M. (Abst) 755
Cerezo, S. (Abst) 1057, 1060
Cernadas, M.R. (Abst) 700
Chagnac, A. 956, (Abst) 766
Chaimovitz, C. (Abst) 755
Chalmers, R.J.G. (Abst) 658
Chambers, K. 817
Chamienia, A.L. (Abst) 680
Chan, F.L. 137
Chan, P.C.K. 93, 137
Chan, T.M. 835
Chanard, J. (Abst) 717, 720, 749, 782
Chanliau, J. (Abst) 742
Channon, S. (Abst) 459, 1143
Chapman, R.S. (Abst) 457
Chapuy, M.C. (Abst) 762
Charasse, C. (Abst) 711
Charpentier, B. 944
Charra, B. (Abst) 714, 722
Chary-Valckenaere, I. (Abst) 750
Chatelet, F. S1/9
Chauveau, D. (Abst) 688
Chazot, C. (Abst) 714, 722
Cheng, H.F. (Abst) 661
Cheng, I.K.P. 93, 137, 835
Cheng, J. (Abst) 462
Chew, S.L. 1194
Chiappini, D. (Abst) 731
Chiappini, M.G. (Abst) 723
Chiarelli, C. (Abst) 706
Chicca, S. (Abst) 756
Chin, S.E. (Abst) 687
Chong, G. (Abst) 771

Chopin, D. (Abst) 666
Choremi, M. (Abst) 678
Chowdry, J. (Abst) 657
Choy, A.-M.J. (Abst) 549
Christophoraki, M. (Abst) 757
Chugh, K.S. 1133
Church, S.E. 986
Cianciaruso, B. (Abst) 705
Ciani, F. (Abst) 657
Ciceri, R. (Abst) 687
Ciechanowski, K. (Abst) 714
Ciftci, D. (Abst) 764
Cignetti, E. (Abst) 736
Cilla, G. (Abst) 1058
Cimadevilla, R. (Abst) 776
Cinotti, G.A. (Abst) 756
Cintin, C. 1249
Cioni, L. (Abst) 694
Cirami, C. (Abst) 754
Cittanova, M.-L. S1/9
Civati, G. (Abst) 669, 723
Clarke, A. (Abst) 745, 1149
Clarke, E.A. S1/42
Clfdes, J. (Abst) 659
Clement, J. (Abst) 970
Clerc, M. (Abst) 706
Clyne, N. (Abst) 706, 765, 769
Cochez, Ph. (Abst) 973
Coen, G. (Abst) 756
Cofan, F. (Abst) 705, 749
Cohen, A.S. (Abst) 684, 748
Coldwell, R.D. 63
Coleman, J.C. 1226
Coles, G.A. (Abst) 546, 666, 671, 697, 745, 747,1148, 1151, 1152
Colina, F. (Abst) 778
Collart, F. (Abst) 166
Colleoni, N. (Abst) 703
Collins, P. (Abst) 1160
Colombo, A. (Abst) 745
Colombo, V. (Abst) 669
Colon, S. (Abst) 667, 690
Colucci, G. (Abst) 688
Colussi, G. 318, 896, (Abst) 665
Combe, C. (Abst) 670, 706, 756
Comerma, I. (Abst) 1061
Comi, N. (Abst) 688
Condon, S. (Abst) 745, 1149
Confalonieri, R. (Abst) 669
Constanzi, S. (Abst) 706
Conway, M. 1226
Cook, H.T. (Abst) 551
Cook, T. (Abst) 661, 663
Cope, G.H. (Abst) 551, 666, 1146
Coppo, G. (Abst) 668
Coppo, R. (Abst) 670, 677, 696
Corazza, F. 311
Cordaro, S. (Abst) 683
Cordoba, M. 541
Cordonnier, D. 1092, (Abst) 724
Coronel, F. (Abst) 726
Correia, A.M. (Abst) 691
Corris, P.A. 362
Corti, M. (Letter) 1164
Cosci, P. 822
Cosseddu, D. 960
Costa, A. (Abst) 1061
Cotes, P.M. 1052
Cotter, F.E. 360
Cotton, R.E. 642
Couette, S. (Abst) 659
Couffinhal, T. (Abst) 670
Coulthard, M.G. (Letter) 652
Coupes, B. S1/32, (Abst) 674, 1146
Coureau, C. (Abst) 659
Couser, W.G. S1/25, (Abst) 662
Coutie, W.J. (Abst) 549
Couttenye, M.M. (Letter) 177, (Abst) 684, 756, 757, 972
Covadonga, H. (Abst) 776
Covarsí, A. (Abst) 1057
Coward, R.A. 357
Cox, D. (Abst) 758
Cozma, G. (Letter) 82
Cozma, M.C. (Letter) 82
Cozzi, M.G. (Abst) 716
Crabbé, J. (Abst) 972
Craig, K.J. (Abst) 692, 1144
Cramp, M. 539
Crawford, D.H.G. (Abst) 687
Crellin, D. (Abst) 673
Cremagnani, L. (Letter) 1068
Criffò, A. (Abst) 733
Cristinelli, L. 587
Cristol, J.P. (Abst) 723, 771
Critchley, M. (Abst) 1153
Critchley, P. (Abst) 660
Crost, T. (Abst) 736
Crout, J. (Abst) 783
Cruceyra, A. (Abst) 726
Cruz, A. (Letter) 981
Cubero, J. (Abst) 766
Cuesta, M.A. (Abst) 701
Cuevas, X. (Abst) 756
Cuhadaroglu, S. (Abst) 780
Cumming, A.D. (Abst) 457, 458, 674, 692, 1144, 1155
Cunazza, M. (Abst) 755
Cunningham, J. 63, 360, 829, 1019, (Abst) 551, 709, 753, 1148
Curtis, J.R. 1226
Curtoni, E.S. 587
Czajbók, E. (Abst) 784
Czapla, C. (Abst) 555
Czapla, K. 1246, (Abst) 460, 757
Czekalski, S. (Abst) 714
d'Aloya, G. (Abst) 669, 720
D'Amico, G. 200, 672, (Abst) 676, 677, 679, 703
D'Eglise-Favre, A. (Abst) 778
D'Haese, P.C. 931, (Letter) 177, (Abst) 684, 756, 757, 972
Da Costa, M. (Abst) 1064
Daelemans, R. 1194
Daha, M.R. 618, (Abst) 167
Dahill, S. (Abst) 709
Dahl, K. (Abst) 774
Dakić, G. (Abst) 742
Dal Canton, A. (Abst) 671, 688
Dalmak, S. (Abst) 719
Dambacher, T. (Abst) 772
Damhuis, E.H.W. (Abst) 167
Daniel, W.G. (Abst) 732
Danielsson, A. (Abst) 681
Daoud, S. 1190, (Abst) 717
Darnell, A. (Abst) 785
Dash, A. (Abst) 685
Daugaard, H. (Abst) 755
Dauzat, M. (Abst) 721
Dávalos, A. (Abst) 778, 1062
Davaris, P. (Abst) 664, 693
Davenport, A. 391, 632, (Abst) 670, 685, 783, 1155, 1156
Davies, J.E. (Letter) 655
Davies, M. (Abst) 556, 666, 671, 747, 1148, 1151
Davies, S.J. (Abst) 1142
Davies, S.P. 848
Davin, J.-C. (Abst) 970
Davison, A. (Abst) 673
Davison, A.M. 450, 673, S1/114, (Abst) 689
Davison, G. (Abst) 555
Dawborn, J.K. 1199
Dawnay, A. 781
Dawnay, A. (Abst) 550, 554, 718, 744, 1160, 1161
Dawnay, A.B.S. (Letter) 272, (Abst) 548, 758, 1153
Day, M. 647
De Alvaro, F. (Abst) 742, 743
De Antoni, E. (Abst) 756
De Arriba, G. 246
De Broe, M.E. 225, 479, 931, (Letter) 177, (Abst) 667, 684, 702, 703, 756, 757, 972, 973
de Bruin, W. (Abst) 167
de Caestecker, M.P. (Abst) 684
de Castro, G. (Abst) 753
de Castro, M. (Abst) 1058
de Châtel, R. (Abst) 680
De Clerck, L.S. 1194
de Fazio, C. (Abst) 720
De Ferrari, M.E. 318, 896, (Abst) 665
De Fijter, C.W.H. (Abst) 166
De Filippi, P.G. (Abst) 668, 677, 695
de Grandi, R. (Abst) 762
de Heer, E. S1/1, (Abst) 661
de Jong, G.M.Th. (Abst) 167, 170
de Jong, P.E. S1/91, (Abst) 165
de Koning, J. 350
de la Torre, B. (Abst) 1059, 1060, 1063
de Leeuw, P.W. 917
de los Mozos, J.J. (Abst) 1058
De Marchi, S. (Abst) 685, 766, 767
De Nayer, P. 1082
De Nicola, L. (Abst) 658, 701
de Nicolas, R. 293
de Oña, M. (Abst) 776
De Paepe, M. 479
De Paoli Vitali, E. (Abst) 723
de Roo, G.M. S1/1
De Rossi, N. 1035
De Santo, N. (Abst) 670
De Santo, N.G. (Abst) 657, 665
De Smet, R. (Abst) 971
De Stefano, D. (Letter) 366
De Tommaso, G. (Abst) 657
De Vecchi, A. (Abst) 720
De Vos, J.Y. 965
de Weerd, A.W. 1213
de Zeeuw, D. S1/91
De'Oliveira, J. (Abst) 685
Deary, I.J. 240
Debska-Slizien, A (Abst) 657
Degaute, J.-P. 45
Degli Esposti, E. (Abst) 686
Deguchi, N. (Letter) 980
Deibert, B. 8
Deicher, H. 87
Del Bo, S. (Abst) 725
del Rio, G. (Abst) 1063
Del Rosso, G. (Abst) 710, 714
Delarue, F. 288, (Abst) 665
Delgado, E. (Abst) 1056
Dell'Aquila, R. (Abst) 971
Dell'Oro, C. (Abst) 694
Della Volpe, M. (Abst) 694
Delmas, P.D. (Abst) 762
Delons, S. (Abst) 735
Demaille, J.G. 1106, (Letter) 881
Demaine, A.G. 1159
Deminiere, C. 158
Demirkan, F. (Abst) 704
Demirtaş, M. (Abst) 771

Demol, J. (Abst) 973
Demopoulos, C.A. (Abst) 680
Denadai, B.S. (Abst) 710
Denef, J.F. (Abst) 972
Denneberg, T. (Abst) 691
Deppisch, R. (Abst) 726
dePrécigout, V. (Abst) 756
Deprez, G. (Abst) 973
Derancourt, J. 1106
Deray, G. 300, (Abst) 699, 702
Derfler, K. (Abst) 739, 775
Derumeaux, G. (Abst) 727
Desassis, J.F. (Abst) 671
Descamps-Latscha, B. 16
Deschodt-Lanckman, M. (Abst) 970
Desmyter, J. (Abst) 167, 170
Deteix, P. (Letter) 367
Devuyst, O. (Abst) 972
Di Cillo, M. (Abst) 662
Di Filippo, S. (Letter) 274, 1164
Di Liberato, L. (Abst) 767
Di Maggio, A. (Abst) 685, 724
Di Paolo, B. (Abst) 767
Di Paolo, N. (Abst) 686, 699
Di Paolo, S. (Abst) 662
Diab, N. (Abst) 779
Diaz, J.M. (Abst) 1059
Diaz-Noguera, A. (Abst) 1065, 1066
Dieperink, H. 1124
Dieu, J.P. (Abst) 976
Diéval, J. (Abst) 731
Digenis, G.E. (Abst) 757
Dillon, M.J. (Abst) 546, 549
Dimitriadis, A. (Abst) 705
Dimković, N. (Abst) 742
Dionisio, P. (Abst) 740
Direskeneli, H. 422
Disney, A.P.S. (Abst) 708
Doblare, E. (Abst) 772
Dodd, S.M. (Abst) 551
Doherty, C.C. (Abst) 667, 1152, 1154
Doladé, M. (Abst) 749
Doman, J. (Letter) 559
Dominguez, M. (Letter) 1163
Dominguez, P. (Abst) 710
Donadio, C. (Abst) 700
Donadio, J.V.Jr. S1/97
Doñate, R. (Abst) 1060, 1063
Doñate, T. (Abst) 1067
Donker, A.J.M. (Letter) 1254, (Abst) 166
Donnay, S. 246
Donovan, K. (Abst) 671, 1148, 1151
Dorhout Mees, E.J. 991
Doucet, A. (Abst) 662
Douek, D.C. (Letter) 1162
Douglas, A.F. (Abst) 1152
Dozio, B. 1035
Draibe, S.A. (Abst) 755, 758
Dratwa, M. 311, (Abst) 166
Drayson, R.A. (Abst) 1156
Dressel, B. (Abst) 721
Droogne, W. (Abst) 973
Drosos, A.A. (Abst) 696
Droz, D. (Abst) 689
Drüeke. T.B. 16, 40, (Abst) 753, 755, 758, 761, 765
Druet, P. (Abst) 671, 714
Drury, P. (Abst) 1161
Dubey, C. (Abst) 671
Dubois, M. (Abst) 702
Dubreuil, P. (Abst) 732
Dun, G.C. 1242
Dündar, S. (Abst) 704
Dunger, D.B. (Abst) 549
Dupre-Goudable, C. (Abst) 678
Durand, D. (Abst) 717
Durand, P.Y. (Abst) 742
Durbo, V. (Abst) 691
Durbec, J.P. (Letter) 1069
Durrington, P.N. S1/109
Dussol, B. (Letter) 366, (Abst) 754
Dutton, J. (Abst) 698, 1146
Duvic, C. (Abst) 770
Dwight, J. (Abst) 730
Dwyer, C. (Abst) 457
Dyer, P.A. S1/42, (Abst) 552
Dyson, E.H. 450

Eadington, D.W. (Abst) 456
Eastwood, J.B. 1098
Ebel, H. (Abst) 769
Echefarreta, G. (Abst) 674
Eckardt, K.U. 40
Edmunds, M.E. 817
Edward, N. 1139, (Abst) 462
Edwards, B.D. (Abst) 658
Edwards, R.D. (Abst) 463
Efficace, E. (Abst) 733
Egberg, N. (Abst) 769
Egido, J. 293, (Abst) 674, 676, 695
Egsmose, C. (Abst) 755
Ehlerding, G. (Abst) 752
Ehrenstein, M.R. (Abst) 1147
Ehrich, J.H.H. 279, 573, 579, 1171
Eichenberger, A. 1002
Eidemak, I. 526
Eisenbach, G.M. 87
Eisenhauer, T. (Abst) 658
Eisinger, A.J. (Abst) 1158, 1160
Eiskjær, H. 69, 493, 1178, (Abst) 718, 767
Ekstrand, A. 908
El Agroudy, A.E. 858
El Esper, N. (Letter) 979, (Abst) 731
El Nahas, A.M. 379, 1185, (Abst) 551, 555, 657, 663, 666, 1146, 1149
El Nujumi, A. (Abst) 709
El Shazly, A. 858
Elisaf, M. (Abst) 696, 712
Elliot, T. (Abst) 745, 1149
Elliott, T.S.J. 967
Ellory, J.C. (Letter) 655
Elorriaga, R. (Abst) 460, 763
Elseviers, M.M. 479, (Abst) 684, 703
Emancipator, S.N. (Abst) 672
Emmen, H.H. 1213
Emoto, Y. (Abst) 732
Encabo, B. (Abst) 700
Endo, T. (Abst) 787
Endreffy, E. (Abst) 784
Engel, B. (Abst) 707, 1158
Engler-Blum, G. 865
Enia, G. (Abst) 724, 757
Eramo, O. (Abst) 671
Erba, G. (Letter) 274, 1164
Erdberg, A. 541
Erdoğan, Y. 1207, (Abst) 764
Erek, E. (Abst) 696, 719
Ericsson, F. (Abst) 733
Eriksson, C.G. (Abst) 733
Eriksson, L.O. (Abst) 775
Erkılıd, M. (Abst) 777
Erkul, İ. 1207
Erley, C.M. 216, (Abst) 715
Erman, M. 422
Ernst, B. (Letter) 368
Errasti, P. (Abst) 1062, 1063
Ersoy, F. (Abst) 777
Esbjörnsson, M. (Abst) 706
Esbrit, P. 608
Escalada, P. (Abst) 778
Esnault, V.L.M. 1238, (Abst) 546, 547
Español, I. (Abst) 1055
Esparrago, J.F. (Abst) 772
Espinosa, G. (Abst) 700
Espinosa, M. (Abst) 729, 1055
Esposito, C. (Abst) 671, 688
Essink, M.J. (Abst) 167
Etienne, I. (Abst) 727
Etienne, T. (Abst) 737
Evans, S.J.W. 829
Evers, J. (Abst) 728
Evers-Schouten, J.H. 618
Excell, L. (Abst) 708

Fabbri, A. (Abst) 686
Fabbri, C. (Abst) 669, 720
Fablan-Bach, C. (Abst) 713
Fabrizi, F. (Letter) 274, 1164
Fabrizii, V. (Abst) 780
Faedda, R. (Abst) 686
Faguer, P. (Abst) 736
Fainekos, K. (Abst) 712
Fairley. K. S1/60
Falkenhagen, D. (Letter) 884
Fan, K.S. (Abst) 463
Farahmand, H. 944
Farfaglia, P. (Abst) 745
Farman, N. (Abst) 716
Farquet, Ch. (Abst) 762
Farrington, K. 539, (Abst) 1142, 1159
Farshidfar, G. 117
Fassbinder, W. 279, 573, 579, 1171
Fauchald, P. 256, 306, (Abst) 774
Favier, A. (Abst) 724
Favre, H. (Abst) 662, 686
Fdez-Fdez, J. (Abst) 763
Fdez-Vega, F. (Abst) 776
Federico, F. (Abst) 706
Feehally, J. 129, 791, 817, S1/21, (Abst) 548, 553
Feest, T.G. (Letter) 1071, (Abst) 553
Feitsma, R.I.J. 618
Fell, G.S. 1246, (Abst) 460, 555, 757
Fellay, G. (Abst) 771
Fellin, G. (Abst) 672, 676, 677
Fener, P. (Abst) 750
Feraille, E. (Abst) 662
Ferdeghini, M. (Abst) 754
Fernádez, A. (Abst) 673
Fernández Menéndez, M.J. (Abst) 460
Fernández, E. (Letter) 1166, (Abst) 758
Fernandez, G. 161
Fernández, M. (Abst) 771
Fernandez-Reyes, M.J. (Abst) 742, 743
Fernando, O.N. 443, 1230
Fernando, R.L. (Abst) 1150
Fernvik, E. (Abst) 740
Feron, R. (Abst) 708
Ferragu, M. (Abst) 731
Ferragu-Goldschmidt, M. (Abst) 765
Ferrari, P. (Abst) 700
Ferrario, F. (Abst) 672, 677, 687
Ferrer, I. (Abst) 1055
Ferrero, S. (Abst) 679, 696
Ferri, C. (Abst) 694
Ferro, M. (Abst) 695
Fiederling, B. (Abst) 710, 714, 767
Fiegel, P. 844
Figueroa, C.D. 516
Figura, M. (Abst) 683

Fijter, C.W.H. (Abst) 701
Filsinger, S. (Abst) 726
Finato, V. (Abst) 754
Fine, A. (Abst) 758
Fine, L.G. (Abst) 545
Fink, E. (Abst) 728
Fiorini, F. (Abst) 725
Fiorini, I. (Abst) 669, 716
Firth, J.D. (Abst) 1154
Fitting, C. (Abst) 735
Flamion, B. (Abst) 974
Flapan, A. (Abst) 461
Flatmark, A. 256
Flavier, J.L. (Letter) 453
Fleming, L.W. 35
Fleming, S. (Abst) 457, 674, 677
Fleming, S.J. (Abst) 687
Fleuren, G.J. 507
Fleury, D. 100
Fliser, D. (Abst) 715
Floege, J. (Abst) 662, 752
Fluck, R.J. (Abst) 718, 758, 1159
Fogazzi, G.B. (Abst) 694
Fondu, P. 311
Fonsale Prost, N. 1190, (Abst) 717
Foraster, A. (Abst) 1055, 1057
Forêt, M. (Abst) 724
Fornasieri, A. (Abst) 672, 676, 703
Forneris, G. (Abst) 713
Forni, G. (Abst) 668
Forslund, T. 306, (Abst) 700
Fort, J. (Abst) 739
Fournier, A. (Letter) 979, (Abst) 717, 731, 762
Fowler, R. 1199
Fox, J.G. (Abst) 697
Foxall, P.J.D. (Abst) 545, 1150
Fracasso, A. (Abst) 710
Frampton, G. (Abst) 675, 676, 1145
Franceschin, F. (Abst) 766
Franco, V. (Abst) 751
Francois, A. (Abst) 692
Francois, B. (Letter) 559
Franz, H.E. (Abst) 783
Freemont, A.J. 1219, (Abst) 759, 1144
Freestone, A. 597
Frei, U. (Abst) 784, 786
Freidberg, M.O. 526
Frensdorff, A. (Abst) 705
Freyschuss, U. (Abst) 681
Friedlander, G. (Abst) 659
Frier, B.M. (Abst) 456
Fries, D. 944, (Abst) 778
Frimat, L. (Abst) 687
Frisenette-Fich, C. (Abst) 765
Fritsch, T. (Abst) 742
Fromentin, L. (Abst) 730
Frommherz, K. (Abst) 721
Frontini, A. 318
Froom, L. (Abst) 1142
Fruchart, J.C. 1026
Fuertes, A. (Abst) 778
Fuhs, M. (Abst) 688
Fuiano, G. (Abst) 671, 688
Fujimi, S. 121
Fujimoto, T. (Abst) 750
Fujishima, M. 121
Fukuda, T. (Abst) 744
Fukushi, K. (Abst) 664
Fulignati, P. (Abst) 706
Funaro, L. (Abst) 696
Funck-Brentano, J.-L. 985
Fünfstück, R. (Abst) 662
Furness, P. (Abst) 550, 659, 1147
Furness, P.N. 642
Furuya, H. (Abst) 738
Furuyoshi, S. (Abst) 750, 751, 752
Fusaroli, M. (Abst) 686
Fyhrquist, F. 306, (Abst) 700, 786

Gabás, J. (Abst) 1055, 1065, 1066
Gabbai, F.B. (Abst) 658
Gafter, U. 956, (Abst) 663
Gaggiotti, E. (Abst) 686
Gaggiotti, M. (Abst) 731
Gagné, E.R. (Abst) 753, 761
Gago, E. (Abst) 776
Gahl, G.M. (Abst) 727, 744, 745
Gaillard, G. (Letter) 367
Gaillard, I. (Abst) 723
Gaimarri, M. (Abst) 677
Gakis, D. (Letter) 273
Galán, A. (Abst) 668, 704, 724, 785
Galceran, J.M. (Abst) 1062, 1065
Galero, F. (Abst) 1059
Gallego, M.J. (Abst) 674, 700
Gallego, N. (Abst) 777
Galletti, P. (Abst) 665
Galli, F. 438, (Abst) 733
Gallicchio, M. 952
Gallo, L. 960
Gambéroni, J. (Abst) 687, 742
Gambertoglio, J.G. 57
Gamez, C. (Letter) 651, (Abst) 777
Gandini, E. (Abst) 672, 677, 687
Gangeri, F. (Abst) 729
Gansevoort, R.T. S1/91
Gantchev, T. (Abst) 774
Ganten, D. (Abst) 667, 713
Garberi, A. (Abst) 750
Garcia Perez, R. (Abst) 668
García Antón, C. (Abst) 1056
García Cantón, C. (Abst) 1058, 1061, 1064, 1066
Garcia Cortés, M.J. (Abst) 1057
Garcia de Vinuesa, M. (Abst) 785
García Díaz, J.E. 161
García Mouriz, E. (Abst) 1064
García Vinuesa, M.S. (Abst) 668
García, C. (Abst) 1057, 1058
Garcia, F. (Abst) 1061
García, F.G. (Abst) 1056
Garcia, M.C. (Abst) 766
Garcia-Cortés, M.J. (Abst) 1060
García-Martín, F. 246
García-Ocaña, A. 608
Garcia-Otero, G. (Abst) 695
García-Valdecasas, J. (Abst) 1057, 1060
Garneri, G. (Abst) 776
Garosi, G. (Abst) 686, 699
Garrido, M.C. (Letter) 655
Gascón, A. (Abst) 784
Gaskin, G. (Abst) 546, 685
Gaspar, M. (Abst) 1057, 1058
Gattuso, E. (Abst) 719
Gaudiano, V. 1007
Gawaz, M.P. (Abst) 707
Gazzano, G. (Abst) 725
Geberth, S. 8, (Abst) 715
Gebuhrer, L. (Abst) 683
Gedroyc, W. (Abst) 552
Geerlings, W. 279, 573, 579, 1171, (Abst) 165
Geffriaud, C. (Abst) 688
Geffroy-Josse, S. (Abst) 727
Geiger, H. (Abst) 679
Gejyo, F. (Abst) 750, 751
Gellert, R. (Letter) 1165
Gennadiu, M. (Abst) 712
Gentric, A. (Abst) 659
Georgoussi, E. (Abst) 728
Gerakis, A. (Abst) 761
Gerrard, J.M. (Abst) 458
Gery, R. (Abst) 755
Geryl, H. (Abst) 756
Gesualdo, L. (Abst) 672
Gesualso, L. (Abst) 662
Ghatei, M.A. 1019
Gheerbrant, J.D. (Abst) 762
Ghiggeri, G.M. (Abst) 750
Ghoneim, M.A. 858
Giacchino, F. (Abst) 776
Giamarri, M. (Abst) 672
Giangrande, A. 412, (Abst) 712
Giani, M. (Abst) 670
Gianoglio, B. (Abst) 668, 670
Gianviti, A. (Abst) 670
Gibelli, A. (Abst) 676
Gibor, Y. (Abst) 755
Gibson, G.J. 1043
Gibson, M. 1030
Gibson, S. (Abst) 459
Gibson, S.P. 1111
Gil, A. (Abst) 1056
Giles, M. (Abst) 1154
Gilge, U. (Abst) 768
Giliberti, A. (Abst) 701
Gilli, P. (Letter) 1259, (Abst) 723
Ginés, P. (Abst) 680
Giordanella, J.P. (Abst) 754
Giordani, R. (Abst) 700
Giordano, A. (Abst) 672
Giusti, R. (Abst) 669, 716
Gladziwa, U. 840, 917, (Abst) 167
Glancey, G.R. 627, (Abst) 554
Glassock, R.J. S1/64
Glibert, B.H. 965
Gluckian, M. (Abst) 693
Göbel, J. (Abst) 784
Godin, M. (Abst) 717, 727
Godino, F. (Abst) 724
Godon, J.P. 479
Goel, S. 632
Goffin, E. (Abst) 776, 976
Gogusev, J. (Abst) 765
Göhl, H. (Abst) 752
Goicoechea, M. (Abst) 785
Gokal, R. 1219, (Abst) 705, 759, 1143, 1144, 1156
Golan, E. 79, (Abst) 720
Goldberg, L.C. (Abst) 551
Goldfarb, B. (Abst) 717
Goldman, M. (Abst) 970
Goldman, M.D. 1111
Goldschmeding, R. (Abst) 693
Goldsmith, D.J.A. (Letter) 654
Golov, K. (Abst) 692
Gomez Ainsua, C. (Letter) 981
Gómez Alamillo, C. (Abst) 1061
Gómez Campderá, F. (Abst) 785
Gómez Recio, M. (Abst) 1064
Gómez, E. (Abst) 776
Gómez, F. (Abst) 668, 704, 724
Gómez, J.R. (Abst) 1057
Gomez-Anson, B. (Abst) 657
Gómez-Campderá, F. (Abst) 691
Gómez-Chiarri, M. (Abst) 676
Gómez-Garre, D. (Abst) 674
Gonella, M. (Letter) 1070

Gonzalez, C. (Abst) 772
González, C. (Abst) 1062
Gonzalez, E. 161
González, E. (Abst) 676, 776, 778
Gonzalez, J. (Abst) 761
González, J.L. (Abst) 778, 1062
Gonzalez, M. (Abst) 763
González, M.T. (Abst) 1055, 1057, 1062, 1065
González-Cabrero, J. 293
González-Rubio, M. (Abst) 711
Gonzalo, A. (Abst) 695, 717
Goode, N. (Abst) 673
Goodship, T.H.J. (Abst) 459, 462, 1143
Gooi, H.C. (Abst) 673
Gooszen, H.C. 433
Gordon, M. (Abst) 661
Gorge, M.P. (Abst) 1153
Gorostidi, M. (Abst) 776, 778
Gorteman, K. (Abst) 667
Gory, P. (Abst) 711
Gotoh, M. (Abst) 708
Götz, R. (Abst) 700, 725
Gower, P.E. 1226
Goździk, J. (Abst) 714
Grabensee, B. 707, (Abst) 688, 703, 735
Graham, K. (Abst) 463
Gramaglia, M. (Abst) 734, 755
Grant, A.C. (Abst) 459
Grass, G. (Abst) 736
Graziani, G. (Abst) 712, 720, 725
Grlevska L 406, (Abst) 750
Greaves, I. 397, 967
Green, N.J. (Abst) 555
Greenfeld, Z. (Abst) 660
Greenwood, C. S1/48
Greenwood, R.N. 539, (Abst) 1142, 1159
Greffard, A. (Abst) 666
Griffel, L. (Abst) 755
Griffiths, D.F.R. 1238
Griffiths, D.G. (Abst) 546, 697
Griffiths, P.D. 1230
Grillo, C. (Abst) 669
Grimes, D. (Abst) 553
Groen, J. (Abst) 970
Groiss, J. (Abst) 766
Groll, J. (Abst) 725
Gronau, C. (Abst) 682
Grönhagen-Riska, C. 908, S1/35, (Abst) 759, 786
Gross, S. (Abst) 731
Grosse-Siestrup, C. 744
Grouev, I. (Letter) 1256
Grundy, J.E. 1230
Grunewald, R.W. (Abst) 783
Grünfeld, J.P. 647, (Abst) 688, 689, 717
Gruss, E. (Abst) 1056, 1060, 1061, 1064, 1066
Grützmacher, P. (Abst) 752
Grzeszczak, W. 221
Guarena, C. (Abst) 686, 713
Guarnieri, A. (Abst) 699
Guaschino, R. (Letter) 1070
Guastoni, C. (Abst) 723
Guérard, A. (Abst) 711
Guerin, A. 323
Guettier, C. (Abst) 714
Guiberteau, R. (Abst) 742
Guidi, E. (Abst) 716
Guidoni, C. (Abst) 754
Guillodo, M.P. (Abst) 659
Gulinska, M. (Abst) 714
Gullo, M. (Abst) 671
Guns, M. 311
Günther, K. (Abst) 739
Gürbilek, M. 1207
Gurland, H.J. (Abst) 707, 751, 783
Gurreri, G. (Abst) 725
Gurwicz, S. (Abst) 705
Gusmano, R. (Abst) 670, 750

Haberal, M. (Abst) 780
Hachache, T. (Abst) 724
Hacini, J. (Abst) 779
Hadj Aissa, A. (Abst) 659
Hahn, H. (Abst) 744
Haites, N.E. (Abst) 456, 547, 663
Halbwachs-Mecarelli, L. 534
Halimi, S. 1092
Hall, C. (Abst) 670
Hall, C.L. (Abst) 1156
Hall, T.J. (Abst) 547
Halls, D.J. 1246, (Abst) 460, 555, 757
Hallson, P.C. (Abst) 1157
Halma, C. 618, (Abst) 167
Halwachs, G. (Abst) 777, 782
Hamad, S. (Abst) 553
Hamberger, B. (Abst) 733
Hamilton, D.V. (Letter) 882
Hamilton-Miller, J.M.T. 133
Hampl, H. 117
Han, D.C. (Abst) 769
Hand, M.F. (Letter) 653
Hannedouche, T. (Abst) 717
Hanrotel, C. (Abst) 761
Hánsch, G.M. (Abst) 726
Hansen, H.V. 1124
Haran, N. (Abst) 705
Harding, K. (Abst) 1157
Harley, S. (Abst) 1160
Harmer, A. (Abst) 552
Harper, J.M. (Abst) 1157
Harper, S.J. (Abst) 548
Harris, K.P.G. (Abst) 550, 659, 1147
Harrison, K. 251
Hart, P.D. (Abst) 707, 1158
Hartmann, H. (Abst) 658
Hartung, R. (Abst) 712
Harwood, S.M. (Abst) 548, 758, 1153
Hasegawa, S. (Abst) 751
Hasslacher, Ch. 501
Hastings, M. (Abst) 1149
Hattersley, J. (Abst) 548, 1149
Haufe, C.C. (Abst) 667, 713
Hay, C. (Abst) 698, 1146
Hayes, P.C. (Abst) 692
Haylor, H. (Abst) 1149
Haylor, J. 1185, (Abst) 555, 657
Hazzan, M. 100
He, C.J. 288
Hed, J. (Abst) 740
Hedman, K. (Abst) 703
Heeg,J.E. S1/91
Heering, P. (Abst) 703
Heidbreder, E. (Abst) 700, 725
Heidenreich, S. (Abst) 774, 775, 783
Heidland, A. (Abst) 679, 700, 725, 768
Heilberg, I.P. (Abst) 758
Heimbürger, O. 50
Heinrichs, A. (Abst) 760
Heinz, G. (Abst) 775
Heisse, C. 944, (Abst) 778
Helin, H. (Abst) 703
Helmers, C. (Abst) 765
Henderson, I.S. 235, (Abst) 461, 549, 554, 773, 1143, 1158
Henderson, M. (Abst) 741
Hendry, B.M. (Letter) 655, (Abst) 730
Hennessy, A. 267
Henny, F.C. (Abst) 166
Herbelin, A. 16
Herlitz, H. 1130
Hermandez, J. (Abst) 763
Hernandez, D. (Letter) 1163, (Abst) 726
Hernández, R. (Abst) 1057, 1058
Hernando, L. 293, (Abst) 674, 700
Herrath, D.V. (Abst) 752
Herrero, J.A. (Abst) 726
Herri, B. (Abst) 723
Herrmann, P. (Abst) 763
Hesse, U.J. (Abst) 679
Hestin, D. (Abst) 687
Hillebrand, G. (Abst) 783
Hilson, A.J.W. 211
Hinwood, M. (Abst) 458
Hirsch, J.D. 143
Hirschl, M.M. (Abst) 775
Hitman, G.A. 200
Hoedemaeker, P.J. S1/1, (Abst) 661
Hoefliger, N. (Abst) 971
Hoek, F.J. (Abst) 168
Hoenich, N.A. 340
Hoffbrand, B.I. (Abst) 1156
Höffken, H. (Abst) 769
Hohenthal, U. (Abst) 786
Holdaas, H. 256
Holemans, J.A. (Letter) 270
Holzer, H. (Abst) 698, 737, 777, 782
Holzer, M. 216, (Abst) 715
Hombrouckx, R.O. 965
Homma, N. (Abst) 750, 751
Homma, S. (Abst) 738
Hong-Zhou (Abst) 690
Honkanen, E. 908, S1/35, (Abst) 759
Horie, M. (Abst) 726
Horina, J.H. (Abst) 698, 767, 782
Hörl, W.H. (Abst) 721
Horn, S. (Abst) 698
Horn, S.U. (Abst) 737
Hornych, A. (Abst) 736
Hortal, L. (Abst) 673
Houhou, S. (Abst) 688
Houtman, P.N. (Abst) 549
Howie, A.J. 397, (Abst) 555
Hristea, D. (Abst) 760
Hsu, C.H. (Abst) 971
Huarte, E. (Abst) 1056, 1061
Huegel, U. (Abst) 760
Hug, F. (Abst) 726
Hughes, A.E. (Abst) 667, 1154
Hughes, C. (Abst) 698, 1146
Hughes, R.T. 1052
Huisman, R.M. (Abst) 165
Hüller, M. (Abst) 739
Hulme, B. 855, (Abst) 552
Hulstijn-Dirkmaat, G.M. (Abst) 167
Humes, J. (Abst) 1148
Hunt, L.P. S1/53, S1/109, (Abst) 705, 1156
Hussein, M.M. (Letter) 173
Husseini, S. (Abst) 719
Hutchinson, A.J. (Abst) 759
Hutchinson, M. (Letter) 455
Hutchinson, P. (Abst) 747
Hutchison, A.J. 1219
Hutchison, A.J. (Abst) 1143, 1144
Huttunen, K. (Abst) 760
Huysmans, F.T.M. 1242
Huzsar, M. (Abst) 678
Hwang, S.D. (Abst) 769
Hylander, B. (Abst) 765, 769

Iadarola, G.M. (Abst) 734, 735
Iaina, A. (Abst) 701

Iatrou, C. (Abst) 680
Iberer, F. (Abst) 777
Ikäheimo, R. (Abst) 759
Ikéni, A. (Abst) 689
Ilhan, S. (Abst) 764
Imai, H. 373
Imholz, A.L.T. (Abst) 743
Ingrosso, D. (Abst) 665
Iniotaki, A. (Abst) 678
Innes, A. 467, 642, (Abst) 458, 673, 726, 1159
Inuma, H. (Abst) 664
Ippolito, E. (Abst) 738
Iseki, K. 121
Isenberg, D. (Abst) 1147
Isles, C. (Abst) 462, 701
Isles, C.G. (Abst) 459
Issad, B. (Abst) 746
Ittel, T.H. (Abst) 688, 760
Ivens, K. (Abst) 688
Iversen, B.M. (Abst) 746

Jaar, B. (Letter) 979
Jaber, K. (Abst) 722
Jackson, J.S. (Abst) 1153
Jackson, R. 191
Jacob, C. (Abst) 702
Jacob, C.J. 1039
Jacob, C.K. (Letter) 272
Jacobs, C. 300, (Abst) 699, 737, 746
Jacobson, S. (Abst) 740
Jacobson, S.H. 1085, (Abst) 769
Jacobsson, H. 1085
Jacquot, C. (Abst) 692
Jadoul, M. (Abst) 975
Jahn, H. (Abst) 772
Jahn, M. (Abst) 772
Jain, S. 1133
Jannsson, E. (Abst) 706
Jansen, A. (Abst) 663
Jardine, A. (Abst) 463
Jauregui-Adell, J. 1106
Jean, G. (Letter) 559
Jeffrey, R.F. (Abst) 673
Jenkins, D.A.S. 613, 1136, (Abst) 457, 458, 674, 1155
Jenkins, H.R. (Abst) 553
Jensen, F.T. 1178, (Abst) 718
Jensen, G. 400
Jensen, H.Æ. (Abst) 732
Jensen, J.D. (Abst) 767
Jensen, L.T. (Abst) 755
Jeppsson, J.-O. (Abst) 691
Jermakova, I.P. (Abst) 762
Jetten, M.L.J. (Abst) 167
Jimenez, C. (Abst) 742, 743
Jimenez, W. (Abst) 680
Jindal, K.K. 143
Joannides, R. (Abst) 727
Joannidis, M. (Letter) 558
Joffe, P. 1249
Jofré, R. (Abst) 691, 710
Jogestrand, T. (Abst) 706
Johansson, A.-C. (Abst) 727, 765
Johns, E.J. (Abst) 680
Johns, J.A. 1199
Johnson, J.R. 267
Johnson, R.J. (Abst) 662
Johnson, R.W.G. 447, (Abst) 552
Johnston, G.D. (Abst) 1152
Johnston, P. (Abst) 689
Johnston, P.A. S1/114
Jones, D.R. (Abst) 673
Jones, D.R.E. (Abst) 726
Jones, J.G. 110
Jones, L. (Abst) 747
Jones, M. (Abst) 743
Jones, M.C. (Abst) 458, 547
Jones, R.G. 450
Jones, R.W. (Abst) 1155
Jones, S.J. (Abst) 547
Jonkman, E.J. 1213
Jordana, L. (Abst) 1058
Jordans, J. (Abst) 970
Jorgetti, V. (Abst) 755
Jörres, A. (Abst) 666, 727, 744, 745
Jørstad, S. (Abst) 774
Jos, V. 447, (Letter) 173
Joshi, K. 1133
Jouzeau, J.Y. (Abst) 750
Jovanovic, D. (Abst) 742
Judith, B.D. (Abst) 762
Jungers, P. (Abst) 689, 698
Jungheinrich, C. (Abst) 752
Junor, B.J.R. (Abst) 462, 701
Just, H. 875

Kahl, A. (Abst) 744
Kahl, C. (Abst) 744
Kainz, H. (Abst) 781
Kaiser, G.I. (Abst) 784
Kaiser, W. (Letter) 1257
Kaizuka, M. (Abst) 664
Kakizaki, Y. (Abst) 660
Kala, A.-R. (Abst) 759
Kalinowski, L. (Abst) 681
Kalinowski, M. (Letter) 882
Kalra, P.A. 357, 1047
Kamata, K. (Abst) 675
Kandoussi, A. 1026
Kane, K. 967
Kaneko, K. (Abst) 546
Kanfer, A. (Abst) 777
Karabatsos, A. (Abst) 712
Karadołan, I. (Abst) 777
Karkar, A.M. (Abst) 1151
Karkas, J.D. (Abst) 775
Karpuzoğlu, T., (Abst) 777, 782
Kasbarian, M. (Letter) 366
Kasidas, G.P. (Abst) 1157
Kassem, M. 902
Katirtzoglou, A. (Letter) 1071
Katzarski, K.S. (Abst) 681
Kawanishi, H. (Abst) 744
Kawano, Y. (Abst) 768
Kawashima, S. (Abst) 768
Kelleher, J.P. 855
Keller, E. 875, (Abst) 711
Keller, F. 427
Keller, T. (Abst) 678
Kemmer, F.W. (Abst) 707
Kemp, E. 1124
Kemp, M. 1124
Kennedy, L. (Abst) 552
Kenouch, S. (Abst) 716
Kerjaschki, D. S1/16
Kerr, P. 924
Kerr, P.G. (Letter) 453, (Abst) 747, 748
Kessler, M. (Abst) 687, 742, 750
Khan, A.A. (Abst) 673
Khan, I. (Abst) 462
Khandan-Nia, N. 1019
Khasho, K. (Abst) 694
Khoa Man, N. 16
Khouri, N.A. (Abst) 676
Kibriya, M.G. (Abst) 689
Kido, M. (Abst) 752
Kierdorf, H. (Abst) 657
Kiersztejn, M. 221
Kikawa, K. (Abst) 752
Kilicturgay, S. (Abst) 780
Kincaid-Smith, P. 805, S1/60
Kinnaert, P. (Abst) 970
Kino, K. (Abst) 727
Kinugasa, E. (Abst) 727
Kirazli, S. (Abst) 704
Kiroycheva, M. (Letter) 1256
Kishimoto, T. (Abst) 741
Kiyota, A. (Abst) 741
Kjellstrand, C.M. (Abst) 733
Klaar, U. 739
Klaus, G. (Abst) 760, 763
Klauser, R. (Abst) 781
Klehr, H.U. (Abst) 760
Klein, B. (Abst) 760
Kleinknecht, D. 100, (Letter) 1258, (Abst) 692, 699
Klinkmann, H. (Letter) 368, 884
Klock, J.J. (Abst) 165
Klouda, P. (Abst) 783
Knoflach, A. (Abst) 768
Kobayashi, F. (Abst) 752
Kobayashi, N. (Abst) 675
Koch, K.M. 87, (Abst) 729, 732, 742, 786
Koch, M. (Abst) 690, 707
Kock, R. 840
Koenig, B. (Abst) 760
Koeser, T. (Abst) 707
Kokot, F. 221, (Abst) 768
Kolta, A. (Abst) 708
Kon, S.P. (Abst) 674, 1146
Konieczkowski, M. (Abst) 672
König, P. (Letter) 558
Konner, K. (Abst) 728
Konstadinidou, I, (Letter) 1071
Kontesis, P.S. (Abst) 728
Kooistra, M.P. (Abst) 166
Kooman, J.P. 917, (Abst) 167
Koomans, H.A. 991
Koomen, G. (Abst) 747
Koomen, G.C.M. (Abst) 168, 169, 171, 657, 743
Koopman, M.G. (Abst) 657
Kopec, W. (Abst) 690
Kopolovici, J. (Abst) 748
Korzets, A. 956, (Abst) 766
Korzets, Z. 79, 541, (Letter) 271, (Abst) 720
Koshiba, K. (Abst) 787
Koshikawa, S. (Abst) 727, 765
Koshino, Y. (Abst) 1151
Kostakis, A. (Abst) 664
Kourti, A. (Abst) 712
Koutsikos, D. (Letter) 365, 1071
Kovarik, J. (Abst) 739, 781
Kox, W.J. 848
Koyama, A. (Abst) 708
Kramar, R. 1013
Krámer, B.K. 216
Kraus, M. (Abst) 679
Krediet, R.T. (Abst) 165, 168, 169, 171, 743, 747
Kress, H.G. (Abst) 700
Kriaa, F. 944
Krian, A. (Abst) 688
Kronenberg, F. (Letter) 558
Kröner, G. (Abst) 751
Kruhøffer, P.K. (Letter) 883
Kubrusly, M. (Abst) 761
Kuczera, M. 221
Kuentz, F. (Abst) 724
Kuhlbäck, B. 908
Kuhlmann, U. (Abst) 769
Kuhn, J. (Abst) 671
Kühn, W. 865
Kumano, K. (Abst) 787
Kun, K. (Letter) 559
Kunkel, S.L. (Abst) 1148
Kuroda, Y. (Abst) 768
Kurtz, A. 40
Küster, S. (Letter) 1073
Kuzniar, J. (Abst) 690
Kuzniar, T.J. (Abst) 690
Kwan, J.T.C. 360, 829

Labastie-Coeyrehourcq, J. (Letter) 1069
Labeeuw, M. 1190, (Abst) 659, 667, 690, 717
Lacombe, C. (Abst) 765
Lacombe, M. 647
Lacombe, P. (Letter) 1069
Lacour, B. (Abst) 761, 765

Ladefoged, S.D. 147, 526, 1249
Ladkani, D. (Abst) 755
Lago, M. 871
Laing, I. (Abst) 1143
Lair, M. 16
Lama, G. (Abst) 670
Lamb, E. (Abst) 550, 554, 744, 1160
Lambert, M. 1082
Lamberts, L.V. 931, (Abst) 684, 756, 757, 972
Lambré, C. (Abst) 666
Lambropou Iou, A. (Abst) 678
Landais, P. 647, (Abst) 699, 717
Landriani, N. (Abst) 721
Landwehr, P. (Abst) 725
Lang, C.C. (Abst) 549
Lang, D. (Abst) 783
Langan, S.J. 240
Lange, H. (Abst) 769
Langenbeck, D. (Abst) 745
Langendijk, P.N.J. (Abst) 168
Lannoy, N. (Abst) 785, 975
Lapra, C. 1190, (Abst) 717
Largen, P. (Abst) 661, 663
Larkin, K.A. (Abst) 667, 1154
Larrad, L. (Abst) 1063
Larsen, S. 147
Larsson, R. (Abst) 765
Larsson, S. 1085
Larue, J.R. 158
Lasierra, P. (Abst) 1063
Laske, V. (Abst) 775
Lattuada, S. (Abst) 721
Lauchart, W. 865
Lauder, I. (Abst) 548
Laupacis, A. 811
Laurens, W. (Abst) 973
Laurent, B. (Abst) 693
Laurent, G. (Abst) 714, 722
Lauwerys, R.R. 225
Lavaud, S. (Abst) 720, 749, 782
Laverrifre, C. (Abst) 737
Lavilla, J. (Abst) 1062, 1063
Lawler, W. (Letter) 173
Lawrence, R. 422
Layward, E. (Abst) 1149
Layward, L. (Abst) 548
Lazarou, A. (Abst) 694
Lazarov, ? (Abst) 689
Lazizi, Y. (Abst) 732
Le Guen, E. 158
Le Hoang, P. (Abst) 699
Le Petit, J.C. (Abst) 683
Leaker, B. (Abst) 547, 1147
Lee, H.B. (Abst) 712, 769
Lee, S.J. 265, 397
Lee, S.K. (Abst) 712, 769
Leenaerts, P. (Abst) 169, 741
Lefevre, A. (Abst) 970
Legallicier, B. (Abst) 727
Legendre, J.M. (Abst) 659
Lehmann, H. 1249
Lei-shl, L.I. (Abst) 690
Leirs, H. (Abst) 970
Lemaitre, V. 100
Lemke, H.-D. (Abst) 728
Lemoine, R. (Abst) 686
Lemoniatou, E. (Abst) 972
Lenkei, Z. (Abst) 679
Lens, X.M. (Letter) 1166
Leonardis, D. (Abst) 717, 719
Leonetti, F. (Abst) 754
Lerma, J. (Abst) 676
Lesavre, P. 534, (Letter) 454, (Abst) 688
Leski, M. (Abst) 737, 739
Letac, B. (Abst) 727
Leunissen, K.M.L. 917, (Abst) 167, 170, 171
Levati, M. (Abst) 745
Leventon-Kriss, S. (Abst) 678
Levi, J. 956, (Abst) 663, 766
Levitsky, E.R. (Abst) 753, 762
Lewis, M.A. (Abst) 552
Lewis, M.J. (Abst) 1144
Leyssac, P.P. 1124
Lhotta, K. (Letter) 558
Li Min (Abst) 676
Li Vecchi, M. (Abst) 970
Li Volti, S. (Abst) 670
Li, M. (Abst) 672
Liaño, F. (Letter) 271, (Abst) 740, 771
Lianos, E. (Abst) 661
Liberek, T. (Abst) 745
Libetta, C. (Abst) 751
Lightstone, E. (Abst) 553
Liisanantti, R. (Abst) 700
Limido, A. (Abst) 745
Linari, F. 960
Lindell, Å. (Abst) 691
Lindholm, B. 50
Lindner, A. (Abst) 678
Lindner, G. (Abst) 751
Linnenweber, S. (Abst) 786
Lins, L.E. (Abst) 706, 769
Lins, R. 479
Lins, R.L. 1194
Lipa, R. (Abst) 731
Lipkin, G.W. (Abst) 548, 1153, 1154
Litherland, J. 1030
Liuzzo, G. (Abst) 683
Lloveras, J. (Abst) 1060, 1061, 1065
Lobatto, S. (Abst) 166
Locatelli, F. S1/85, (Letter) 274, 1164, (Abst) 694, 712
Lock, R. (Abst) 685
Lock, R.J. (Abst) 1155
Lockwood, C.M. 546, (Abst) 547
Logemann, E. 875
Loirat, Ph. (Abst) 699
Løkkegaard, H. 526
Løkkegaard, N. (Abst) 732
Lomeña, F. (Abst) 781
London, G. 323
Longombardo, G. (Abst) 694
Lonnemann, G. (Abst) 729
Loperfido, A. (Abst) 685, 724
López, C. (Abst) 1058
López, G. (Abst) 1057
Lopez, T. 1007
Lopez-Armada, M.J. (Abst) 676
Lopez-Berestein, G. 1
López-Farré, A. (Abst) 674, 700
López-Gómez, J.M. (Abst) 691, 710, 724
López-Larrea, C. (Abst) 778
López-Longo, J. (Abst) 691
Lopez-Revuelta, K.V (Abst) 742, 743
Lopez-Velez, R. (Letter) 651
Lord, R.H.H. 360
Lorenz, J.L. (Abst) 1066
Lorenzo, V. (Letter) 1163
Lorho, R. (Abst) 771
Lornoy, W. 479, (Abst) 703, 974
Losada, A. (Abst) 673
Losi, B. (Abst) 669, 720
LoVecchio, L. (Abst) 682
Lozanče, L. (Abst) 719
Lübbe, M. (Abst) 735
Lübbecke, F. (Abst) 659
Lucas, E.Y. 200
Lucas, G.S. 447
Lucchetti, A. (Abst) 700
Luciak, M. (Abst) 669
Luciano, A. (Abst) 703
Lucio, F.J. (Abst) 730
Lucio, J. (Abst) 711
Luck, V.A. 636
Lüders, S. (Abst) 682
Lufft, V. (Abst) 729
Lui, S.F. 1230
Luik, A.J. 917
Luke, D.R. 1
Lund, J. 879
Lundahl, J. (Abst) 740
Luño, J. (Abst) 774
Luong, N. (Abst) 736
Lupton, E. 1030
Lusenti, T. (Abst) 751
Luttmann, W. (Abst) 666

M'Kaddem, A. (Abst) 702
Macarrón, P. 161
McClelland, P. (Abst) 698, 704, 1146
McColl, K.E.L. 986, (Abst) 709
MacDonald, D.M. (Abst) 551
McDonald, P. 357
Macdougall, A.I. 1246, (Abst) 459, 460, 549, 555, 757
McGilchrist, A.J. (Abst) 692
McGraw, M.E. (Abst) 550
McGregor, A. (Abst) 698, 704, 1146, 1157
McGregor, E. (Abst) 462, 701
McGregor, J.M. (Abst) 551
McGregor, S. (Abst) 460
Machida, J. (Abst) 741
Macia, J.M. (Letter) 1166
Macia, M. (Abst) 673
Macias, H.U. (Abst) 761
Maciver, A.G. 391, 516, (Abst) 670, 1156
McIvor, J. (Letter) 270
Mckay, N.G. (Abst) 456, 663
Mackenzie, J.C. 391, 516, 632, (Abst) 670, 685, 783, 1156
McKenzie, A. 1199
Mackie, A. (Abst) 1159
McKirdy, M.J. (Abst) 551
McLaren, M. 235, (Abst) 773, 1158
McLaughlin, K.J. (Abst) 1144
McLay, A.L.C. 191
McLean, A.G. 211
McLelland, P. (Abst) 1157
MacLeod, A.M. (Abst) 462
Mcleod, A.M. (Abst) 547
McLigeyo, S. (Abst) 459
McMahon, A.C. (Abst) 718, 758, 1159
McMahon, L.P. 1199
McMillan, M.A. (Abst) 459, 460, 549, 663
McNally, P.G. 791
McNamee, P.T. (Letter) 174
MacRae, K.D. 1098
Madsen, B. 1178
Madsen, B. (Abst) 718, 767
Maeda, K. (Abst) 732
Maeda, T. (Abst) 765
Maffei, S. (Abst) 734, 735, 736
Maffei, T. (Abst) 662
Magri, F. 1035
Maher, E.R. 211
Mahieu, P. (Abst) 970
Mahiout, A. (Abst) 742
Main, J. (Letter) 175, (Abst) 463
Maiorca, R. 587, (Abst) 731
Maistre, G. 300
Majewska, E. (Abst) 669
Majón, M. (Abst) 1060
Makin, H.L.J. 63

Makris, P. (Abst) 705
Maksud, P. (Abst) 699, 702
Mal, F. (Abst) 692
Malacarne, F. (Abst) 723
Malachi, T. (Abst) 663
Malaguti, M. (Abst) 729
Malberti, F. 822
Maldague, B. (Abst) 776, 976
Malevska, V. (Abst) 719
Malghem, J. (Abst) 776, 975, 976
Malik, N. 1133
Mallafré, J.M. (Abst) 1056, 1058
Mallamaci, F. (Abst) 717, 719, 729, 735, 764
Mallick, N.P. 1171, S1/21, S1/32, S1/42, S1/109, S1/119, (Abst) 553, 674, 705, 1146, 1156
Maltby, P. (Abst) 660, 1153
Malyszko, J. (Abst) 770, 772
Malyszko, J. (Letter) 882, 980
Mampaso, F. 293
Mamtora, H. 1047
Mancini, E. (Abst) 738
Mandelbaum, A. (Abst) 715
Manganoni, A. 587
Mangiarotti, R. (Abst) 722
Manjón, M. (Abst) 1057
Mann, H. 840
Mansell, M.A. (Abst) 1157
Mantelli, C. (Abst) 762
Marabello, L. 1022
Marabini, M. (Abst) 725
Marai, P. (Letter) 274, 1164
Marangella, M. 960
Marcelli, D. (Letter) 274, (Abst) 712
Marcen, R. (Letter) 651, (Abst) 740, 771, 777
Marchais, S. 323
Marcinkowski, W. (Abst) 768
Marco, A. (Abst) 1065
Mardaras, J. (Abst) 758
Maree, A. (Abst) 701
Marigliano, N. (Abst) 1057
Marini, A. (Abst) 767
Marinoso, L.L. (Abst) 756
Mariñoso, M.L. (Abst) 758
Markovic-Lipovski, J. 865
Marsh, F.P. (Abst) 707, 781, 1158
Marshall, S.M. 181
Martín de Francisco, J. 161
Martín, F. (Abst) 1058
Martin, J. (Abst) 784, 1055
Martin, S. (Abst) 552
Martin-Escobar, E. 246
Martin-Malo, A. (Abst) 729
Martínez Bruna, M.S. (Abst) 1064
Martínez Circós, R. (Abst) 1056
Martínez Elbal, M. (Abst) 1064
Martinez Velasco, C. (Abst) 1064
Martinez, A. (Abst) 776
Martínez, A. (Abst) 704
Martínez, E. (Abst) 1059, 1060, 1067
Martinez, F. (Abst) 689
Martinez, J. (Abst) 761
Martínez, J. (Abst) 1059, 1060, 1067
Martinez, M.L. (Abst) 710
Martini, L.A. (Abst) 758
Martins Prata, M. (Abst) 691
Martis, L. (Abst) 743
Márton, J. (Abst) 784
Martorano, C. (Abst) 735
Martos, R. (Abst) 730
Mason, H. (Abst) 698, 704, 1146, 1157
Mason, R.M. (Abst) 556
Masramón, J. (Abst) 1060, 1061, 1065
Massara, C. (Abst) 734
Masson, F. 300
Maté, G. (Abst) 778, 1062, 1065, 1066, 1067
Mateo, L. (Abst) 1062
Mateos, M. (Abst) 740
Mathew, C.M. (Letter) 272
Mathieson, P. (Abst) 675
Mathieson, P.W. (Abst) 546
Matsumura, T. (Abst) 750
Matsushita, K. (Abst) 741
Mattes, U. (Letter) 82
Matthews, J.N.S. 340
Matthys, E. 479
Matuszkiewicz-Rowinska, J. (Abst) 761
Mauri, J.M. (Abst) 778, 1062, 1065, 1066, 1067
Mauro, M.M. (Abst) 671
Maury, C.P.J. (Abst) 751
Mavrikakis, M. (Abst) 757
Mawer, E.B. (Abst) 759, 1143, 1144
Maximov, N. (Abst) 692
Maxwell, P.H. (Abst) 1154
Mayeux, D. (Abst) 687
Mayeux, P. (Abst) 765
Mazerska, M. (Abst) 770, 772
Mazzaferro, S. (Abst) 756
Mazzola, G. 587
Mazzotta, L. (Abst) 669
Mazzucco, G. (Abst) 668
MBewu, A. S1/109
Meager, A. (Abst) 1151
Medcraft, J. 200
Medina, J. (Abst) 711
Meduri, G. (Abst) 778
Meeus, F. (Abst) 692
Megalos, J. (Abst) 761
Mehls, O. (Abst) 713, 745, 760, 763, 780
Mei, E. (Abst) 669
Melin, J.P. (Abst) 720, 782
Mellotte, G.J. (Abst) 1158, 1160
Melón, J. (Abst) 1056
Melón, S. (Abst) 776
Melpidou, A. (Abst) 728
Melzer, H. (Abst) 657
Memmos, D. (Abst) 668
Memoli, B. (Abst) 751
Mendelson, E. (Abst) 678
Menegatti, E. (Abst) 713
Menéndez, P. (Abst) 763
Menth, M. 844
Mentre, F. (Abst) 708
Merkus, J.W.S. 1242
Merlino, C. (Abst) 776
Merlo, C. (Letter) 1254
Méry, J.P. (Abst) 716
Merzouk, T. (Letter) 366
Mesa, L. (Abst) 1062, 1063
Meshalkin, L.D. (Abst) 753
Messina, C. 1022
Messina, M. (Abst) 776
Metaxatos, G. (Abst) 761
Metsárinne, K. 908
Meyboom, F. 191
Meyrier, A. S1/80, (Abst) 692
Mezzarobba, P. (Abst) 699
Michael, J. 397, 967, 1077, (Abst) 676, 745, 1142, 1145, 1149
Michalak, E. (Abst) 675, 1145
Michel, C. (Abst) 708, 730, 765, 770
Michel, J.B. (Abst) 714
Michelacci, Y.M. (Abst) 754
Michielsen, P. (Abst) 741
Miescher, P.A. (Abst) 686
Miglietti, N. 587
Miglio, A. (Abst) 703
Migliorini, P. (Abst) 694
Mignon, F. (Letter) 979, (Abst) 708, 717, 730, 765, 770
Millán, P. (Abst) 700, 1058
Millward, B.A. (Abst) 1159
Millwater, C. (Abst) 659, 1147
Mimura, N. (Abst) 765
Min, L. (Abst) 703
Minakuchi, J. (Abst) 768
Minetti, E.E. (Abst) 716
Minetti, L. 318, 896, (Abst) 665, 669, 723
Mion, C.M. 924, 1106, (Letter) 453, (Abst) 723, 747, 748
Mion, M. (Letter) 453
Mir, M. (Abst) 1061
Mirapeix, E. (Abst) 748, 749
Miserlis, Gr. (Abst) 746
Mistry, C.D. (Abst) 553
Mitchell, R. (Abst) 459
Miura, A.B. 373
Miyata, M. (Abst) 664
Miyata, Y. (Abst) 730
Miyazaki, T. (Abst) 732
Mjörnstedt, L. 1130
Moalla, M. (Abst) 702
Möcks, J. (Abst) 773
Moelby, L. (Letter) 883
Moeremans, C. 479
Mohammed, K.E. (Letter) 1162
Molina, R. (Abst) 748
Monaco, L. (Abst) 738
Monaco, P. (Abst) 785
Moncalián, J. 871
Monova, D. (Abst) 683
Montagnani, E. (Abst) 754
Montellón, J.L. (Abst) 1060, 1061, 1064
Montemurro, N.E. (Abst) 685, 724
Montes, M. (Abst) 1058
Montinaro, V. (Abst) 675
Montolin, J. (Letter) 1166
Montoliu, J. (Abst) 758
Montón, M. (Abst) 674, 700
Montseny, J.J. (Abst) 692
Monzani, F. (Abst) 754
Moodie, F.D.L. (Abst) 547
Moon, C. (Abst) 769
Moore, M.R. 986
Moore, N. (Abst) 727
Moore, R.H. 200
Moorhead, J.F. 211, 443, 597, (Abst) 1147, 1150
Mora, F. (Abst) 1055
Morales, J.M. (Abst) 778
Morales, M. (Abst) 753
Morcos, S.K. (Abst) 1149
Morduchowicz, G. (Abst) 708, 731
Moreau, C. (Abst) 670
Morel, D. 158
Moreno, E. (Abst) 1055
Moreno, F. (Abst) 770
Moreno, J.A. (Abst) 1058
Moreno, R. (Abst) 1058
Moreso, F. (Abst) 1065
Morgan, A.G. 467, 642, (Abst) 458, 673, 726, 1159
Morgan, R. (Abst) 697
Morgan, S.H. (Abst) 1158, 1160
Morganti, A. (Abst) 722, 725
Morgenstern, A. (Abst) 731
Moriconi, L. (Abst) 694
Moriishi, M. (Abst) 744
Morin, P.P. (Abst) 659
Morinifre, P. (Letter) 979, (Abst) 731, 762
Morita, H. (Abst) 732

Morley, A.R. 155, 1043
Morris, K. 125
Morris, R.W. (Abst) 551
Moshage, H. (Abst) 167, 170
Mosquera, D.A. 1111
Moss, G.D. (Abst) 550
Mosso, R. (Abst) 695
Mostacci, S.D. 1007
Motellón, J. (Abst) 1056
Motta, M. (Abst) 668
Motz, W. (Abst) 688, 707
Mouawad, J. (Abst) 714
Moulopoulos, S. (Abst) 757
Mountokalakis, T. (Abst) 712
Mourad, G. (Letter) 881, (Abst) 771
Mouri, T. (Letter) 176
Moustafa, F.E. 858
Moustakas, G. (Abst) 680
Moutafis, S. (Abst) 680
Moutsopoulos, H.M. (Abst) 696
Movilli, E. (Abst) 731
Moynot, A. (Abst) 731, 732, 765
Muchaneta-Kubara, E.C. 1185
Muchaneta-Kubara, E.C. (Abst) 663
Muchin, N. (Abst) 692
Mühlbacher, F. (Abst) 780
Muir, A.L. (Abst) 461
Muirhead, N. 811
Müller, C. (Abst) 727, 744
Müller, C.A. 865
Müller, G.A. 865
Mundy, J. (Abst) 551
Muñoz, J.L. (Abst) 668
Muñoz-Gomez, J. 749, (Abst) 748, 779
Muraca, R. (Abst) 713
Murakami, O. (Letter) 176
Muralikrishna, G.S. 1246, (Abst) 460, 555, 757
Muratori, A. (Abst) 738
Murer, L. (Abst) 670
Murnaghan, D.J. (Letter) 1166
Murphy, B.G. (Letter) 174
Murray-Lyon, I.M. 1226
Musa, A.R. (Letter) 1162
Muso, E. (Abst) 693
Mustonen, J. 200, (Abst) 703
Mysliwiec, M. 882, (Letter) 980, (Abst) 770, 772
Mytilineos, J. (Letter) 1256

Nagase, S. (Abst) 708
Nagy, J. (Abst) 970
Najdovski, T. (Abst) 970
Nakai, S. (Abst) 732
Nakamoto, M. 121
Nakamoto, Y. 373
Nakatani, M. (Abst) 752
Nakazawa, R. (Abst) 750, 752
Nakopoulou, I. (Abst) 664
Nakopoulou, L. (Abst) 693
Namba, S. (Abst) 744
Nand, N. 155
Nanra, R.S. 384, (Abst) 708
Napodano, P. (Abst) 672
Narasimham, D.L. (Abst) 713
Nasini, M.G. (Abst) 766
Nastasi, A. (Abst) 705
Nauta, J.J.P. (Abst) 166
Navas, A. (Abst) 1057, 1060
Naves, M. (Abst) 763
Naves, M.L. (Abst) 460
Naya, M.T. (Abst) 1056, 1060, 1061, 1066
Nazhat, N.B. (Abst) 709, 1148
Negrey, N. (Abst) 774
Negus, R. (Abst) 552
Neild, G.G. (Abst) 1153
Neild, G.H. (Abst) 545, 1148
Neilsen, A.L. (Abst) 732
Neithercut, W.D. (Abst) 709
Nelson-Piercy, C. (Letter) 272
Nenov, D. (Abst) 774
Neri, M. (Abst) 716
Netter, P. (Abst) 750
Netzer, K. (Abst) 784
Neuberger, J. 1077
Neufeld, D. 79, 541
Neusser, M. (Abst) 774
Neverov, N. (Abst) 692
Nevin, N.C. (Abst) 667, 1154
Newland, A.C. (Abst) 1160
Newstead, C.G. 447, (Letter) 173
Ng, L.L. (Letter) 655
Nicholson, J.K. (Abst) 545, 1150
Nicolaides, K. (Abst) 1161
Nicolas, J. (Abst) 693
Nielsen, J.T. 1178, (Abst) 718
Nielsen, O.J. 400
Nielsen, P. (Abst) 755
Niembro, E. (Abst) 774
Niemczyk, S. (Abst) 761
Nieuwhof, C. (Abst) 693
Nigro, M. (Abst) 671
Nikolopoulou, N. (Abst) 761
Nikolov, D. (Abst) 689
Nikolov, K. (Letter) 1256
Nishi, K. (Abst) 741
Niwa, T. (Abst) 732
Nochy, D. (Abst) 692
Noël, L.H. 534, (Letter) 454, (Abst) 688, 689
Nogués, S 623
Nolla, J.M. (Abst) 1062
Nonnast-Daniel, B. (Abst) 732
Noonan, K. 63, 829, (Abst) 753
Nortier, J. (Abst) 970
Notgi, A. 613
Nouwen, E.J. (Abst) 667, 702, 973
Novikov, A.I. (Abst) 753, 762
Novillo, R. (Abst) 1057
Nowack, R. 501, (Abst) 715
Nündel, M. 117
Nusbaum, P. 534
Nutini, M.T. 323
Nuyts, G.D. 225
Nyberg, G. 1116

O'Connor, B. 636
O'Donaghue, D.J. (Abst) 1155
O'Donnell, M. 636
O'Donoghue, D.J. 534, (Letter) 454, (Abst) 693, 1144
O'Malley, A.H. 450
O'Reilly, S. (Letter) 455
Obineche, E.N. 346
Odar-Cederlöf, I. (Abst) 733
Oe, P.L. (Abst) 166, 168, 701
Offermann, G. 427, (Abst) 786
Ofstad, J. (Abst) 746
Ogg, C.S. 627, (Abst) 554
Ögmegül, A. (Abst) 764
Oh, Y. 121
Okada, H. (Letter) 980
Okada, M. (Abst) 751
Oksman, F. (Abst) 678
Okubo, M. (Abst) 675
Olausson, M. 1116, 1130
Oldroyd, S. (Abst) 1149
Olgaard, K. (Abst) 755
Oliva, J.A. (Abst) 1056, 1058
Oliveira, C. 913
Oliveira, D.B.G. (Abst) 546
Oliver, A. (Abst) 1059
Oliver, D.O. (Abst) 730
Oliveras, A. (Abst) 1060, 1065
Olmer, J. (Abst) 682
Olmos, J. (Abst) 739
Olmos, J.M. (Abst) 761
Önen, K. (Abst) 696, 719
Ong, A. (Abst) 1159
Ong, A.C.M. 443, (Abst) 1147
Ono, H. (Abst) 752
Ono, K. (Abst) 752
Ono, T. (Abst) 752
Onodera, K. (Abst) 664
Onoyama, K. 121
Onwubalili, J.K. 346
Ootaka, T. (Abst) 660
Opatrná, S. (Letter) 1072
Opatrný, K. (Letter) 1072
Opatrný, K. Jr. (Letter) 1072
Opelz, G. (Letter) 1256
Oppenheimer, F. (Abst) 779, 781, 785
Öqvist, B.W. (Abst) 694
Orfao, A. (Abst) 784
Orfila, A. (Abst) 1065
Ori, Y. 956
Orofino, L. (Letter) 651, (Abst) 777
Orradre, B. (Abst) 1064
Orsatti, A. (Letter) 1068
Orte, L. (Letter) 651, (Abst) 695, 717, 718
Orth, S. (Abst) 664
Ortíz, A. 293, (Abst) 676
Ortuño, J. 771, (Letter) 271, 275, 651, 652, (Abst) 695, 717, 718, 740, 777
Osawa, H. (Abst) 664
Osman, E.M. (Letter) 1162
Östenson, C.-G. 1085
Osterhaus, A. (Abst) 970
Ostrowski, K. (Letter) 1165, (Abst) 761
Oswald, A. (Abst) 752
Otero, G.G. (Letter) 652
Owen, J. (Abst) 552
Özakgün, R. (Abst) 771
Ozawa, K. (Abst) 664
Özcebe, O. (Abst) 704
Özdemir, O. (Abst) 704
Özdemir, S. (Abst) 682
Özen, S. (Abst) 682
Özener, C. 422
Özgün, S. 422

Paar, D. (Abst) 760
Pacchiano, G. (Abst) 751
Pachinger, O. 1013
Pacholok, S. (Abst) 1148
Pacitti, A. (Abst) 734, 735
Packham D. S1/60
Page, B. (Abst) 698, 733
Pagniez, D. 1026
Paillard, F. (Abst) 777, 779
Paleologo, G. (Abst) 694
Palestra, P. (Letter) 1254
Palidda, I. (Abst) 683
Palkovits, M. (Abst) 679
Pall, A. (Abst) 676, 1145
Pall, A.A. (Letter) 883
Palla, R. (Abst) 754
Pallot, J.L. 100
Palmer, A. (Abst) 552
Palop, L. (Abst) 673
Palwuczyk, I. (Abst) 1147
Pamphile, R. (Abst) 762
Panades, M.J. (Letter) 1166
Panayotou, M. (Abst) 728
Panichi, V. (Abst) 754
Pannatier, J.G. (Abst) 771
Paoletti, E. (Abst) 762
Paolini, F. (Abst) 738

Papadakis, J. (Abst) 693
Papadimitriou, M. (Abst) 668, 746
Papagalanis, N. (Abst) 712
Papageorgakis, N. (Abst) 728
Papagiannis, A. (Letter) 273
Papanikolaou, V. (Letter) 273
Papantoniou, A. (Abst) 757
Papantoniou, V. (Abst) 757
Papoz, L. 1092
Pappalettera, M. S1/85
Paraíso, V. (Abst) 1061, 1064, 1066
Parera, M. (Abst) 695
Paris, J.M. (Abst) 736
Park, M.S. (Abst) 769
Paroni, G. (Abst) 733
Parratt, D. 35
Parrini, M. (Abst) 754
Pascual, J. (Letter) 271, 275, 652, (Abst) 695, 740, 771, 777
Pascual, M. (Abst) 739
Pascuali, M. (Abst) 756
Pasquariello, A. (Abst) 694
Pasquier, R. (Abst) 714
Passalacqua, S. (Abst) 706
Passerini, P. S1/85
Passlick-Deetjen, J. (Abst) 744, 764
Pasternack, A. (Abst) 703, 763
Pastor, C. (Abst) 749
Pastor, M.C. (Abst) 705
Paterson, J.R. (Abst) 663
Patrick, A.W. (Abst) 698, 704, 1146, 1157
Patsias, Ch. (Abst) 694
Patterson, D. (Abst) 698, 1146
Paul, H. (Letter) 1070
Paul, M. (Abst) 667
Paulsen, D. 256
Pauwels, E.K.J. 618, (Abst) 167
Pawlak, K. (Abst) 772
Payan, E. (Abst) 750
Paydaş, S. (Abst) 771
Pazianas, M. 1098
Pec, M. (Abst) 780
Peces, R. (Abst) 778
Pechfre Bertschi, A. (Abst) 737
Pedersen, E. 526
Pedersen, E.B. 69, 493, 1178, (Abst) 718, 767
Pedro-Botet, J. 623
Peer, G. (Abst) 701
Pehrsson, S.K. (Abst) 706
Pei. Y. S1/48
Peiris, M. (Abst) 463
Pelayo, J.C. (Abst) 545
Pelegrí, A. 623
Pellerey, M. (Abst) 740
Pelletier, L. (Abst) 714
Peltenburg, H. (Abst) 167
Penas, J.L. (Abst) 1064
Penders, R. (Abst) 171
Peraldi, M.N. 288, (Abst) 665
Perdiguero, M. (Abst) 695
Perdomo, M. (Abst) 673
Perego, A. (Abst) 723
Pereira Miguel, M.J. (Abst) 691
Pérez Garcia, R. (Abst) 785
Pérez Trallero, E. (Abst) 1058
Pérez, R. (Abst) 724, 729, 774
Pérez-Fontán, F.J. 871
Pérez-Fontán, M. 871
Pérez-Garcia, R. (Abst) 770
Perini, L. (Abst) 723
Perna, A.F. (Abst) 665
Perrino, M.L. (Abst) 723
Perrone, B. (Abst) 733
Perry, G.J. (Abst) 676
Persaud, J.W. 597
Persson, H. 1116
Peruzzi, L. (Abst) 668
Pestana, M. (Abst) 660
Peters, A.M. 205
Petersen, M.M. (Abst) 745
Petitclerc, T. 300
Petitjean, Ph. (Abst) 772
Petrarulo, M. 960
Petri, I.B. (Abst) 784
Petris, C. (Abst) 696
Petronić, V. (Abst) 785
Petrova, E. (Abst) 774
Peuchant, E. (Abst) 706
Phillips, M.E. 1098
Piazza, A. (Abst) 785
Piazza, V. 438, (Letter) 1254, (Abst) 733
Picardi, L. 438
Pidarro, I.C. (Abst) 710
Picciotto, A. (Abst) 725
Picciotto, G. (Abst) 668, 677
Piccoli, G. (Abst) 668, 677, 686, 695, 696, 713, 735
Piccoli, G.B. (Abst) 734, 735, 736
Pickering, S.J. (Abst) 1161
Piera, L.L. (Abst) 739
Pierides, A. (Abst) 694
Pierini, A. (Abst) 722
Pietilá, K. (Abst) 703
Pietraszek, M. (Letter) 980
Pignone, E. (Abst) 713
Pilatte, Y. (Abst) 666
Pillot, J. (Abst) 732
Pinerolo, C. (Abst) 672, 676
Pippard, M.J. 1052
Pires, C. 913
Pirisi, M. (Abst) 686
Pirson, Y. 1082, (Abst) 776, 785, 975, 976
Piszczek, I. (Abst) 747
Pizarro, J.L. (Abst) 766
Plá, J.M. (Abst) 1065
Planes, A.M. (Abst) 739
Plant, M. 636
Plant, W.D. (Abst) 458, 1144, 1155
Plaza, C. (Abst) 673
Plum, J. (Abst) 735
Poch, E. (Abst) 785
Pochet, J.M. (Abst) 976
Podjarny, E. (Abst) 660, 682
Poggi, E. (Abst) 785
Poggio, F. 438, (Letter) 1254
Pogglitsch, H. (Abst) 737
Poignet, G.L. (Abst) 735
Polenaković, B. (Abst) 719
Polenaković, M. 406, (Abst) 750
Poli de Figueredo, C.E. (Letter) 655
Pollock, L.E. 360
Pollok, M. (Abst) 678
Polonio, F. (Abst) 729
Ponticelli, C. S1/85, (Abst) 694, 722, 725
Pontoriero, G. (Letter) 274
Ponz, E. (Abst) 779
Ponzio, A. (Abst) 738
Poortvliet, D.C.J. 1213
Porcellini, M.G. (Abst) 668, 670
Postec, E. 158
Postlethwaite, R.J. (Abst) 552
Postorino, M. (Abst) 729, 735, 764
Potaux, L. 158, (Abst) 756
Potting, C.M.J. (Abst) 169
Pourrat, J. (Abst) 678
Poveda, R. (Abst) 1065
Powell, J. (Abst) 677
Powell-Tuck, J. (Abst) 707, 1158
Power, D.A. (Abst) 456, 547, 663
Pozet, N. 1190, (Abst) 659, 717
Pozzi, C. (Abst) 679, 694
Prati, E. 587
Prieto, J.A. (Abst) 753
Prieto, M.L. (Abst) 1055, 1057
Pringle, J.H. (Abst) 548
Prins, F. (Abst) 661
Prischl, F.C. 1013
Proesmans, W. (Abst) 975
Pronchenko, I.A. (Abst) 762
Proudfoot, A. (Abst) 1151
Pruchno, C.J. S1/25
Przedlacki, J. (Abst) 760
Puccini, R. (Abst) 694
Pugh, C.W. (Abst) 1154, 1155
Puglisi, R.M. 1022
Puig, J.M. (Abst) 1060, 1061, 1065
Pullig, O. (Abst) 784
Pun, K.K. 835
Punzengruber, C. 1013
Purroy, A. (Abst) 1062, 1063
Pusey, C.D. (Abst) 546, 685

Quarello, F. (Abst) 713, 734, 735, 736
Quattrocchio, G. (Abst) 677, 695
Quereda, C. (Letter) 651, (Abst) 695, 717, 718
Quick J. 1002
Quirós, J. (Abst) 676
Qunibi, W. 327, 939

Raasveld, M.H.M. 530
Rabczyński, J. (Abst) 690
Radake, H. (Abst) 783
Radice, A. (Abst) 679
Radmilovic, A. (Abst) 742
Radovanovic, Lj. (Abst) 742
Raffaele, L. (Letter) 1164
Raffard, G. (Abst) 706
Raftery, M.J. 360, 1019, (Abst) 781
Raghavachar, A. (Abst) 786
Rahilly, M.A. 1136, (Abst) 677
Rahn, K.H. (Abst) 719, 774, 775, 783
Raine, A.E.G. 1171, (Letter) 272, (Abst) 548, 718, 758, 1153, 1154, 1159
Rambausek, M. (Letter) 1070, 1256
Ramirez-Orellano, M. (Abst) 756
Ramos, J. (Letter) 1166
Rampino, T. (Abst) 751
Randmaa, I. (Abst) 681
Ranzini, C. (Abst) 669
Rao, M. 1039
Raskó, I. (Abst) 784
Ratcliffe, P.J. (Abst) 1154, 1155
Rathaus, M. 541, (Abst) 660, 682
Ratschek, M. (Abst) 782
Rayner, H.C. (Abst) 555
Reach, I. (Abst) 737
Reade, R. 1026
Reaich, D. (Abst) 459, 1143
Reaveley, D.A. 636
Rebibou, J.M. 288
Recas, I. (Abst) 1065
Redaelli, B. (Abst) 712
Rees, A. 1238, (Abst) 553, 556
Rees, A.J. 997, (Abst) 685, 1150, 1151
Rees, J.A.E. (Abst) 697

Reetze-Bonorden, P. (Abst) 711, 721
Rehling, M. 1178, (Abst) 718
Reichel, H. 8, (Abst) 762
Reid, A.W. (Letter) 883
Reilly, M. (Letter) 455
Reinaerts, H.H.M. 1242
Remuzzi, A. (Abst) 546, 697
Remy, P. (Abst) 692, 736
Renaux, J.L. (Abst) 736
Renders, L. (Abst) 784
Rengel, M. (Abst) 668
Renoult, E. (Abst) 687
Renzetti, G. (Abst) 745
Requejo, R. 246
Restrick, L.J. (Abst) 1156
Revert, L.I. (Abst) 680, 748, 749, 779
Revillard, J.P. (Abst) 749
Ricart, M.J. (Abst) 779, 781
Ricart, W. (Abst) 1065
Richard, M.J. (Abst) 724
Richards, N.T. 265, 397, 967, 1077, (Abst) 745, 1142, 1149
Riddervold, F. 306
Riechers, G. (Abst) 732
Riedel, E. 117
Riegel, W. 875
Riesco, A. (Abst) 674
Rifai, A. (Abst) 675
Rigden, S.P.A. (Abst) 551
Rincón, B. (Abst) 1056, 1058, 1061, 1064, 1066
Ringoir, S. 333, (Abst) 971, 972
Riñón, C. (Abst) 742, 743
Rio, M. 756
Rippe, B. (Abst) 694
Rischen-Vos, J. 433
Risler, T. 216, 865, (Abst) 715
Risteli, J. (Abst) 760
Risteli, L. (Abst) 760
Ritz, E. 8, 501, (Letter) 1070, 1073, 1256, (Abst) 664, 667, 690, 712, 713, 715, 726, 760, 762, 763, 764
Riuz, P. (Abst) 711
Rivera, F. (Abst) 680, 695
Rivera, M. (Abst) 695, 717, 718
Rizzolo, L. (Abst) 720
Rizzoni, G. 279, 573, 579, 1171
Rizzoni, G.F. (Abst) 670
Roberts, R. (Abst) 553
Robertson, I. (Abst) 463
Robertson, W.R. (Abst) 459
Robeva, R. (Abst) 683
Robinson, J.D. 93
Robles, N.R. (Letter) 981, (Abst) 772
Roca, R. (Abst) 739
Roccatello, D. (Abst) 668, 677, 695, 696
Röckel, A. 844
Rodá, M. (Abst) 1059, 1060, 1067
Rodger, R.S.C. 1246, (Abst) 459, 460, 462, 555, 701, 757
Rodgers, O.G. (Abst) 748
Rodicio, J.L. (Abst) 778
Rodoy, Y. (Abst) 755
Rodrigues, M.C. (Abst) 691
Rodriguez Mahou, M. (Abst) 691
Rodriguez, A. (Letter) 1163
Rodriguez, J.C. (Abst) 673
Rodriguez, M. (Abst) 729
Rodriguez, R. (Abst) 748, 749
Rodríguez-Puyol, D. (Abst) 711, 730
Rodríguez-Puyol, M. (Abst) 711, 730
Roelandt, R. (Abst) 973
Roels, H.A. 225
Rogada, A.G. (Abst) 779
Roger, S.D. (Abst) 718, 1159
Roig Escofet, D. (Abst) 1062
Roig, L. (Abst) 1056
Roig, R. (Abst) 1066
Roithinger, F.X. 1013
Rolla, D. (Abst) 762
Rollino, C. (Abst) 696
Romagnoni, M. (Abst) 669, 720
Romano, G. (Abst) 686
Rombolà, G. 318, 896, (Abst) 665
Romeo, G. (Abst) 757
Romeo, M. (Abst) 717, 719
Romero, J.R. (Abst) 742, 743
Romero, M. (Abst) 1055, 1066
Romero, R. 623, (Abst) 749
Ronco, P. S1/1, S1/9
Ronda, N. 1238
Rondeau, E. 288, (Abst) 665, 777, 779
Roob, J.H. (Abst) 698
Roob, J.M. (Abst) 737, 782
Roos, C.M. (Abst) 165
Roose, R. 479
Ropolo, R. (Abst) 668, 677
Ros, T. (Abst) 1056, 1058
Rosati, C. (Abst) 713, 735, 736
Roselaar, S.E. (Abst) 709, 1148
Rossert, J. (Abst) 692
Rossi, M. (Abst) 733, 738
Rossoll, M. 1013
Rostoker, G. (Abst) 666
Rotellar, E. (Abst) 1057, 1058
Rottembourg, J. (Abst) 746
Rotunno, M. (Abst) 776
Roujouleh, H. (Letter) 173
Round, A. (Abst) 553
Rousaud, F. (Abst) 1060, 1067
Rousseau, P. 944
Roussel, B. (Abst) 731
Rousselot, M. (Abst) 662
Roussi, D. (Abst) 728
Rowe, P.A. 467, (Abst) 459, 709
Roy-Chaudhury, P. 1139, (Abst) 547
Rozadilla, A. (Abst) 1062
Rozeman, C.A.M. 1213
Rubiés-Prat, J. 623
Rüden, H. (Abst) 744
Ruder, H. (Abst) 780
Rudka, R. (Abst) 768
Ruedin, P. (Abst) 737, 739
Ruiz, A. (Abst) 724
Ruiz, J.E. (Abst) 781, 1058
Ruiz, M.C. (Abst) 726
Ruiz, S.S. (Abst) 753
Ruschitzka, F. (Abst) 682
Russell, G.I. (Abst) 1142
Rustom, R. (Abst) 660, 1153
Rutherford, P.A. 1043, (Abst) 456, 548
Ryan, J.J. 997
Ryckelynck, J.P. (Abst) 737
Rylance, P.B. (Abst) 697

Saatçi, Ü. (Abst) 682
Sabadini, E. (Abst) 672, 677
Sabaté, I. (Abst) 1065
Sabater, J. (Abst) 717, 718, 777
Sabbatini, M. (Abst) 658, 701
Sacchi, G. 587
Safak, H. (Abst) 727
Sage, H. (Abst) 662
Sagliker, Y. (Abst) 771
Saha, H. (Abst) 763
Sahali, D. S1/9
Saijonmaa, O. (Abst) 700
Sakairi, Y. (Abst) 738
Sakhuja, V. 1133
Sakurai, T. (Abst) 738
Saliou, P. 323
Salmela, K. (Abst) 786
Salomone, M. (Abst) 734, 735, 736
Salvadeo, A. 438, (Letter) 1254, (Abst) 733
Salvadori, M. (Abst) 738
Salvaggio, A. (Abst) 721
Salzano, S. 379
Sambrook, P. 1030
Sambuc, R. (Abst) 754
Sampedro, J. 161
Sampietro, J. (Abst) 1055, 1057
Samuel, K. (Abst) 677
Samuell, C.T. (Abst) 1157
Samuilidi, E. (Abst) 757
San Miguel, J. (Abst) 784
Sánchez Casajús, A. (Letter) 369, (Abst) 1056, 1061
Sánchez Vásquez, C. (Abst) 1064
Sánchez, O. (Abst) 1057
Sanchez-Casado, E. (Abst) 766, 772
Sanchez-Madrid, F. (Abst) 674
Sánchez-Tomero, J.A. (Abst) 1056, 1058, 1060, 1061, 1064, 1066
Sanders, E. (Abst) 1156
Sandrini, M. (Abst) 731
Sangiovanni, A. (Abst) 720
Sansone, G. (Abst) 701
Santarsia, G. 1007
Santini, G. (Abst) 767
Santoferrara, A. (Abst) 710, 714
Santoro, A. (Abst) 738
Sanz-Guajardo, D. (Abst) 763
Sanz-Moreno, C. (Abst) 763
Sapsford, D.J. 110
Sardella, D. (Abst) 756
Sarrias, X. (Abst) 1055, 1065, 1066
Sarsmaz, N. 422
Saruta, T. (Letter) 980
Sasaki, T. (Abst) 664
Satta, A. (Abst) 686
Saura, M. (Abst) 711
Sauron, C. (Abst) 779
Savage, C.O.S. (Abst) 1145
Savica, V. 1022
Savige, J.A. 952
Savill, J. (Abst) 556
Savin, M. (Abst) 785
Savin, V. (Abst) 775
Savoldi, S. 587
Sawanishi, K. (Abst) 693
Sawyer, N. 63
Sayed-Ahmed, N. (Abst) 551, 666, 1146
Scaini, P. 587
Scanferla, F. (Abst) 710
Scanziani, R. 1035
Scatizzi, A. 685, (Abst) 724
Scentkiraliy, A. (Abst) 780
Schaefer, F. (Abst) 745
Schaefer, K. (Abst) 725, 752
Schaeffer, J. (Abst) 752
Schalekamp, M.A.D.H. 29
Schárer, K. (Abst) 745
Schatteman, L. (Abst) 974
Schedel, I. 87
Scheler, F. (Abst) 682
Scheler, S. (Abst) 707

Schena, F.P. (Abst) 662, 672
Schenn, G. (Abst) 780
Schiaffino, E. (Abst) 672, 703
Schifferli, J. (Abst) 739
Schiffl, H. (Abst) 709, 718
Schindler, R. (Abst) 729, 742, 786
Schipper, M.E.I. (Abst) 165
Schmid, M. 501
Schmidt, C. (Abst) 715
Schmidt, T. (Abst) 662
Schmidt-Gayk, H. 8
Schmitt, Y. (Abst) 738
Schmitz-Rode, M. (Abst) 679
Schneider, D. (Abst) 659
Schneider, H. (Abst) 738
Schneider, N. (Abst) 720
Scho, N. (Abst) 758
Schollmeyer, P.J. 875, (Abst) 711, 721
Scholte, H.R. (Abst) 166
Schor, N. (Abst) 710, 754
Schöter, K.-H. (Abst) 773
Schrader, J. (Abst) 682
Schramm, L. (Abst) 700, 725
Schrier, R.W. (Abst) 556, 1147, 1151
Schröder, C.H. (Abst) 169
Schubert, K. (Abst) 739
Schulz, E. (Abst) 682
Schulze, M. S1/25
Schurek, J. (Abst) 763
Schütterle, G. (Abst) 659
Schützenmeister, R. (Abst) 732
Schwaberger, G. (Abst) 767
Schwartz, D. (Abst) 701
Schwarz, A. 427, (Abst) 786
Scialo, A. (Abst) 751
Scigalla, P. (Abst) 773
Scoble, J. (Abst) 1159
Scoble, J.E. 211, 443, (Abst) 1147
Scolari, F. 587
Scott, S.J. (Abst) 463
Sedky, A. (Abst) 663
Sedlacek, P.L. (Abst) 739
Sedor, J.R. (Abst) 672
Seed, M. 636
Segaert, M. (Abst) 973
Segagni, S. 438
Segal, A.W. (Abst) 547, 1147
Segarra, A. (Abst) 739
Segoloni, G.P. (Abst) 776
Segovia, J. (Abst) 763
Seidel, A. (Letter) 1070, (Abst) 763
Seiderer, M. (Abst) 751
Seidl, S. (Abst) 781
Seifert, A. (Abst) 725
Seignalet, J. (Abst) 771
Seino, S. (Abst) 664
Selgas, R. (Abst) 742, 743
Selvaggi, F.P. (Abst) 662
Selvaggi, G. (Abst) 723
Selwood, N.H. 279, 573, 579, 1171
Sena, L.M. (Abst) 668
Sennesael, J.J. (Letter) 366
Sentí, M. 623
Sepe, V. (Abst) 688
Sepiacci, G. (Abst) 766, 767
Serban, I. (Abst) 701
Serdengeđti, K. (Abst) 696, 719
Sereni, F. (Abst) 670
Serra, D. (Abst) 1066, 1067
Serrano, P. (Letter) 275, (Abst) 771
Serrano, S. (Abst) 756, 758
Serre, A.F. (Letter) 367
Severijnen, R.S.V.M. (Abst) 169
Sewell, R.F. (Letter) 882
Shah, V. (Abst) 546, 549
Shaldon, S. (Abst) 729, 741
Shannon, M. 539
Sharma, R. (Abst) 775
Sharpe, P. (Abst) 661
Shastry, J.C.M. 1039, (Letter) 272
Shaw, G. 1238
Shepherd, H.T. 450
Shestakova, M. (Abst) 692
Shewring, L (Abst) 666
Shimozawa, Y. (Abst) 708
Shirahama, T. (Abst) 748
Shires, M. (Abst) 673
Shokeir, A.A. 858
Short, A.K. (Abst) 547
Short, C.D. S1/21, S1/32, S1/42, S1/109, (Abst) 658, 674, 1146
Shortland, J. (Abst) 551, 666, 1146
Siakotos, M. (Abst) 761
Siamopoulos, K. (Abst) 712
Siamopoulos, K.C. (Abst) 696
Sicoli, R. (Abst) 729
Sicuso, C. (Abst) 724, 764
Sieberth, H.-G. 840, (Abst) 657, 688, 760
Sierens, L. (Abst) 703
Sierra, C. (Abst) 705
Silva, J.G. 913
Simon, P. (Abst) 711
Simonsen, O. (Abst) 765
Simonsen, S. 306
Simpson, J.G. 1139, (Abst) 547
Sindjić, M. (Abst) 785
Sinico, R.A. 200, (Abst) 672, 677, 679
Sirieix, M.-E. 647
Siskind, M.S. (Abst) 684
Sitter, T. (Abst) 709
Skamel, H.J. (Abst) 769
Skehel, M. (Abst) 547
Skielboe, M. 526
Skinner, M. (Abst) 684, 748
Skovbon, H. 69
Smaers, M. (Abst) 785
Smetana, S.S. (Abst) 678, 748
Smetana, Z. (Abst) 678
Smith, A. (Abst) 1161
Smith, C.H. (Abst) 551
Smith, D. (Abst) 459, 549
Smith, J. (Abst) 556, 1150
Smith, K. (Abst) 663
Smith, N. (Abst) 676, 1145
Smith, S.A. (Abst) 1158
Smits, J.F.M. 602
Smye, S. (Abst) 1144
Snell, M.E. 855, (Abst) 552
Snoek, F.J. (Abst) 166
Snyder, J. (Abst) 786
Soares-da-Silva, P. (Abst) 660
Sobh, M. 327, 939
Sobh, M.A. 858
Sødal, G 256
Soffritti, S. (Abst) 723
Sofia, A. (Abst) 725
Sokolova, T.Y. (Abst) 762
Solbiati, L. 412
Solé, M. (Abst) 748, 749, 779
Soler, C. (Abst) 678
Soler, R. 871
Sone, M. (Letter) 176
Sørensen, S.S. 69, 493
Sorgato, G. (Abst) 669, 720
Souweine, B. (Letter) 367
Söylemezoğlu, O. (Abst) 682
Spannagl, M. (Abst) 709
Sperschneider, H. (Abst) 739
Spieker, C. (Abst) 775
Spithaler, C. (Abst) 678
Splendiani, G. (Abst) 706
Spongano, M. (Abst) 738
Spooner, R.J. (Abst) 663
Spring, K.R. (Abst) 974
Spurio, A. (Abst) 756
Sraer, J.D. 288, (Abst) 665, 777, 779
Stábler, A. (Abst) 751
Stachowski, J. (Abst) 678
Stamatiades, D. (Abst) 678
Starklint, H. 1124
Stathakis, Ch. (Abst) 678
Steenssens, L. (Letter) 366
Stefanaki, K. (Abst) 664, 693
Steger, G. (Abst) 775
Stegmayr, B. (Abst) 773
Stein, G. (Abst) 662, 712, 739
Steiner, M. (Letter) 368
Steininger, R. (Abst) 780
Stevens, C.R. (Abst) 551
Stewart, W.K. 35, 235, (Abst) 461, 554, 773, 1143, 1158
Stock, B. (Abst) 783
Stockdale, H.R. (Abst) 1153
Stockenhuber, F. (Abst) 780
Stoermann, C. (Abst) 737, 739
Stöger, H. 105
Storari, A. (Letter) 1259, (Abst) 723
Stramignoni, E. (Abst) 734, 735
Stratta, P. (Abst) 679, 696
Straube, E. (Abst) 662
Strauer, B.E. (Abst) 707
Strieter, R.M. (Abst) 1148
Stroumza, P. (Letter) 1069
Struijk, D.G. (Abst) 168, 169, 171, 743, 747
Struthers, A.D. (Abst) 549
Strutz, F. 865
Struyker-Boudier, H.A.J. 602
Sturniolo, A. (Abst) 706
Suberg, J. (Abst) 658
Suc, J.M. (Abst) 678
Sugimura, T. (Abst) 741
Süleymanlar, G. (Abst) 782
Sunder-Plassmann, G. (Abst) 739, 775
Sungur, C. (Abst) 704
Surachno, S. 530
Sureda, A. (Letter) 271
Surian, M. 822, 1035
Suzuki, H. (Letter) 980
Suzuki, M. (Abst) 752
Svalander, C. 1116
Svarstad, E. (Abst) 746
Swainson, C.P. (Abst) 456, 458, 1144
Swaminathan, S. 267
Sweny, P. 211, 443, 1230
Swoboda, K. (Abst) 739, 775
Syrenicz, A. (Abst) 714
Szabo, A. (Abst) 762
Szczepańska-Konkel, M. (Abst) 681
Szejnfeld, V.L. (Abst) 758
Szewczyk, Z. (Abst) 690

Tabei, K. (Abst) 730, 738
Tabernero, J. (Abst) 784
Tacquet, A. 1026
Tadros, M. (Abst) 672, 679
Taher, S. 327, 939
Takahashi, K. (Letter) 176
Takahashi, N. (Abst) 744
Takata, S. (Abst) 750, 751, 752
Takaue, Y. (Abst) 768
Takemura, K. (Abst) 708
Takoudas, D. (Letter) 273
Talartschik, J. (Abst) 682
Talbot, R. (Abst) 779
Tam, F.W.K. 997, (Abst) 1150

Tam, S.C.F. 137
Tamagnini, J. (Abst) 751
Tamargo, D. (Abst) 1056
Tamer, N. 1207, (Abst) 764
Tamura, N. (Abst) 664
Tan, C.C. (Abst) 1155
Tani, N. (Abst) 750, 751, 752
Taraphdar, A. 1133
Tasse, S. (Abst) 779
Tattersall, J.E. 539, (Abst) 1142, 1159
Taube, D. (Abst) 551, 552
Taya, M.T. (Abst) 1058
Taylor, C.M. 1077, (Abst) 676, 1145
Taylor, J.E. 235, (Abst) 461, 554, 773, 1143, 1158
Taylor, R. (Abst) 456, 548
Tchankova, P. (Abst) 774
Tchórzewski, H. (Abst) 669
Teatini, U. (Abst) 723
Tegzess, A.M. 433
Teisner, B. 902
Tejedor, A. (Abst) 668, 704, 710, 724, 774
Temple, R.M. 240, 613, (Abst) 461
ten Berge, R.J.M. 530, (Abst) 171
Tepel, M. (Abst) 719, 774
Teppo, A.M. (Abst) 786
ter Wee, P.M. (Abst) 166, 168
Terrat, J. (Abst) 714, 722
Teruel, J.L. (Letter) 271, 275, 652, (Abst) 740, 771, 777
Terzidis-Trabelsi, H. (Abst) 666
Thakrar, D.S. 211
Theelen, B. 479
Theodorsson, E. (Abst) 733
Theunissen, R. (Abst) 693
Thick, M. (Abst) 551, 552
Thirion, X. (Abst) 754
Thiru, S. (Abst) 546
Thomas, B. (Abst) 690
Thomas, D.B.L. (Abst) 1148
Thomas, D.M. (Abst) 546, 697
Thomas, G.J. (Abst) 556
Thomas, M.E. 597
Thomas, P.P. (Letter) 272
Thomas, T.H. 251, (Letter) 175, (Abst) 456, 548
Thompson, F.D. (Abst) 545
Thompson, R.A. 1077
Thomsen, K. 69, 493
Thorgaard Andersen, P.I. (Letter) 883
Thuraisingham, R. (Abst) 1142
Thylén, P. (Abst) 740
Thysell, H. (Abst) 694, 775
Tibbs, C. 1226
Tielemans, C. 45
Tietze, I.N. 493
Tikkanen, I. (Abst) 786
Tiselius, H.-G. (Abst) 691
Tishkov, I. (Abst) 689
Tislér, A. (Abst) 680
Tjandra, Y.I. 1213
Tokyay, R. (Abst) 780
Tomlanovich, S. (Abst) 786
Tomlinson, C. (Abst) 1159
Tomson, C.R.V. 129, 817, (Abst) 553
Tönshoff, B. (Abst) 780
Topaloflu, R. (Abst) 682
Topley, N. (Abst) 666, 745
Tordoir, J. (Abst) 171
Torlone, N. (Abst) 785
Tornero, F. (Abst) 726
Törnroth, T. S1/35
Torralbo, A. (Abst) 726
Torregrosa, J.V. (Abst) 779, 781
Torrente, J. (Abst) 726
Torres, A. (Letter) 1163
Torvik, D. 306
Tóth, M. (Abst) 680
Totsune,K. (Letter) 176
Toupance, O. (Abst) 720, 749, 782
Towers, J. (Abst) 555
Toyota, T. (Abst) 744
Tozer, T.N. 57
Traietti, P. (Abst) 723
Traindl, O. (Abst) 781
Tramonti, G. (Abst) 700
Tran, D.D. (Abst) 701
Traver, J.A. (Abst) 1056, 1058, 1060, 1061, 1064
Treacher, D.F. (Letter) 1162
Trembecki, J. (Abst) 768
Trembecki, R. (Abst) 768
Trevisan, R. (Abst) 728
Triolo, G. (Abst) 736
Trobo, J.L. (Abst) 726
Trolliet, P. (Letter) 559
Troniou, A. (Abst) 727
Trovato, G.M. (Abst) 682
Tryggvason, K. (Abst) 784, 785
Tsakiris, D. (Abst) 746
Tsang, M.T.S. 93
Tscheliesnigg, H.P. (Abst) 777
Tschöpe, W. (Abst) 690
Tsianas, M. (Abst) 761
Tsobanelis, T. (Abst) 752
Tsoufakis, G. (Abst) 680
Tsuchia, T. (Abst) 744
Tucker, B. (Letter) 272, (Abst) 1154
Tufveson, G. 279, 573, 579, 1171
Turgan, ¨ (Abst) 704
Türk, S. 1207, (Abst) 764
Turney, J.H. 110, 230
Tzanatos, H. (Letter) 1071
Tzanatos-Exarchou, H. (Letter) 365
Tzanno-Martins, C. (Abst) 763

Uccello, F. (Abst) 701
Ueda, S. (Abst) 741
Uhl, J. (Abst) 762
Ülkü, U. (Abst) 719
Ulrich, W. (Abst) 781
Underwood, P. (Abst) 970
Urbieta, M.A. (Abst) 1064
Ureña, P. 16, 40, (Abst) 753
Urra, J.M. (Abst) 778
Usón, J. (Abst) 1058

v. Acker, B. (Abst) 747
Vaananen, K. (Abst) 760
Vadiei, K 1
Vagace, J. (Abst) 766
Vagelli, G. (Letter) 1070
Vaheri, A. (Abst) 703
Valderrábano, F. (Abst) 668, 691, 710, 770, 774, 785
Válek, A. (Letter) 1072
Valenti, M. (Abst) 740
Valeri, M. (Abst) 785
Valle, F. (Abst) 725
Vallero, A. (Abst) 696
Vallés, M. (Abst) 778, 1062, 1065, 1066, 1067
van 't Wout, J.W. 350
van Acker, B.A.C. (Abst) 657
van Bortel, L. 917
van Breda Vriesman, P.J.C. (Abst) 693
Van Caesbroeck, D. 479
van Cuyk, W. (Abst) 170
Van Damme, B. (Abst) 973
van de Borne, P. 45
van de Meulen, J. (Abst) 166, 168
van den Akker, P.J. 433
van den Born, J. (Abst) 671
Van Der Biest, I. (Abst) 667
van der Groen, G. (Abst) 970
van der Maas, A.P.C. 1213
Van der Merwe, W.M. (Abst) 459
van der Meulen, J. (Abst) 701
Van der Niepen, P. (Letter) 366
van der Woude, F.J. 350, 433
van Dorp, W.T. 350
van Duyl, W.A. 29
Van Dyck, M. (Abst) 975
van Es, A. (Abst) 166
van Es, L.A. 350, 433, 618, (Abst) 167
Van Haecke, E. 333
van Holthe, M.S.T. 618
van Hoof, J.P. 917, (Abst) 167, 170, 171
Van Hoof, V.O. (Abst) 756
Van Landschoot, N. (Abst) 971
van Leer, E.H.G. 507, S1/1, S1/9
Van Orshoven, A. (Abst) 762
van Velthuysen, M.-L.F. 507
van Ypersele de Strihou, C. 1082, (Abst) 776, 975, 976
Vande Berg, B. (Abst) 776, 975, 976
Vandenberghe, T. (Abst) 973
Vanderschueren-Lodeweyckx, M. (Abst) 975
Vandewiele, I. (Abst) 973
Vandromme, S. (Abst) 667
Vanel, T. (Abst) 722
Vanherweghem, J.-L. 45, (Abst) 970
Vanhille, P. 100, (Letter) 454
Vanholder, R. 333, (Abst) 971, 972
Vanrenterghem, Y. (Abst) 973
Vanuytsel, J.L. (Letter) 177, (Abst) 972
Varagona, G. (Abst) 725
Varagunam, M. (Abst) 676, 1145
Varghese, Z. 597, (Abst) 1147, 1150
Vargunam, M. 1077
Vasconcelos, M. (Abst) 786
Vatne, K. 256
Vázquez, C. (Abst) 1062, 1063
Veale, D. 1043
Vecchio, G. (Abst) 750
Vecina, F. (Abst) 721
Vega, N. (Abst) 673
Velidedeoglu, E. (Abst) 780
Velilla, J.P. (Abst) 1064
Veljović, R. (Abst) 785
Veneroni, G. (Abst) 669, 720
Venton, T.R. (Abst) 554
Venturi, M.G. (Abst) 716
Verbanck, J. 479, (Abst) 973
Verbeelen, D.L. (Letter) 366
Vercellone, A. 755, (Abst) 679, 696, 734, 736, 776
Verdy, E. (Letter) 979
Verellen-Dumoulin, C. (Abst) 785, 975
Verger, C. (Abst) 737
Vergoulas, G. (Letter) 273
Verhagen, R. (Abst) 970
Vermylen, J. 1194

Veronese, S. (Abst) 669
Verpooten, G.A. 931
Verpooten, G.F. 225
Verresen, L. (Abst) 167, 169, 170, 741
Verrier-Jones, K. (Abst) 553
Verroust, P. S1/1, S1/9
Verstrepen, W.A. (Abst) 702, 973
Vettraino, M.D. (Abst) 1144
Veys, N. 333, (Abst) 972
Vicente, O. (Abst) 691
Vidal-Barraquer, F. (Abst) 1056
Vidaur, F. (Abst) 1058
Vieira, J.G.H. (Abst) 755
Vienken, J. (Abst) 727
Viglis, B. (Abst) 678
Vigneron, N. (Abst) 753
Vila, A. (Abst) 1056, 1063
Vila, T. (Abst) 718
Vilardell, J. (Abst) 779, 781
Villa, G. 438, (Abst) 733
Villafruela, J.J. (Abst) 717
Villalta, D. (Abst) 767
Vincent, C. (Abst) 749
Vincent, H.H. 29, (Abst) 170
Vincent, J.P. (Abst) 708
Vincenti, F. (Abst) 775, 786
Vinciguerra, M. (Abst) 657
Violet, I. (Abst) 779
Viot, P. (Abst) 754
Viron, B. (Letter) 979, (Abst) 708, 730, 762, 770
Visvardis, G. (Abst) 746
Vit, L. (Letter) 1072
Vita, G. 1022
Vitale, C. 960
Vites, N.P. (Abst) 705, 1156
Vives, M. (Abst) 749
Vlassopoulos, D. (Abst) 746
Vogt, B. (Abst) 662
Volk, S. (Abst) 667
Volkmann, R. 400
von Appen, K. (Letter) 368
Vos, M.C. 29, (Abst) 170
Vos, P.F. 991
Vosnides, Gr. (Abst) 664, 678, 693
Voss, S. (Abst) 679
Vriesendorp, R. S1/91
Vychytil, A. (Abst) 781

Wada, S. (Abst) 741
Wade, A.J. (Abst) 707, 1158
Wagner, J. (Abst) 667, 713
Wagner, S. 840
Walb, D. 844
Waldek, S. 1047
Walford, S. (Abst) 697
Walker, R.G. 805
Wallington, T.B. (Abst) 685, 1155
Wallis, J. (Abst) 659
Walls, J. 129, 817, (Abst) 550, 553, 555, 1147, 1149
Walshe, E. (Letter) 455
Walter, J. (Letter) 559
Wamser, P. (Abst) 781
Wang, Min-Xia 805
Wang, Y. 1085
Wanic-Kossowska, M. (Abst) 747
Waniewski, J. 50
Ward, K.M. 155
Ward, L. (Abst) 682
Ward, M.K. (Abst) 462
Wardle, E.N. 889, (Abst) 1157
Wardle, E.V. (Abst) 697
Wardyn, K. (Letter) 1165
Warwick, G.L. (Abst) 697
Washio, M. 121
Wasler, A. (Abst) 777
Watanabe, K. (Abst) 787
Waterloos, M.A. (Abst) 971
Watschinger, B. (Abst) 781
Wauters, J.P. (Abst) 771
Webb, A.T. 636, (Abst) 709
Webb, G.I. 472
Weber, M. (Abst) 784
Weening, J.J. 602
Wei, D.C.C. 137
Weih, M. (Abst) 664
Weil, B. (Abst) 666
Weinreich, Th. (Abst) 664, 764
Welsh, K.I. (Abst) 551, 552
Wenham, P.R. (Abst) 663
Wens, R. (Abst) 166
Were, A.J. (Abst) 1143
Werynski, A. 50
Westenend, P.J. 602
Weston, M.J. (Abst) 1156
Westwick, J. (Abst) 666, 1148
Whalen, M.A. 143
White, A. (Abst) 459
White, M.C. (Abst) 698, 704, 1146, 1157
Whitehouse, R.W. (Abst) 759, 1144
Whitworth, C.E. (Abst) 458, 1155
Wicks, A.C.B. (Abst) 548
Widecka, K. (Abst) 714
Widerøe, T.E. (Abst) 774
Widhalm, K. (Abst) 775
Widstam-Attorps, U. 487
Więcek, A. 221, (Abst) 768
Wight, J.P. 379, 1185, (Abst) 555
Wijnen, J.A.G. 917, (Abst) 167
Wild, S.R. 613
Wilders-Truschnig, M. (Abst) 777
Wilkie, M.E. 1019, (Abst) 551, 781, 1160
Wilkinson, R. 251, 362, 1043, (Letter) 175, (Abst) 456, 462, 548
Will, E.J. 450, (Abst) 673, 741
Willems, M. (Abst) 170
Williams, A.J. (Abst) 1156
Williams, B. (Abst) 556, 1147, 1151
Williams, C. (Abst) 709
Williams, J.D. (Abst) 546, 666, 671, 697, 745, 747, 1148, 1151, 1152, 1157
Winearls, C.G. 1052, (Abst) 553
Wing, A.J. 279, 573, 579
Wingen, A.-M. (Abst) 713
Winkler, J. (Abst) 708
Winklhofer-Roob, B.M. (Abst) 737
Winney, R.J. 240, 613, 1155, (Abst) 458, 461, 693, 1144
Winyard, P.G. (Abst) 709, 1148
Wirnsberger, G.H. (Abst) 698, 782
Wirtz, J.J.J.M. (Abst) 170, 171
Wise, P. (Abst) 684
Wlodarczyk, D. (Letter) 1165
Wojtacha, D.R. (Abst) 457, 674
Wolffindin, C. 340
Wong, C. 811
Wong, T. (Abst) 720, 749, 782
Woo, D.D.L. (Abst) 545
Woodrow, G. 230
Woolf, A.S. 563, (Abst) 545
Woolfson, R.G. (Abst) 1157
Worth, D. (Abst) 741
Wramner, L. 1130
Wrenger, E. (Abst) 742
Wright, G.D. (Abst) 667, 1154
Wrong, O. (Letter) 1071
Wynckel, A. (Abst) 720, 749, 782
Wystrychowski, A. (Abst) 713

Xiao, X. (Abst) 787
Xiaosheng, Y. (Abst) 702, 973

Yakupoğlu, G. (Abst) 777, 782
Yamabe, H. (Abst) 664
Yamagami, S. (Abst) 741
Yap, S.H. (Abst) 167, 170
Yaqoob, M. 125, (Abst) 698, 704, 1146, 1157
Yasavul, Ü. (Abst) 704
Yashiro, M. (Abst) 693
Yasuda, A. (Abst) 750, 751, 752
Yasuda, T. 373
Yatzidis, H. (Letter) 365
Yazbeck, F. (Abst) 733
Yde-Andersen, E. 902
Yeksan, M. 1207, (Abst) 764
Yeung, H.W.D. 93
Yeung, W.C. 93, 137
Ylinen, K. 908
Yoshida, M. (Abst) 741
Yoshikawa, S. (Abst) 664
Yoshinaga, K. (Letter) 176
Young, G. (Abst) 743
Youngs, G.R. 986
Yung, S. (Abst) 747

Zabadani, B. (Abst) 721
Zacchello, G. (Abst) 670
Zach, R. (Abst) 698, 737, 777, 782
Zacharewics, S. 501
Zacharof, A. (Abst) 712
Zachee, P. 1194
Zafirovska, K. (Abst) 719
Zappia, V. (Abst) 665
Zavros, M. (Abst) 694
Zazgornik, J. 105
Zbróg, Z. (Abst) 669
Zech, P. 1190, (Abst) 659, 667, 690, 717
Zeier, M. 501, (Abst) 715
Zeis, P. (Abst) 693
Zemel, D. (Abst) 168, 171, 747
Zerefos, N. (Abst) 728, 757
Zevin, D. 956, (Abst) 663, 755, 766
Zhi-hong, L.I.U. (Abst) 690
Zidek, W. (Abst) 719, 774, 775
Zimmer, A. (Abst) 769
Zingraff, J. 16, (Abst) 698, 733, 753
Zins, B. (Abst) 698, 733
Ziroyannis, P. (Abst) 680
Zmirou, D. 1092
Zoccali, C. (Abst) 717, 719, 724, 729, 735, 757, 764
Zortcheva, R. (Abst) 774
Zucchelli, P. S1/105, (Abst) 738
Zwinderman, A.H. 433

Subject index to Volume 7

α-Ketoanalogues 117
α-Thalassaemia 1052
α_1 selective adenosine receptor antagonist, renal response (Abst) 1152
α_2-Macroglobulin (Letter) 881
  serum levels increase in dialysis (Abst) 748
Abstracts 165, 456, 545, 656, 970, 1055, 1142
Abuse, analgesic 479
    circumstances (Abst) 974
  diuretic 896
ACE (*see* Angiotensin converting enzyme)
Acetaminophen 427
Acidosis, metabolic (Abst) 976
    renal growth and proteinuria in (Abst) 659, 1147
  renal, Na depletion and (Abst) 976
ACKD (*see* Acquired cystic kidney disease)
Acquired cystic kidney disease, natural history 613
  urothelial neoplasia complicating 1136
Acute kidney failure, mycotoxin inhalation and (Abst) 699
Acute metabolic alkalosis, bicarbonate flux during (Abst) 657
Acute myeloid leukaemia, after transplantation and Wilms' tumour (Letter) 653
Acute rejection 530
Acute renal failure 1, 100, 260, 406, 879
  after *E. coli* gastroenteritis (Abst) 458
  anaemia and transfusion haemolysis (Letter) 559
  and pancreatitis (Abst) 701
  causes of death in, 230
  cisplatin-induced 1
  cytokines and immunoglobulins in septicaemia (Abst) 700
  in intensive care units (Abst) 699
  incidence and outcome (Abst) 701
  ischaemic, in ageing rats (Abst) 701
  pathogenesis 260
  post-traumatic 260
  prophylaxis 260
  reversible 267
  severe, prospective study (Abst) 553
Acute tubular necrosis, function of diltiazem (Abst) 1061
Acyclovir (Abst) 463
  CMV infection with (Abst) 782
Adenosine, erythropoietin production and 400
ADH (*see* Antidiuretic hormone)
Adhesion molecules, expression of in renal transplant biopsies (Abst) 783
ADPKD (*see* Autosomal dominant polycystic kidney disease)
Adriamycin, nephropathy, in the rat, CsA and (Abst) 671
  nephrosis, evidence of immunological involvement (Abst) 668
Adult polycystic kidney disease, unlinked to PDK1 locus (Abst) 1154
Adult respiratory distress syndrome, and endotoxaemia (Abst) 1157
Adynamic bone disease, trace metals and, in dialysis patients (Abst) 757
Adynamic bone in uraemia, characteristics in CAPD (Abst) 759
AECA (*see* Antiendothelial cell antibodies)
Agranulocytosis from nafamostat mesilate (Letter) 980
Albumin, and cholesterol in primary glomerular disease (Abst) 697
  and retinol-binding protein excretion in pregnancy (Abst) 1161
  excretion, acute oral protein load and (Abst) 712
    influence of protein intake (Abst) 657
  transport, peritoneal (Abst) 550
Albuminuria 487
Alfacalcidol 63
Alkaline phosphatase 412
  intestinal type 225
Alkaline phosphatase isoenzyme of bone, quantification in dialysis patients (Abst) 756
Alkalosis, metabolic 896
    bicarbonate flux during (Abst) 657
Allograft membranous nephropathy S1/114
Allografts, chickenpox and (Letter) 272
  renal 267, 360
  skin, in rats, *Tripterygium wilfordii* in (Abst) 787
Alpha blockade, dyslipidaemic changes on low-salt diet (Abst) 715
Alport syndrome 563
  and antithyroid antibodies 1082
  deletion of COL4A5 gene (Abst) 785
  COL4A5 gene in (Abst) 784
Aluminium 939
  and haem biosynthesis (Abst) 460
  deposition associated with defective osteoblast function (Abst) 758
  hydroxide (Abst) 165, 460
  levels in dialysis patients, retrospective study (Abst) 684
  toxicity (Abst) 460
    reduced by ranitidine 1246
Aluminoxamine 931
Amino acids 117, 501, (Abst) 547
  excretion 493
  infusion 493
  oxidation (Abst) 459
Amyloid deposits 1106
Amyloid fibrils, β_2-microglobulin (Abst) 749
Amyloidogenesis, cell participation in (Abst) 747
Amyloidosis (Letter) 273
  β_2-M 924
  β_2-microglobulin dialysis-related, detection (Abst) 748
  dialysis, elimination effects of β_2-microglobulin and (Abst) 752
    ^{131}I β_2-microglobulin scan in CAPD (Abst) 752
    β_2-M downregulates α_2-macroglobulin binding (Abst) 747

Amyloidosis (*continued*)
synovial fluid examination and β_2-microglobulin (Abst) 751
ultrasonography and (Abst) 975
Finnish type, gelsolin metabolism and (Abst) 751
haemodialysis-associated 1106
evolution after kidney tansplantation (Abst) 779
in dialysis treatment 908
primary, involving intrarenal blood vessels (Abst) 750
prediction of renal and patient survival (Abst) 684
protein structural analysis of amyloid fibrils in (Abst) 750
renal, complicatingTakayasu's arteritis 1133
transplantation for (Abst) 780
AN69 membranes 29, 275
ACE inhibitors and (Abst) 722
mortality and risk in short-dialysis patients (Abst) 720
Anaemia 40, 129, 1052, (Letter) 173, (Abst) 461
dialysis-associated, erythropoietin dose in (Abst) 1158
erythropoietin in the treatment of 811
renal 240
low-dose s.c. erythropoietin in CAPD (Abst) 765
myocardial perfusion in treatment of with erythropoietin (Abst) 769
serum macrophage colony-stimulating factor and erythropoietin (Abst) 768
renal transplant 143
Analgesic abuse 479
circumstances (Abst) 974
Analgesic nephropathy 384
and renal transplantation 427
changing pattern of renal failure (Abst) 708
comparison with glomerulonephritis 384
diagnosis 384, 479
haematuria in 384
in Belgium (Abst) 703
pattern of renal dysfunction in 384
without phenacetin or paracetamol (Abst) 703
Anaphylactoid reactions, absence of with haemodiafiltration 275
with AN69 membranes (Abst) 169
ANCA (*see* Antineutrophil cytoplasmic antibodies)
Aneurysm, renal artery, after percutaneous renal biopsy (Letter) 883
ANF (*see* Atrial natriuretic peptide)
Angioplasty, balloon catheter (Letter) 270
in diagnosis of renovascular hypertension 1178
Angiotensin II (Abst) 456
and arginine vasopressin receptor downregulation in rats (Abst) 556
decrease of intracellular pH with (Abst) 1066
enalapril and 991
enhancing erythropoietin production 400
high-salt diet and 991
mesangial cell hypertrophy induced by (Abst) 664
Angiotensin II-mediated thirst in HD patients (Abst) 725
Angiotensin-converting enzyme inhibition 100, 216, 267, 275, 400, 602, 1130, (Abst) 459
anaphylactoid reactions and (Abst) 169
and nephrotic syndrome (Abst) 706
angioplasty and 1178
antihypertensive therapy in CRF (Abst) 1152
reduced serum erythropoietin in RAS (Abst) 767
renography (Abst) 718
ANP (*see* Atrial natriuretic peptide)
Antiendothelial cell antibodies 422
Anti-HCV antibodies 913
Anti-hepatitis C virus antibodies in chronic HD (Abst) 170
Anti-HLA antibodies, and allograft rejection (Abst) 552
immunoadsorption of 944
Anti-IL-2R antibody in rats injected with HgCl2 (Abst) 671
Antilymphocyte antibodies 422
Antimonocyte antibodies 422
Antibodies, cytotoxic, after renal transplantation (Abst) 783
monoclonal, anti-CD45, optimizing kidney perfusion (Abst) 551
of interstitial infiltrates, characterization (Abst) 672
to brush-border-related podocyte antigens S1/9
to inducible podocyte antigens S1/9
to podocyte-specific antigens S1/9
to glomerular antigens S1/9
panel-reactive 422
to hepatitis C virus in dialysis (Abst) 724
Antibody response to hepatitis B vaccination in ESRD (Abst) 678
Anticardiolipin antibodies 1194, (Abst) 459, 549
and lupus anticoagulant on RRT (Abst) 709
in CGN and SLE (Letter) 1256
Antidiuretic hormone 306,
measurement in kidney tubules (Abst) 974
Antiendothelial antibodies 805
in lupus nephritis, platelet binding (Abst) 1145
Antiepithelial cell antibodies in paediatric renal transplant (Abst) 552
Antigen
Antigens, glomerular, monoclonal antibodies to S1/9
HLA, in membranous nephropathy S1/42
renal tubular 293
Antiglomerular basement membrane disease (Letter) 454
Antihypertensive therapy 917
Antimesangial cell antibodies detected by elisa in IgA nephropathy (Abst) 676
Antimyeloperoxidase antibodies 534, 1077, (Letter) 454
from peripheral blood (Abst) 1147
in vasculitis (Abst) 679
Antineutrophil cytoplasmic antibodies 454, 534, 952, (Abst) 546, 547
and Henoch–Schönlein purpura 1238
and systemic vasculitis, treatment and outcome (Abst) 1144
clinical significance (Abst) 688
significance of testing (Abst) 1155
Antineutrophil cytoplasmic antibody renal disease
histological appearances (Abst) 673
Antiphospholipid antibodies, in glomerulopathies (Abst) 695
clinical relevance of 1194
Antithymocyte globulin 1130
Antithyroid antibodies 1082
Apolipoprotein (a), decrease after renal transplantation (Letter) 174
Apolipoprotein B gene polymorphism in diabetic nephropathy (Abst) 663
Apolipoproteins in plasma and dialysate fluid in CAPD 1026
Apoptosis (Abst) 556
Aprotinin, improves renal function in cirrhosis (Abst) 692
uptake and metabolism (Abst) 660
ARDS (*see* Adult respiratory distress syndrome)
ARF (*see* Acute renal failure)
Arterial disease, peripheral, on RRT (Abst) 709
Arteriovenous fistula, and endothelin-1 release 1019
flow, assessment by Doppler colour ultrasonography (Abst) 732
Arthropathy, dialysis-associated, hyaluronic acid a marker of (Abst) 750
Artificial intelligence 472
Aspirin and platelet hyperaggregability with erythropoietin (Abst) 554
ATG (*see* Antithymocyte globulin)
Atherogenesis, ascorbate and (Abst) 709
Atheroma 211
Atherosclerosis 636
oxidizing activity detected by electron spin resonance spectroscopy (Abst) 1148
risk factors in haemodialysis (Abst) 722
Atrial natriuretic peptide 221, 306
a marker for 'dry' weight in HD? (Abst) 681
and endothelin in poststreptococcal GN (Abst) 682
cardiovascular resistance to during volume expansion (Abst) 729

Atrial natriuretic peptide (*continued*)
in dehydration (Abst) 679
in HD, influenced by vasopressin and noradrenaline (Abst) 681
release of in phaeochromocytoma (Abst) 680
renal response to (Abst) 681
Autonomic neural function in chronic uraemia 1022
Autosomal dominant polycystic kidney disease 501, 647, (Abst) 545, 975
chronic HD and hepatic cysts (Abst) 731
trait, blood pressure and (Abst) 715
Autosomal recessive polycystic kidney disease 545
Autotransplantation (Letter) 271
Avascular necrosis 1039
Azathioprine 251, 362
glomerular filtration and tubular reabsorption (Abst) 703
Azathioprine-related interstitial pneumonitis (Letter) 1166

β-adrenoreceptors, downregulation of in rat kidney (Abst) 659
β-blockers and glomerular hyperfiltration (Abst) 711
β_2-M (*see* β_2-Microglobulin)
β_2-Microglobulin 924, (Letter) 881
affinity to bone marrow and synovium (Abst) 752
amyloid deposits, plasma proteinase inhibitors in (Abst) 748
amyloid fibrils, spontaneous synthesis of (Abst) 749
and T cell activation in HD (Abst) 751
binding onto dialysis membranes, *in-vivo* measurement of (Abst) 749
biochemical characterization 1106
dialysis-related amyloidosis, detection (Abst) 748
effect of acetate-free biofiltration (Abst) 749
elimination of with adsorbent column (Abst) 752
in ESRD 1106
in lymphocyte culture supernatant (Abst) 749
in-vitro synthesis (Abst) 748
intensive removal of with adsorbent column (Abst) 750
reduction of cystic radiolucencies by removal of (Abst) 751
synovial fluid examination and, in dialysis amyloidosis (Abst) 751
β_2-Microglobulin-related amyloidosis causing atlantoaxial spondylarthropathy (Abst) 751
Backdiffusion and backfiltration 333
Bacterial contamination 333
Bacterial growth 627
Barbiturates, diagnosis of brain death in presence of (Abst) 778
Bartter's syndrome 896
Basement membrane 191
Benazepril (Abst) 459
Benziodarone in CsA-induced hyperuricaemia (Abst) 777
Beta thalassaemia (Letter) 82
Bezafibrate 623
Bicarbonate powder and precipitation of calcium carbonate (Abst) 1157
Biocompatibility 333, 340
acetate-free biofiltration vs bicarbonate dialysis (Abst) 738
glucose polymer dialysis fluid for CAPD (Abst) 744
participation of leukotrienes B4 (Abst) 736
Bioelectric impedance analysis (Abst) 725
Biofiltration, acetate-free, β_2-microglobulin and (Abst) 749
without acetate vs HD with bicarbonate (Abst) 1060
Bioimpedance as measure of lean body mass and total body water in HD (Abst) 727
Biopsy, renal 472
district general hospital survey (Abst) 1156
renal transplant, expression of adhesion molecules (Abst) 783
Blood flow 29
Blood group 191
Blood pressure 379, 917
ambulatory 45
changes in ADPKD trait (Abst) 715
endothelin and (Letter) 176
modulation by autoreactive T cells in rats (Abst) 714
monitoring in HD patients (Abst) 167
spectral analysis of (Abst) 721
Blood transfusion
autologous (Letter) 366
donor-specific, in live donor renal transplantations (Abst) 780
Bone densimetry in haemodialysis (Letter) 369
Bone disease, aluminium-related, fluoride in (Abst) 760
Bone mineral density in HD and CAPD 835
Book Reviews 84, 172, 977, 1252
Bradykinin antagonist, effect on glycine response in rats (Abst) 658
Bradykinin generation in presence of ACE inhibitor (Abst) 728
Brain death, transcranial Doppler in diagnosis of (Abst) 778
Breakpoint analysis 379
Bronchiolitis obliterans 1043
Brown tumour 956
Brush border antigens, antibodies against 293
Buerger's disease, epidemiology (Abst) 687

C-peptide values in renal transplant recipients (Abst) 775
C_{1q} nephropathy 391
hypertension and 391
immunoproteins and 391
C_3 mesangial deposition, isolated (Abst) 667
C_{3d_g} and $C_{5b\text{-}9}$, clinical aspects in membranous nephropathy S1/32
$C_{3d_g}/C_{5b\text{-}9}$ excretion, relationship to clinical parameters (Abst) 1146
Cachexia on dialysis (Abst) 734
Calcitriol 829, 1207, (Abst) 971
influence on immune response to erythropoietin (Abst) 772
intermittent vs continuous (Abst) 762
Calcium, acetate (Abst) 165
carbonate 63, 632, 1219, (Abst) 165
ion 121
uptake and glucose concentrations (Abst) 1147
low, in CAPD (Abst) 759
parathyroid response to 829
reduction in CAPD (Letter) 979
set point 822
stone formers, influence of diet on urinary risk in (Abst) 754
cAMP, extracellular, phosphaturic effects of (Abst) 659
Canadian Erythropoietin Study Group, The 811
Candida parapsilosis 967
CAPD (*see* Continuous ambulatory peritoneal dialysis)
Captopril 211
effect in organ transplantation 1130
Carcinoma, bladder 427
renal 265
transitional cell 1136
urothelial 427
Cardiac arrhythmias 318
Cardiac function, amelioration of by L-carnitine (Abst) 166
Cardiac mass, effects of dialysis on (Abst) 722
Cardiovascular disease, cause of death in ARF 230
mortality from in CRF (Abst) 705
Cardiovascular instability (Letter) 453
Cardiovascular reflex tests 1022
Cardiovascular risk after insulin resistance study in hypertension (Abst) 717
Catabolism 117
Cataract in chronic renal failure (Letter) 1162
Catheters, endoscopic placement of in CAPD 855
jugular and femoral routes in HD (Abst) 723
jugular vein, for permanent dialysis access (Abst) 741
jugular, treatment of sepsis (Abst) 739
percutaneous, PermCath (Abst) 737
silver device to prevent infections in peritoneal dialysis (Abst) 744
Tenckhoff 79
CAVHP (*see* Continuous arteriovenous haemoperfusion)
CCPD: benefits and drawbacks versus CAPD (Abst) 746
CD4+ T lymphocytes in allogeneic responses, interferon-η and (Abst) 1145

Cell surface marker expression in HD (Abst) 723
Cellulose acetate 340
Cellulose triacetate 340
Cellulosic membranes 340
Central venous catheterization, new Doppler probe (Abst) 721
Cerebral death, diagnosis of in potential organ donors (Abst) 1062
Cerebrovascular accidents 433
CGN (*see* Chronic glomerulonephritis)
Children with CRF, motor and cognitive development in (Abst) 167
Children with urinary tract infection, faecal loading (Abst) 553
Cholecystosonography 840
Cholelithiasis, prevalence of in dialysis patients (Abst) 720
Cholesterol, and albumin in primary glomerular disease (Abst) 697
  effect on unilaterally nephrectomized rats (Abst) 555
  for myocardial infarction in dialysed diabetics (Abst) 690
Chronic alcohol abuse, tubular dysfunction in (Abst) 685
Chronic cisplatin nephropathy in rats (Abst) 702
Chronic dialysis 613
Chronic glomerulonephritis 379
Chronic haemodialysis 541, 939, 1013
Chronic renal failure 246, 300, 379, 623, 956, 986, 1098, (Letter) 368, (Abst) 971
  1,25$(OH)_2$D3 receptors in (Abst) 761
  ACE inhibition as antihypertensive therapy in (Abst) 1152
  adynamic bone disease in (Abst) 755
  age and thyroid abnormalities in dialysis patients (Abst) 708
  aluminium in (Abst) 972
  ANP–VIP relationship (Abst) 682
  antihypertensive therapy in (Abst) 717
  blood pressure and (Abst) 710, 712
  bone reporption in (Abst) 760
  calcitriol for the treatment of renal osteodystrophy (Abst) 761
  calcium–PTH set point in (Abst) 754
  cardiovascular disease in (Abst) 705
  comparative cardiovascular mortality (Abst) 1156
  compliance with low-protein diets (Abst) 707
  correction of metabolic acidosis (Abst) 1149
  diagnosis of *Helicobacter pylori* in (Abst) 709
  dietary phosphorus restriction and (Abst) 756
  dietary proteins and (Abst) 705
  ECG findings with erythropoietin (Abst) 771
  effect of erythropoietin in highly sensitized patients (Abst) 771
  effect of parathyroidectomy (Abst) 756
  evolution of 2-3 diphosphoglycerate after erythropoietin treatment (Abst) 772
  fetal antigen 2 and 902
  hypertension and 379
  in Asians (Abst) 553
  in rats, exercise and (Abst) 710
  incidence in Glasgow (Abst) 462
  intestinal Ca transport in rats (Abst) 761
  iron status in (Abst) 972
  metabolic acidosis in (Abst) 459
  modifications of RBC nucleotides after erythropoietin (Abst) 772
  motor and cognitive development in (Abst) 167
  natural history of 379
  neutral endopeptidase inhibition in (Abst) 1153
  plasma thrombocytopoietin in HD patients treated with erythropoietin (Abst) 774
  plasma TNF soluble receptors in (Abst) 705
  progressive (Abst) 459
  quality of life in (Abst) 707
  rates of progression 379
  reduced DNA repair in (Abst) 663
  renal tubular protein degradation and urinary ammonia in (Abst) 1153
  retrospective study 379
  s.c. erythropoietin: frequency of administration (Abst) 771
  volume overload (Abst) 549
Chronic renal insufficiency 8
  pattern of referral (Abst) 462
Chronic tubulointerstitial nephropathy 379
Chronic tunnel infection (Abst) 169
Chronobiological (Cosinor) evaluation of arterial pressure in HD (Abst) 1066
Chronobiology techniques in hypertension (Abst) 1065
Cimetidine as filtration marker (Abst) 657
Ciprofloxacin 848
Cirrhosis, aprotinin improves renal function in (Abst) 692
  of the liver, and insulin-like growth factor I in rats (Abst) 658
Cisplatin 1
Citrate anticoagulation, regional (Abst) 168
Classification, diabetes mellitus 181
  histological 472
Clearance, lithium 493
  solute 29
CMV (*see* Cytomegalovirus)
Colchicine in the nephrotic syndrome (Abst) 696
Compensatory renal growth, effect of L-nitroarginine on 1185
Complement 35
  typing 587
Complications, late, in renal transplant (Abst) 1061
Congestion, medullary 1
  vascular 1
Congestive heart failure 306
Contamination, bacterial 333
Continuous ambulatory peritoneal dialysis 57, 63, 79, 279, 433, 526, 618, 627, 632, 1194, (Abst) 165, 462, 550
  0.6 mM calcium dialysate in (Abst) 753
  1,25$(OH)_2$D3 potentiates effect of erythropoietin (Abst) 766
  ^{131}I β_2-microglobulin scan for amyloid (Abst) 752
  adequacy of long-term (Abst) 742
  adynamic bone characteristics in (Abst) 1144
  analysis of peritoneal permeability in (Abst) 171
  and body composition, infrared reactance and (Abst) 746
  anterior abdominal wall leaks in 1030
  apolipoproteins in 1026
  biocompatibility of new glucose polymer dialysis fluid (Abst) 744
  bone densities in 835
  catheter removal and replacement in one operation (Abst) 169
  characteristics of adynamic bone in (Abst) 759
  clinical assessment and kinetic modelling (Abst) 744
  control of phosphate in (Abst) 759
  dialysate calcium reduction in (Letter) 979
  dialysis adequacy and nutritional status (Abst) 743
  effect of erythropoietin-induced haemopoiesis (Abst) 769
  effect of transcapillary ultrafiltration (Abst) 743
  effects of s.c. calcitriol on PTH in uraemia (Abst) 762
  elimination of exit-site infections (Abst) 1149
  elimination of *Staph. aureus* exit site infections (Abst) 745
  encephalopathy and 1213
  endoscopic placement of catheters 855
  evaluation of adequacy (Abst) 744
  fluid, catalyses fluorescent protein formation (Abst) 744
  fluid, inhibition of neutrophil function (Abst) 745
  hyaluronic acid and (Abst) 747
  in elderly patients (Abst) 746
  interleukin-6 in (Abst) 171
  long-term, peritoneal function in (Abst) 743
  low dialysate calcium and oral calcium carbonate in (Abst) 759
  low-calcium dialysate in (Abst) 764
  low-calcium dialysis fluid in 1219
  P_{50} in uraemic patients on (Letter) 1071
  peritoneal equilibration test in children (Abst) 745
  peritoneography in 1035
  peritonitis 133
  peritonitis and 967, (Abst) 747

Continuous ambulatory peritoneal dialysis (*continued*)
peritonitis, intraperitoneal free elastase in (Abst) 1148
poor drains of dialysate fluid in 1030
prostaglandins and peritoneal permeability (Abst) 747
RBC IgG in (Abst) 673
reduction of dialysate calcium (Abst) 1143
silver device to prevent catheter infections (Abst) 744
Staph. epidermidis during (Abst) 554
Staph. epidermidis vaccination (Abst) 742
tuberculous peritonitis in 443
ultrasonography of Tenckhoff catheter course (Abst) 745
UV-Flash® germicidal exchange device (Abst) 742
versus CCPD (Abst) 746
versus HD in HIV carriers (Abst) 1060
Continuous arteriovenous haemodiafiltration, estimation of drug clearance (Abst) 170
Continuous arteriovenous haemoperfusion, for paraquat poisoning 875
Continuous venous–venous HD and continuous venous–venous HF (Abst) 730
Contrast media, and the isolated rat kidney (Abst) 1149
renal effects of (Abst) 700
Convective transport 50
Coronary artery bypass in dialysis patients (Abst) 688
Coronary artery disease, in diabetic patients with ESRD 707
Coronary heart disease 597
Cosinor (chronobiological) evaluation of arterial pressure in HD (Abst) 1066
Creatine metabolism (Abst) 550
Creatine phosphokinase 965
Creatinine, excretion and filtration fraction in renal failure (Abst) 659
limitation of during cimetidine administration (Abst) 657
Creatinine clearance, in nephrotic syndrome 406
influence of protein intake (Abst) 657
Cremophore responsible for CsA-induced endothelial injury (Abst) 1160
CRF (*see* Chronic renal failure)
Crohn's disease 960
Cryoglobulinaemia, kinetics and fate of cryoglobulins (Abst) 677
plasma exchange and methylprednisolone in (Abst) 692
Cryptogenic organizing pneumonitis and mesangiocapillary glomerulonephritis 1043
CsA (*see* Cyclosporin A)
CTIN (*see* Chronic tubulointerstitial nephropathy)
Cuprammonium rayon 844
Cuprophan 340
Cyclophosphamide in idiopathic membranous nephropathy (Abst) 689
Cyclosporin A 69, 251, 267, 346, 427, 636, (Letter) 455
action on proximal tubules in the pig (Abst) 704
acute arteriolopathy and 791
altered renal haemodynamics with 791
and endothelin synthesis (Abst) 1147
and hypomagnesaemia (Letter) 1257
antiproteinuric effect in rat adriamycin nephropathy (Abst) 671
antiproteinuric and immunological effects S1/80
chronic nephropathy and 791
delayed renal allograft function and 791
endothelial injury, cremophore responsible (Abst) 1160
endothelin and 791
excess adrenergic nerve stimulation and 791
excess renin–angiotensin system activity and 791
glomerular filtration and tubular reabsorption (Abst) 703
glomerular permeability changes 791
in glomerular diseases S1/80
in idiopathic nephrotic syndrome (Abst) 688
in SLE with severe nephropathy (Abst) 686
in treatment of adult nephrotic syndrome (Abst) 1065
increased risk of malignancy with (Abst) 781
induces decrease in cellular potassium uptake (Abst) 777
intrinsic vasoconstrictor activity and 791
low-dose, detection of kidney dysfunction after (Abst) 658
nephrotoxicity, animal studies in 791
calcium channel blockers and 791
effect of felodipine on 1124
not ameliorated by nifedipine (Abst) 781
pathophysiology of 791
with idiopathic uveitis (Abst) 699
overdose (Letter) 272
prostaglandins and 791
reversible renal functional impairment and 791
toxicity, reduced endothelin immunostaining in (Abst) 781
tubular toxicity and 791
Cyclosporin-induced hyperuricaemia, benziodarone in treatment of (Abst) 777
Cystic diseaseof the kidney, acquired, natural hisory 613
Cystine urolithiasis, treatment and prevention (Abst) 691
Cystinuria, analysis (Abst) 694
Cytokines 16, 147
effect of dialyser membranes on production of (Abst) 727
gene expression in renal allograft rejection (Abst) 786
increase fibronectin synthesis in cultured mesangial cells (Abst) 663
production from mononuclear cells in HD, effect of membranes on (Abst) 727
production induced by OKT3 (Abst) 778
Cytomegalovirus 350, (Abst) 463
detection of on peripheral polymorphonuclear cells (Abst) 777
in acyclovir-treated renal transplant recipients (Abst) 782
in rejected kidney grafts 865
in renal transplants 776, (Abst) 782
localization in glomerular cells of renal allograft recipients (Abst) 778
Cytosolic autoantigens (Abst) 547

D-penicillamine therapy 161
DDAVP (*see* Desmopressin)
Death, causes of 908
Decubitus perforation 79
Delayed antilymphocyte globulin adverse rections (Letter) 559
Densitometry, in diagnosis of osteopathy in CRF (Abst) 1055
osseous, in hyperparathyroidism (Abst) 1062
Deproteinization of uraemic serum (Abst) 971
Desferrioxamine 931
effect on osteoblast proliferation (Abst) 763
in porphyria cutanea tarda 438
toxicity 438
Desferrioxamine (Letter) 366, (Abst) 461
and rHuEpo (Abst) 1057
Desmopressin in uraemia (Abst) 704
Dextran antibodies 35
DFO (*see* Desferrioxamine)
DHPG (*see* Ganciclovir)
Diabetes, misclassification rate 1092
Diabetes mellitus 181, (Abst) 550
and HD, cholesterol for myocardial infarction in (Abst) 690
and uraemia (Letter) 654
epidemiology 181
histomorphometric bone patterns in uraemic patients on dialysis (Abst) 756
historical perspective 181
hypertension and 889
improving outcome of dialysis in (Abst) 736
in France 1092
increased morbidity and mortality after transplantation 433
insulin-dependent, SPECT in 1085
juvenile 889
morbidity and mortality 433
nephropathy and (Abst) 548
non-diabetic renal pathology and (Letter) 1258
post-transplant 346, 1039
renal function in young people 487
sodium retention in (Abst) 680
type I 105, 397

Diabetes mellitus (continued)
type II 397, (Abst) 456
histology 397
increased risk of renal disease (Abst) 697
Diabetic glomerulonephropathy, renal biopsy and 397
Diabetic ketoacidosis 346
Diabetic nephropathy 105, 181, 433
apolipoprotein B gene polymorphism in (Abst) 663
cell biology and 889
EGF, EGF-R, and IGF-1R in (Abst) 690
endothelial dysfunction and oxidant injury (Abst) 698
experimental, epidermal growth factor in (Abst) 666
IGF-I in (Abst) 663
high hydrocarbon exposure and (Abst) 698, 1157
hyperlipidaemia and (Abst) 710
oxidant injury and (Abst) 1146
and tubular damage in (Abst) 704
renal biopsy and (Abst) 1065
Diabetic neuropathy 433
Diabetic renal disease and renal artery stenosis (Abst) 684
Diabetic retinopathy 433
Diabetic vasculopathy 433
Diagnosis 191, 211, 479
Dialysate 333
Dialysate calcium 822
Dialyser clearance 1007
Dialysis 35, 235, 573, 579, 908, (Abst) 549
α_2-macroglobulin levels increase in 748
age and CRF in thyroid abnormalities (Abst) 708
ageing population, nephroangiosclerosis and (Abst) 735
and coronary artery bypass surgery (Abst) 688
antibodies to hepatitis C virus in (Abst) 724
aspirin and erythropoietin in (Abst) 554
cachexia on (Abst) 734
chronic 613
cuprophane, downregulates CD3− CD8+ cells (Abst) 671
effect of age on protein catabolic rate, morbidity , and mortality (Abst) 731
effects on left ventricular filling (Abst) 727
efficiency (Abst) 165
estimation of soft-tissue calcification by scintigraphy (Abst) 753
fistula dynamics and erythropoietin (Abst) 171
heparin and contact phase in (Abst) 736
high-flux, adsorption of exogenous pyrogens (Abst) 729
high-flux, kinetic modelling and (Abst) 1161
improving outcome of diabetic patients on (Abst) 736
in infants 1171
in the elderly (Abst) 708
maintenance, anti-HCV reactivity in (Abst) 720
HIV infection and 730
vascular complications with erythropoietin (Abst) 770
membranes, effect on production of TNFα and IL-6 (Abst) 727
pore size 333
nutrition in (Abst) 724
nutritional status, bioelectric impedance and anthropometry (Abst) 740
over the age of eighty (Abst) 708
paired filtration 1007
panel reactive cytotoxic antibodies in patients on erythropoietin (Abst) 785
parameters for estimation of dry weight (Abst) 735
pathogenesis of impaired salivary function (Abst) 735
patients, hepatitis C in 1226
prevalence of cholelithiasis in (Abst) 720
peritoneal 443
population, modifications in (Abst) 734
prevalence of low bone turnover in (Abst) 756
quantification and urea kinetics 1007
s.c. erythropoietin in (Abst) 773
serum aluminium and iron depletion (Letter) 177
thalassaemia in (Letter) 82
trace metals and adynamic bone disease (Abst) 757
Dialysis-induced hypotension, prediction of (Abst) 738
DIC (*see* Disseminated intravascular coagulation) (Letter)
Diethylenetriaminepenta-acetate (DTPA) 205, 211
Diffusion 50
Diltiazem and acute tubular necrosis (Abst) 1061
Disabilities 573
Disseminated intravascular coagulation (Letter) 272
Diuretic abuse 896
Donor-specific antibodies (Abst) 552
Dopamine, in rat kidney, influence of monoamine oxidase (Abst) 660
regulation of phosphate excretion in the rat by (Abst) 657
Doppler duplex colour in diagnosis of pseudoaneurysm (Abst) 1056
Doppler, transcranial, in diagnosis of cerebral death (Abst) 1062
Dose finding 931
Downregulation of β-adrenoreceptors in rat kidney (Abst) 659
DRβ RFLP analysis (Abst) 784
DTPA (*see* Diethylenetriaminepenta-acetate)
Dual-energy X-ray absorptiometry 835
Dyslipidaemic changes on low-salt diet, attenuation by α-blockade (Abst) 715

E. coli 0157 gastroenteritis and acute renal failure (Abst) 458
EBV (*see* Epstein–Barr virus)
Echography in haemodialysis (Abst) 973
EDTA (*see* Ethylenediaminetetra-acetate)
EDTA Registry Report 279
Effective renal plasma flow, effects of enalapril and verapamil on (Abst) 777
Elderly adults, renal biopsy in (Abst) 690
Elderly patients
dialysis modalities in ESRD (Abst) 737
GFR in (Abst) 659
on CAPD (Abst) 746
cachexia on dialysis and (Abst) 734
high-flux HD in (Abst) 723
periodic haemodialysis in (Abst) 724
Electrolyte changes during haemodialysis 318
Electron spin resonance spectroscopy, oxidizing activity and (Abst) 1148
Embolization, renal arterial, renal recovery after 1047
Employment 579
Enalapril 267
angiotensin II and 991
Apo(A) and cholesterol in nephrotic syndrome (Abst) 697
Enalaprilat 400
Encephalopathy in chronic haemodialysis and CAPD 1213
End-stage renal disease 181, 311, 479, 840, 924, 944, 1194, (Letter) 272, 366
β_2-M in 1106
coronary artery disease in diabetics with (Abst) 707
dialysis modalities in elderly patients (Abst) 737
historical perspective 181
hyperparathyroidism in 1098
in sickle-cell anaemia 817
increase of pancreatitis in (Abst) 460
provision of services for adult patients (Abst) 1156
safety profile of erythropoietin (Abst) 773
End-stage renal failure 855
cytometric analysis of platelets in (Abst) 707
diabete mellitus in 1092
dialysis in the elderly (Abst) 708
effects of HD on cytosolic calcium homeostasis (Abst) 758
in infants 1171
Endopeptidase
and captopril, effect on renal function (Abst) 680
inhibition (Abst) 548
urinary (Abst) 970
Endothelial cells, antibodies in animal model of systemic vasculitis (Abst) 675
antigens 805
cultured, monocyte adhesion to (Abst) 670
platelet binding to (Abst) 675

Endothelial-derived relaxation factor in glycerol ARF in rats (Abst) 701
Endothelin 288
a potent vasoconstrictor (Abst) 682
an activator of plasmatic coagulation (Abst) 682
and arterial pressure in glomerulonephritis (Abst) 716
concentration in nephropathia epidemica (Abst) 700
effect of renal ischaemia on (Abst) 1154
immunoreactive, in uraemia (Letter) 176
immunostaining, reduced in CsA toxicity (Abst) 781
in chronic renal failure 300
receptors 288
stimulates PMN adhesion (Abst) 674
synthesis and CsA (Abst) 1147
urinary, in IgA nephropathy (Abst) 695
Endothelin-1, stimulation by AV fistula 1019
Endothelium 1077
Endotoxaemia, and ARDS (Abst) 1157
and ARF (Abst) 1157
Endotoxins 16, 333
in high-flux dialysis (Letter) 884
penetration, direct detection of during haemodialysis (Abst) 741
Energy and nitrogen balances in haemodialysis (Abst) 719
Epidemiology 181, 1092
of renal disease, changing, in France (Abst) 698
Epidermal growth factor (Abst) 547
and diabetic nephropathy (Abst) 1146
in experimental diabetic nephropathy (Abst) 666
receptor, immunohistochemical expression (Abst) 664
Epiphyseal microfractures after renal transplantation (Abst) 776, 976
Epithelial cells 288
influence of L-methionine on bacterial adhesion (Abst) 662
Epithelial proteins, modulation of vasopressin-stimulated water flow (Abst) 682
Epo (*see* Erythropoietin)
Epstein–Barr virus 360
reactivation in renal transplant patients (Abst) 776
Erectile dysfunction in nephrotic syndrome (Letter) 1073
Ergotamine intoxication, chronic 879
ERPF (*see* Effective renal plasma flow)
Erythrocyte, magnesium 251
sodium–lithium countertransport (Abst) 456
Erythrocytosis 137
post-transplant, in cadaver kidney recipients (Abst) 779
Erythrocytosis (Letter) 365
after renal transplant (Abst) 1061
and nephrocalcinosis (Letter) 1071
Erythroid burst forming units 311
Erythroid progenitors 311
Erythrokinetics 1052
Erythropoiesis 40
Erythropoietin 40, 45, 121, 125, 143, 221, 235, 240, 311, (Letter) 82, 271, 366, 652
(*see also* Recombinant human erythropoietin)
2,3-diphosphoglycerate and (Abst) 767
and male sex hormones 137
and peripheral microcirculation (Abst) 461
and postoperative transfusion haemolysis (Letter) 559
and quality of life in elderly patients on HD (Abst) 770
and rat vascular smooth musle cells (Abst) 765
and uraemic pruritus (Abst) 767
and vascular complications in HD (Abst) 770
blood coagulation in HD patients (Abst) 773
blood pressure, and intracellular calcium in hypertension (Abst) 718
cardiac alterations in uraemia reversed with (Abst) 771
cardiovascular changes (Abst) 461
dialysis fistula dynamics and (Abst) 171
dose efficiency in dialysis-associated anaemia (Abst) 1158
dose reduction 526
ECG findings in CRF (Abst) 771
effect in highly sensitized CRF patients (Abst) 771
effect of on fibrinolysis inhibitors in uraemia (Abst) 772
effect on erythropoiesis 817
effect on uraemic brain (Abst) 767
effects on macrocirculation in HD (Abst) 170
effects on skin microcirculation in HD (Abst) 170
effects potentiated by 1,25$(OH)_2$D3 in CAPD patients (Abst) 766
erythrocyte zinc protoporphyrin and (Abst) 766
evolution of 2-3 diphosphoglycerate after treatment in CRF (Abst) 772
hypertension induced by (Abst) 774
impairs glucose tolerance in HD (Abst) 766
in iron-overloaded CAPD patients, increased PTH and (Abst) 754
in renal anaemia (Abst) 768
in renal failure and sickle-cell disease (Abst) 765
influence of calcitriol on immune response to (Abst) 772
intravenous vs subcutaneous 526
long-term effects 811
low-dose s.c. in CAPD, in renal anaemia (Abst) 765
low-dose, treatment of anaemia with (Letter) 559
measurement in renal artery stenosis 400
mode and frequency of administration (Abst) 771
modifications of RBC nucleotides after treatment, in CRF (Abst) 772
myocardial perfusion in treatment of renal anaemia with (Abst) 769
oxygen-sensing control of synthesis (Abst) 1154
panel reactive cytotoxic antibodies in dialysis patients on (Abst) 785
peripheral blood flow with (Abst) 554
phagocytosis with (Abst) 972
recombinant human, intravenous vs subcutaneous 129
reduction of fibrinolytic activity in HD patients treated with (Abst) 769
renal venous, in hypertensive patients (Abst) 717
concentrations in hypertension 1190
response and hippuric acid accumulation (Abst) 768
response in haemodialysis 939
s.c. in dialysis patients (Abst) 773
s.c. in predialysis uraemic patients (Abst) 765
safety profile in ESRD (Abst) 773
serotonin involved in effect of (Abst) 770
serum, measurement of (Letter) 367
reduced, in renal artery stenosis after ACE inhibition (Abst) 767
stimulation by hypobaric hypoxia 1002
therapy, serum ferritin changes in (Letter) 1254
thrombin–antithrombin III complex during (Letter) 1072
withdrawal, prothrombotic effects in HD patients (Abst) 1158
treatment of haemodialysis-related porphyria cutanea tarda 438
Erythropoietin gene, oxygen-regulated control element (Abst) 1155
Erythropoietin-induced hypertension, serotonergic mechanism of (Letter) 882
ESRD (*see* End-stage renal disease)
Ethanol injection 412
Ethylenediaminetetra-acetate (EDTA) 205
Excretion, sodium 493
Exogenous pyrogens, adsorption onto high-flux dialysers (Abst) 729
Extracellular fluid volume 205

Faecal loading in children with urinary tract infection (Abst) 553
Familial lecithin cholesterol acyltransferase deficiency (Abst) 698
Familial Mediterranean fever (Letter) 273
and renal transplantation (Abst) 782
Fatty acids, highly unsaturated, in chronic haemodialysis (Abst) 738
Fc receptor function in haemodialysis (Abst) 167

Felodipine 69
effect on CsA nephrotoxicity 1124
Ferric gluconate, intravenous, adverse reactions (Letter) 271
Ferrioxamine 931
Fetal antigen 2 902
Fibrin-related components, polarized secretion by glomerular epithelial cells (Abst) 665
Fibronectin (Abst) 457, 970
modifies TNF in proliferative GN (Abst) 676
synthesis (Abst) 456
increased by cytokines (Abst) 663
sodium, and potassium in essential hypertension (Abst) 719
Fibrosis, interstitial 1124
Filtration fraction and creatinine excretion in renal failure (Abst) 659
Filtration markers 205
Fistula obstruction, anticardiolipin antibodies and (Abst) 733
Fistulae, arteriovenous (Brescia–Cimino), in diabetic and elderly patients (Abst) 728
Fluorescence measurement of ADH (Abst) 974
Fluoride in aluminium-related bone disease (Abst) 760
Fluorophores, protein-derived, stimulated in PD fluid (Abst) 1160
Fragmentation, red-cell 965
Frusemide 8
Fucose or fucose-like residues on cellulose dialyser membranes (Abst) 726
Fx1A antigens, antibodies against 293

Gallbladder motility 840
Ganciclovir (DHPG) 350
Garland pattern 155
Gastrin 840
Gene polymorphism 200
in IgA nephropathy (Letter) 1256
in membranous nephropathy S1/42
Gene transfer (Abst) 545
Genetics 563, 587
Gentamicin causing proteinuria in rats (Letter) 653
Gestation in CRF (Abst) 1063
GFR (*see* Glomerular filtration rate)
Glomerular basement membrane, degradation by GBM-stimulated neutrophils (Abst) 671
thinning 191
Glomerular changes in renal allografts S1/114
Glomerular disease 472, 501
cationic gold-stained polyanion in (Abst) 673
primary, albumin, cholesterol and (Abst) 697
Glomerular epithelial cell injury, differential markers (Abst) 662
Glomerular epithelial cells, polarized secretion of fibrin-related components by (Abst) 665
Glomerular filtration rate 93, 493, 501, (Abst) 459, 548
and Cockroft–Gault clearance in the elderly (Abst) 659
and renal plasma flow (Abst) 710
extracellular fluid volume and 205
Glomerular hyperfiltration 216
diet-induced, β-blockers and (Abst) 711
Glomerular mesangial cells ingest human neutrophils (Abst) 556
Glomerular nitrite synthesis in glomerulonephritis (Abst) 661
Glomerulonephritis 93, 384, (Letter) 558, (Abst) 556
anticardiolipin antibodies in (Letter) 1256
C_{1q} in 391
crescentic (Abst) 457
interleukin-1β mRNA localization (Abst) 674
interleukin-2 receptor mRNA and (Abst) 674
endothelin and arterial pressure in (Abst) 716
familial 587
glomerular nitrite synthesis in (Abst) 661
hepatitis, chronic infection in (Abst) 693
hereditary 1082
idiopathic crescentic 1077
IgA 952
incidence of various types in France (Abst) 689
induced by human cryoglobulins in mice (Abst) 672
lupus, and i.v. immunoglobulin G (Abst) 683
membranoproliferative (*see also* Membranoproliferative glomerulonephritis)
treatment vs no treatment (Abst) 687
type II and eye lesions (Abst) 685
virtual disappearance in France (Abst) 689
membranous
and haplotype DR3–DQ2–DQA2 (Abst) 683
and i.v. immunoglobulin G (Abst) 683
mesangial immune complex deposits and (Abst) 1156
mesangial immune deposits and (Abst) 670
outcome in the elderly (Abst) 696
predicting progression in S1/48
pregnancy in S1/60
retrospective study (Abst) 694
secondary S1/64
mesangial proliferative
Iga vs non-IgA (Abst) 669
increased cytokine expression in (Abst) 672
mesangiocapillary, cryptogenic organizing pneumonitis and 1043
minimal-change 357
necrotizing, features (Abst) 677
parasitic infections and 507
postinfectious, in alcoholics (Abst) 692
poststreptococcal 155
ANP and endothelin in (Abst) 682
proliferative, fibronectin modifies TNF in (Abst) 676
rapidly progressive 161
an idiopathic subgroup? (Abst) 672
Glomerulonephropathy, diabetic, renal biopsy and 397
Glomerulopathies, antiphospholipid antibodies in (Abst) 695
Glomerulopathies, PMN leukocyte elastase and α_1 proteinase inhibitor (Abst) 690
Glomerulopathy, acute allograft (Abst) 778
HIV associated 87
idiopathic membranous, antiproteinuric drugs in S1/91
Glomerulosclerosis 602
ageing-related, in rats (Abst) 711
diabetic, without diabetes mellitus 642
experimental, role for fibronectin (Abst) 661
focal segmental 391, 1047, (Abst) 973
in rats, enalapril and lovastatin in (Abst) 712
nodular 642
recurrent focal, plasmapheresis reducing proteinuria in (Abst) 775
Glomerulus 191, 288
Glucose concentrations and calcium ion uptake (Abst) 1147
Glucose intolerance, effect of 1,25 $(OH)_2$ D3 on 1207
Glucose-induced protein kinase C activity (Abst) 1151
Glycerol acute renal failure in rats, endothelial-derived relaxation factor (Abst) 701
Glycine, response to, effect of bradykinin antagonist in rats (Abst) 658
Glycosaminoglycans in urolithiasis in rats (Abst) 754
gp 330 507
in Heymann nephritis S1/16
Graft function, renal 69
Graft rejection 143
Graft rupture, renal, treatment by high steroid dosage (Abst) 779
Granulomata in a renal transplant (Letter) 173
Growth factor expression in model of renal regeneration (Abst) 702
Growth factors 563
distribution of in rat kidney (Abst) 551
Growth hormone 246
in uraemic patients on HD (Letter) 1068
releasing factor 246
treatment in short children after transplantation 780

Haematuria, macroscopic 1139
Haemodiafiltration 275, 333
continuous arteriovenous 29
replacing CAPD (Letter) 453
Haemodialysis 16, 40, 110, 129, 246, 300, 333, 340, 526, 623, 829, 835, 840, 913, 956, 960, 965, 1022, 1194, 1207, (Letter) 366, 368, 369 (*see also* Dialysis)
2,3-diphosphoglycerate improves oxygen tissue supply with erythropoietin (Abst) 767
acetate, dl-lactate, and bicarbonate, animal study (Abst) 726
acid–base changes during 318
agranulocytosis from nafamostat mesilate (Letter) 980
anaphylactoid reactions during (Abst) 722
and anti-IL-6 autoantibodies (Abst) 739
and body composition, infrared reactance and (Abst) 746
and hypertension, influence of on vessel wall elasicity (Abst) 775
and macrophage Fc receptor function 618
and mesenteric ischaemia 541
and β_2-microglobulin levels (Abst) 752
ANP a marker for 'dry' weight? (Abst) 681
ANP influenced by vasopressin and noradrenaline (Abst) 681
antioxidant trace elements in (Abst) 724
atherosclerosis risk factors in (Abst) 722
β_2-M in 924
β_2-microglobulin, and T cell activation in (Abst) 751
in-vitro synthesis and (Abst) 748
bioelectrical impedance changes in children (Abst) 1144
bioimpedance as measure of lean body mass and total body water (Abst) 727
blood coagulation in patients on erythropoietin (Abst) 773
blood pressure control in (Abst) 721
Brescia–Cimino fistulae in diabetic and elderly patients (Abst) 728
Ca^{2+} the key trigger for neutrophil degranulation (Abst) 721
cardiovascular changes in (Abst) 461
cardiovascular resistance to ANP during volume expansion (Abst) 729
catheters, percutaneous transluminal repositioning of (Letter) 1162
central venous puncture with pulsed Doppler probe (Abst) 721
chronic 45, 117, 121, 125, 240, 279, 323, 327, 541, 939
α-tocopherol and β-carotene status in (Abst) 737
ADPKD and hepatic cysts (Abst) 731
AV fistula and endothelin-1 release 1019
bioelectric impedance analysis (Abst) 725
CVVHD vs CVVHF (Abst) 730
diminished allergic reaction (Abst) 735
encephalopathy and 1213
hypertriglyceridaemia and (Abst) 738
improvement of hyperparathyroidism by i.v. alfacalcidol (Abst) 762
low Ca^{2+} and i.v. 1α(OH)D3 in (Abst) 755
nutritional status in diabetic patients (Abst) 728
panel-reactive antibodies in 422
combined oral 24,25$(OH)_2$D3 and 1α(OH)D3 regulates PTH (Abst) 755
continuous arteriovenous 848
depressed phagocytosis (Abst) 971
dialysis membranes and PTH changes in (Abst) 753
direct detection of endotoxin penetration during (Abst) 741
echography in (Abst) 973
effect of AN69 and CU membranes on erythrocyte structure (Abst) 730
effect of calcitriol on evoked potentials in uraemia (Abst) 764
effect of membranes on cytokine production (Abst) 727
effect on brain natriuretic peptide (Abst) 549
effects on calcium homeostasis in ESRD (Abst) 758
effects on cardiac mass (Abst) 722
electrolyte changes during 318
endocavitary electrocardiography (Abst) 733
energy and nitrogen balances (Abst) 719
erythrocyte zinc protoporphyrin during erythropoietin therapy 766
erythropoietin, and quality of life (Abst) 770
for anaemia in 811
impairs glucose tolerance in (Abst) 766
evaluation of autonomic function (Abst) 721
febrile syndrome with non-functioning graft (Abst) 781
fibrillar particles in cytoplasm (Abst) 1055
fucose or fucose-like residues on cellulose membranes (Abst) 726
growth hormone in uraemic patients on (Letter) 1068
HCV infection in (Letter) 1259
hepatitis B surface antigen in ultrafiltrate (Abst) 732
hepatitis C virus prevalence (Abst) 725
high-flux 539
in elderly patients (Abst) 723
hyperkalaemia from nafamostat mesilate (Abst) 738
hyperparathyroidism control by oral calcitriol pulse therapy (Abst) 760
hypertension in, enalapril vs nifedipine (Abst) 1066
immunoglobulin deposition on RBCs (Abst) 726
inhibition of lymphocyte blast formation by furancarboxylic acid (Abst) 732
interdialytic period 917
intradialytic well-being (Abst) 733
iron overload in 931
KT/V and nPCR at a Japanese dialysis centre (Abst) 726
long-term, β_2-microglobulin causing spondylarthropathy in (Abst) 751
malignant hypertension and 541
microcirculatory blood flow with erythropoietin (Abst) 554
mobilization of Mac-1 (CR3) on monocytes and granulocytes (Abst) 740
modest increment in serum phosphate and (Abst) 758
mucormycosis 931
neoplasias in (Abst) 1056
normal DNA repair as opposed to reduced repair in CRF (Abst) 663
normal dose, effect of age on protein catabolic rate (Abst) 731
nosocomial HCV transmission (Abst) 740
nutritional status in (Abst) 723, 731
periodic, in elderly patients (Abst) 724
permanent access, PermCath catheters (Abst) 737
plasma thrombocytopoietin in CRF treated with erythropoietin (Abst) 774
platelet aggregation reduced with NO in (Abst) 1153
polyamide membranes, classical complement pathway and (Abst) 739
polyester–polymer alloy (PEPA) synthetic membrane (Abst) 739
procollagen type I as a parameter of bone metabolism (Abst) 757
prothrombotic effects of erythropoietin therapy and withdrawal (Abst) 1158
PTA vs stent implantation (Abst) 725
ranitidine reduced aluminium toxicity (Abst) 757
reactive oxygen species production in (Abst) 723
role of buffer and Na dialysate in plasma volume and vascular stability (Abst) 729
screening test for dialysis osteomalacia (Abst) 762
severe hypoxia during (Abst) 732
suppression of pituitary–adrenal axis in uraemia (Abst) 768
thirst and weight gain in patients (Abst) 741
thirst mediated by angiotensin II in (Abst) 725
transthyretin and protein intake in (Letter) 1069
vascular access (Abst) 1056
clotting and anticardiolipin antibodies (Abst) 733
vascular reactivity to noradrenaline and angiotensin II (Abst) 741
vasoactive agents during hypotension in (Abst) 733
venous catheters, jugular and femoral routes (Abst) 723
versus CAPD in HIV carriers (Abst) 1060

Haemodialysis (*continued*)
with bicarbonate versus biofiltration without acetate (Abst) 1060
with ESRD, erythropoietin and (Abst) 768
with haemorrhagic risk, various MW heparins and (Abst) 731
[^{125}I] P component, kinetics (Abst) 753
Haemodialysis patients, with chronic uraemia on erythropoietin therapy (Abst) 768
reduction of fibrinolytic activity with erythropoietin (Abst) 769
Haemodialysis recirculation, three-sample detection method an artefact (Abst) 1159
Haemodialysis unit, HCV transmission in (Letter) 981
Haemodialysis-related porphyria cutanea tarda, erythropoietin treatment of 438
Haemodynamic changes with rHuEpo 1199
Haemodynamics 306
acetate, dl-lactate, and bicarbonate in uraemic dogs (Abst) 726
renal 216, 602, (Abst) 548
effects of protein (Abst) 712
Haemofilter 844
Haemofiltration 924
anaphylactoid reactions during (Abst) 722
beneficial effect of on β_2-microglobulin not negated by HD (Abst) 752
Haemoglobin 379, (Letter) 82
and rHuEpo 1199
autologous 57
Haemolysis 965
fulminant anti-B autoimmune after group O kidney transplant (Abst) 786
Haemolytic–uraemic syndrome, after *E. coli* gastroenteritis (Abst) 458
and SLE (Abst) 1065
postinfectious (Abst) 1155
Haemoperfusion 875
Haemopoiesis, erythropoietin-induced (Abst) 769
Haemoptysis 161
Haemorrhage, cause of death in ARF 230
Haemorrhagic fever (Abst) 970
Hantavirus (Abst) 970
HBsAg (*see* Hepatitis B surface antigen)
HCV antibodies 1226
HD (*see* Haemodialysis)
Head injury, symptoms after, 260
Heart rate 45
Helicobacter pylori in CRF, diagnosis of (Abst) 709
Hemophan 340
Henoch–Schönlein purpura 534
and ANCA 1238
Heparin, and contact phase in dialysis (Abst) 736
various molecular weights in HD with haemorrhaguc risk (Abst) 731
Hepatitis B surface antigen (Abst) 167
in HD ultrafiltrate (Abst) 732
Hepatitis B vaccination and interferon-α_2 B in HD (Abst) 1060
Hepatitis B virus, DNA (Abst) 167
in glomerulonephritis (Abst) 693
Hepatitis C, antibodies in renal transplant recipients (Abst) 1062
in haemodialysis patients (Letter) 1259
incidence, patient isolation and (Letter) 1070
possible routes of transmission 1226
virus 274, 327, 913
in dialysis patients (Abst) 720
in kidney graft recipients (Letter) 1164
in renal transplantation (Abst) 778
incidence in a haemodialysis programme (Abst) 1058
infection, prevalence in HD patients (Abst) 725
nosocomial transmission (Abst) 740
prevalence of in a haemodialysis unit (Abst) 1058
RNA in chronic HD (Abst) 170
time factors and transmission (Abst) 1059
transmission (Letter) 981
transmission through haemodialysis monitors (Abst) 1058
Hepatitis C virus antibodies
importance of in haemodialysis (Abst) 1058
in a haemodialysis unit (Abst) 1057
prevalence of in haemodialysis (Abst) 1058
Hepatitis, non-A, non-B 913
Hexose monophosphate (Abst) 971
Heymann nephritis (see Nephritis, Heymann)
High-flux haemodialysis 539
membranes (Abst) 166
and hepatitis B virus DNA (Abst) 167
Hippuric acid accumulation and erythropoietin response (Abst) 768
Histology 472
Histology of late proteinuria in renal transplantation (Abst) 1060
HIV (*see* Human immunodeficiency virus)
HIV-associated glomerulopathy 87
HLA antibodies 944
HLA sensitization
prevention of (Letter) 366
HLA system 587
HLA-DRβ RFLP analysis (Abst) 784
Human hypertensive nephropathy 516
Human immunodeficiency virus, infection 87
asymptomatic, nephropathy with (Abst) 1067
outcome of HD patients with (Abst) 730
Human papillomavirus in transitional cell carcinoma (Abst) 678
Human peritoneal mesothelial cells synthesize interleukin-8 (Abst) 666
Human tubular cells, cultured 147
HUS (*see* Haemolytic–uraemic syndrome)
Hyaluronic acid and CAPD (Abst) 747
Hyaluronic acid: a marker of dialysis-associated arthropathy (Abst) 750
Hydrogen ion dynamics in kidney evaluation (Abst) 1064
Hydrothorax
aetiology (Abst) 165
due to CAPD (Abst) 165
Hyperaldosteronism, primary 647
Hypercalcaemia 63, 632
low-calcium dialysate in CAPD (Abst) 764
Hypercalcaemia, persistent, 0.6 mM calcium dialysate in CAPD and (Abst) 753
Hypercalciuria, and insulin resistance in essential hypertension (Abst) 718
idiopathic, bone mineral content in renal stone formers (Abst) 758
Hypercalciuric calcium stone formers, intracellular pH regulation in (Abst) 665
Hyperfiltration, reduced, after uninephrectomy in the dwarf rat (Abst) 657
Hyperglycaemia 642
Hyperimmune globulin (Abst) 463
Hyperkalaemia, nafamostat-mesilate-induced, mechanisms (Abst) 738
Hyperlipidaemia 93
after renal grafting (Abst) 774
haemodynamics, and nephrotic syndrome (Abst) 688
Hyperoxalaemia 960
Hyperparathyroidism 8, 40, 63, 829
1,25$(OH)_2$D3 pulse therapy in (Abst) 760
combined oral 24,25$(OH)_2$D3 and 1α(OH)D3 in (Abst) 755
improvement by i.v. alfacalcidol (Abst) 762
in children (Letter) 652
in ESRD 1098
intermittent vs continuous calcitriol (Abst) 762
reversed by dietary phosphorus restriction (Abst) 756
secondary 412, 956, (Letter) 1070
i.v. calcitriol in 822
inadequate ventricular hypertrophy in (Abst) 763

Hyperparathyroidism (*continued*)
oral calcitriol pulse therapy in (Abst) 760
suppression of PTH secretion by calcitriol (Abst) 763
symptoms and signs 412
Hyperphosphataemia 1219
Hypersensitivity reactions in haemodialysis (Abst) 728
Hypertension 45, 100, 125, 216, 251, 379, 516, 917, (Abst) 461
acute porphyria and 986
after anaemia treatments (Letter) 652
and CRF (Abst) 710
and erythropoietin (Letter) 652
and haemodialysis, influence of on vessel wall elasticity (Abst) 775
and kidney disease, renin–angiotensin system in (Abst) 667
arterial 1178
calcium blockers and (Abst) 714
childhood, detection and prevention (Abst) 550
chronic 986
chronobiology techniques in (Abst) 1065
erythropoietin concentrations in 1190
erythropoietin-induced (Abst) 718, 774
serotonergic mechanism of (Letter) 882
essential 1178
cardiovascular risk after insulin resistance study (Abst) 717
changes in phosphate and magnesium (Abst) 717
cytosolic free-sodium and (Abst) 719
fibronectin, sodium, and potassium in (Abst) 719
hypercalciuria and insulin resistance in (Abst) 718
pathophysiological basis for a treatment (Abst) 714
experimental (Abst) 718
glomerular capillary 889
in chronic renal failure (Abst) 459
in HD, enalapril vs nifedipine (Abst) 1066
in hospital staff (Abst) 1066
in renal artery stenosis 400
investigations in young patients (Abst) 715
malignant 541, (Letter) 270
mild, dietary salt and (Abst) 719
not a fatality in dialysis (Abst) 714
organ damage, renal hyperfiltration, and renin activitiy (Abst) 715
primary hyperparathyroidism and (Abst) 718
protein C deficiency presenting as (Abst) 713
renal non-modulation in Italian patients (Abst) 716
renal venous erythropoietin in (Abst) 717
renovascular 221, 1133
ACE inhibitor renography in (Abst) 718
angioplasty and 1178
secondary 1190
serotonin and, in uraemia (Letter) 980
Hypertensive nephrosclerosis (Abst) 458
Hypertrophy, left ventricular 216
of glomerular mesangial cells by prostaglandin (Abst) 556
Hyperuricaemia, CsA-induced, benziodarone in treatment of (Abst) 777
Hypobaric hypoxia, erythropoietin stimulation by 1002
Hypomagnesaemia and CsA (Letter) 1257
Hypophosphataemic rickets, new X-linked (Abst) 757
Hypotension, dialysis-induced, prediction of (Abst) 738
vasoactive agents during, in HD (Abst) 733
Hypothalamo–pituitary–adrenal axis (Abst) 459
Hypoxaemia 110
Hypoxia, and control of erythropoietin synthesis (Abst) 1154
hypobaric, erythropoietin stimulation by 1002
severe, during haemodialysis (Abst) 732

ICAM-1 (*see* Intercellular adhesion molecule-1)
IDDM (*see* Diabetes mellitus, insulin-dependent)
IgA, ANCA and Henoch–Schönlein purpura 1238
C_{1q} and 391
epidemiology (Abst) 687
glomerulonephritis 952
mesangial nephropathy, and neoplastic diseases (Abst) 687
nephritis, TMN and TGBM in (Abst) 693
nephropathy 534, 805, (Abst) 547, 548, 970
antimesangial cell antibodies detected by ELISA in (Abst) 676
cell membranes bound by IgA antibodies in (Abst) 676
characterization of MoAbs (Abst) 677
gene polymorphism in (Letter) 1256
genetics 200
IgA aggregates in (Abst) 668
IgA immune complexes and (Abst) 675
IL-4 and IL-6 in (Abst) 695
low-antigen diet in (Abst) 694
serology in children (Abst) 670
sodium–lithium countertransport in (Abst) 686
urinary endothelin in (Abst) 695
IgE, specific, detection of (Abst) 669
IgG, C_{1q} and 391
inhibits binding of antimyeloperoxidase antibodies (Abst) 676
nephropathy (Abst) 548
pooled human, and anti-MPO (Abst) 1145
IgM, C_{1q} and 391
IL-4 and IL-6 in IgA nephropathy (Abst) 695
Iliac artery dissection after renal transplantation 1242
Immune complexes 35
Immune regulation 147
Immunity, humoral, in CRF (Abst) 1063
Immunoadsorption, preliminary clinical experience (Abst) 668
Immunocytochemistry (Abst) 972
Immunogenetics 587
Immunoglobulin, anti-ETO on dialysis (Abst) 673
deposition on RBCs of HD patients (Abst) 726
Immunohistochemistry 147
Immunohistology (Abst) 547
Immunosuppression, chickenpox and (Letter) 272
Infants, renal replacement therapy in 1171
Infection, cause of death in ARF 230
exit site, in CAPD, elimination of *Staph. aureus* (Abst) 745
hepatitis C 327
HIV 87
opportunistic 87
prevention of (Letter) 366
tunnel, chronic (Abst) 169
Insulin 1207
Insulin-like growth factor I 40
effect on GFR and RPF in rats (Abst) 658
Intelligence quotient 240
Intercellular adhesion molecule-1, expression in renal allografts 147
Interdialytic blood pressure monitoring (Abst) 167
Interferon prophylaxis of CMV in transplant recipients 1230
Interferon-α_2 B and hepatitis B vaccination in HD (Abst) 1060
Interferon-η-treated human vascular endothelial cells (Abst) 1145
Interleukin 1 receptor antagonist, not synthesized by human mesangial cells 997
Interleukin 1α, synthesis by human mesangial cells 997
Interleukin 1β (Abst) 457
not synthesized by human mesangial cells 997
Interleukin-1 receptor antagonist inhibits chemotactic peptide 1 (Abst) 1148
Interleukin-1β and receptor antagonist in rat nephritis (Abst) 1150
Interleukin-2 (Abst) 1055
receptor (Abst) 1055
expression in chronic kidney allograft deterioration (Abst) 785
Interleukin-6 in CAPD (Abst) 171
Interleukin-8, synthesized by human peritoneal mesothelial cells (Abst) 666
Intermittent peritoneal dialysis, left ventricular function in CRF patients (Abst) 747

Interposition, circumferential mesangial, pathological significance 373
pathomorphogenesis 373
Interstitial pneumonitis 362
Intradialytic well-being (Abst) 733
Intraperitoneal dextran 70 (Abst) 168
Inulin infusion technique in ADPKD (Letter) 1254
IPD (*see* Intermittent peritoneal dialysis)
IQ (*see* Intelligence quotient)
Iron, cellular uptake, role of aluminium in (Abst) 460
Iron deficiency 129
in HD, treatment with i.v. iron dextran (Abst) 1057
Iron depletion, serum aluminium and (Letter) 177
Iron dextran, intravenous 35
Iron overload, hepatic (Letter) 366
Iron status assessment with or without erythropoietin therapy (Abst) 766
Islet transplantation in the pig (Abst) 679

Jugular–axillary bypass in subclavian vein stenosis (Abst) 1056
κ AL-amyloidosis (Letter) 881
K^+ channel blockade decreases prostaglandin synthesis (Abst) 682
Kallikrein, renal tissue 516
Kawasaki disease (Abst) 546
Ketoacidosis, diabetic 346
Ketoacids 117
Kidney 608
Kidney, allograft deterioration, chronic, IL2R expression in (Abst) 785
dysfunction, renal reserve detecting (Abst) 658
failure, acute, mycotoxin inhalation and (Abst) 699
transplantation (*see* Transplantation, renal)
volume 1085
Kimmelstiel–Wilson nodules, without diabetes mellitus 642
Kinetic modelling, b2-M 924
KT/V and nPCR at a Japanese dialysis centre (Abst) 726

L-arginine, and renal ischaemia (Abst) 700
metabolism by mesangial cells (Abst) 663
L-carnitine in haemodialysis (Abst) 166
L-methionine, influence on bacterial adhesion to epithelial cells (Abst) 662
L-nitroarginine methyl ester, effect on cGMP and kidney growth 1185
Laminin 507
Laparotomy 443
LDL-apheresis in steroid-resistant nephrotic syndromes (Abst) 693
Lead nephropathy in rats (Abst) 703
Left ventricular filling, effects of dialysis on (Abst) 727
Leishmaniasis, visceral, in renal transplant patients (Letter) 651
Letters 82, 173, 270, 365, 453, 558, 651, 881, 979, 1068, 1162, 1254
Leukocyte intracellular pH in uraemia and diabetes (Letter) 654
Leukocyte magnesium 251
Leukotrienes B4, biocompatibility and (Abst) 736
Light-chain deposition disease, and renal function (Abst) 694
Lipid concentrations in renal transplant patients 636
Lipoprotein (a) 623
concentrations in renal transplant patients 636
in patients with proteinuria 597
Lipoprotein (a), and heparin administration in dialysis (Abst) 729
in idiopathic membranous nephropathy S1/109
Lipoproteins, triglyceride-rich 623
Liposoluble vitamins in uraemic, dialysis, and transplant patients (Abst) 705
Lithium 69, 991
Lithium clearance 493, (Abst) 456
Liver 608
transplantation, glomerular abnormalities after (Abst) 687
Long-term haemodialysis (Abst) 722

Lovastatin 93
effects on lipoprotein in hyperlipidaemia (Abst) 691
Low protein diet in CRF, work capacity changes (Abst) 1158
Low-antigen diet in IgA nephropathy (Abst) 694
Low-calcium dialysis fluid 1219
Low-calcium peritoneal dialysis (Letter) 652
Low-dose erythropoietin at high altitude (Letter) 173
Low-molecular-weight proteins 844
Lupus anticoagulant 1194
Lupus nephritis, methylprednisolone and 15-deoxyspergualin and (Abst) 675
patient and disease outcome (Abst) 696
plasma-perfusion and (Abst) 683
platelet binding to endothelial cells in (Abst) 675
Lupus nephritis, AECA in, platelet binding and (Abst) 1145
Lupus nephropathy, anti-RNP/Sm and anti Ro/La (Abst) 691
Lymph flow 57
Lymphatic absorption, measurement in CAPD (Abst) 169
of intraperitoneal dextran 70 (Abst) 168
Lymphocytes (Letter) 558
Lymphoma, cerebral 360
Lymphoproliferative diseases 357, 360

Machine learning 472
Macroglobulinaemia, Waldenström's (Letter) 1165
Macromolecules and permeability of peritoneum (Abst) 168
Macrophage Fc receptor function, and haemodialysis 618
Macrophages, fibrillar particles in cytoplasm of in HD patients (Abst) 1055
Macroscopic haematuria 1139
Magnesium, 251
Malignant hypertension 541
Malignant melanoma, in paediatric renal allografts (Abst) 551
Mario Negri Institute, Clinical presentation 260
Mass transport 50
Mathematical modelling 50
Medullary damage, trimethylamine-n-oxide a marker of (Abst) 1150
Melanocytic naevi in paediatric renal transplants (Abst) 551
Membranes 924
cellulosic, biocompatibility 340
performance comparison 340
regenerated 340
cellulosic and non-cellulosic 16
dialysis, and PTH changes in HD (Abst) 753
in-vivo measurement of β_2-microglobulin binding onto (Abst) 749
permeability of 16
polyamide, classical complement pathway and (Abst) 739
polyester–polymer alloy, synthetic (Abst) 739
Membranoproliferative glomerulonephritis 373
Membranous glomerulonephritis
immune complex deposits and (Abst) 670
outcome in the elderly (Abst) 696
retrospective study (Abst) 694
Membranous nephropathy (*see* Nephropathy, membranous)
Mercury 225
Mesangial cell, division, inhibition by retinoic acid (Abst) 660
proliferation (Abst) 547
proteoglycans and (Abst) 666
Mesangial cells 288
antiproliferative effect of Trapidil on (Abst) 662
human, interleukin synthesis and 997
hypertrophy induced by angiotensin II (Abst) 664
metabolize L-arginine (Abst) 663
Mesangial interposition, circumferential, pathological significance 373
pathomorphogenesis 373
Mesangiolysis 373
circumferential 373
Mesenteric ischaemia 541
Metabolic acidosis (Abst) 459
renal growth and proteinuria in (Abst) 659, 1147
Metabolic alkalosis, acute, bicarbonate flux during (Abst) 657

Metabolism, bone, procollagen type I a parameter in haemodialysis (Abst) 757
Metanephros 563
Methylprednisolone, and plasma exchange in cryoglobulinaemia (Abst) 692
Microalbuminuria 216, 487
Microaneurysm 373
Microfractures, epiphyseal, after renal transplantation (Abst) 776
Microscopic polyarteritis 1077
Microscopic polyarteritis, ANCA testing in (Abst) 685
Microsomes, rat liver, peroxidation in experimental renal failure (Abst) 708
Minimal-change glomerulonephritis 357
Minimal-change nephropathy 265
  pathogenetic mechanisms (Abst) 668
Minimal-change nephrotic syndrome, histology 406
  in renal insufficiency 406
MN (*see* Nephropathy, membranous)
Modifications in dialysis population (Abst) 734
Modified low-density lipoproteins and glomerular mesangial cells (Abst) 1150
Monoamine oxidase, influence on dopamine in rat kidney (Abst) 660
Monoclonal antibodies (*see* Antibodies, monoclonal)
Monocyte adhesion to cultured endothelial cells (Abst) 670
Mononuclear phagocyte system 618
Mortality in renal replacement therapy 467
MPGN 373
MPO (*see* Myeloperoxidase)
Multiple myeloma 447
Muscle fibres in uraemia (Abst) 706
Myasthenia gravis (Letter) 455
Mycobacterium tuberculosis 443
Mycotoxin inhalation and acute kidney failure (Abst) 699
Myeloperoxidase 952, (Abst) 546, 547
Myeloperoxidase–antimyeloperoxidase interactions in vasculitis 1077
Myocardial changes in HD 1013

N-acetyl-β-D-glucosaminidase 487
Na^+,K^+ ATPase inhibitors (Abst) 550
Na^+/H^+ antiporter gene in human proximal tubular cells (Abst) 1159
Nafamostat mesilate: protease inhibition and (Abst) 738
NAG 487
Natural history of renal transplantation (Abst) 1062
Na–K–ATPase activity in rats (Abst) 662
Necrosis, avascular 1039
Neoplasia, after transplantation, types 447
  urothelial, complicating ACKD 1136
  in haemodialysis (Abst) 1056
Nephritis 696
  Heymann, a model of human membranous glomerulopathy S1/1
    active, DPP IV in S1/1
    and human membranous nephropathy S1/119
    immune deposit formation in S1/16
    passive, DPP IV in S1/1
    role of additional antigens S1/1
  interstitial, in sicca syndrome (Abst) 702
  nephrotoxic, modulation by TNF and IL-1β (Abst) 1151
    modulation of glomerular injury in by HR-IL6 (Abst) 1151
  SLE 1116
  tubulointerstitial, in nephropathia epidemica (Abst) 703
Nephroangiosclerosis reflecting an ageing dialysis population (Abst) 735
Nephrocalcinosis (Letter) 365
  and erythrocytosis (Letter) 1071
Nephrogenesis and renal disease 563
Nephrological referral in RRT 467
Nephropathia epidemica (Abst) 970
  endothelin concentration in (Abst) 700
  tubulointerstitial nephritis in (Abst) 703
Nephropathy 1085, (Abst) 456
  analgesic 384
    and renal transplantation 427
    changing pattern of renal failure (Abst) 708
    diagnosis 479
    in Belgium (Abst) 703
    without phenacetin or paracetamol (Abst) 703
  C_{1q} 391
  chronic, lead, in rats (Abst) 703
  cisplatin, chronic, in rats (Abst) 702
  diabetic 105, 181, 433, 642
    cell biology and 889
    EGF, EGF-R, and IGF-1R in (Abst) 690
    endothelial dysfunction and (Abst) 1146
      and oxidant injury (Abst) 698
    epidermal growth factor and (Abst) 1146
    high hydrocarbon exposure and (Abst) 698, 1157
    hyperlipidaemia and (Abst) 710
    oxidant and tubular injury precedes microalbuminuria in (Abst) 704
    renal biopsy and (Abst) 1065
  human hypertensive 516
  idiopathic membranous, cyclophosphamide in (Abst) 689
  IgA 534, 547, 805, (Abst) 548
    genetics 200
    growth factors and cytokines (Abst) 661
    IgA aggregates in (Abst) 668
    IgA immune complexes and (Abst) 675
    IL-4 and IL-6 in (Abst) 695
    low-antigen diet in (Abst) 694
    mesangial, epidemiology (Abst) 687
    serology in children (Abst) 670
    sodium–lithium countertransport in (Abst) 686
    urinary endothelin in (Abst) 695
  IgG (Abst) 548
  lupus, anti-RNP/Sm and anti-Ro/La (Abst) 691
  membranous 293
    allograft S1/114
    $C_{3dg}/C_{5b\text{-}9}$ excretion and (Abst) 1146
    clinical aspects of C_{3dg} and $C_{5b\text{-}9}$ S1/32
    clinical parameters (Abst) 674
    defining antigens in S1/21
    family studies S1/42
    future perspectives S1/119
    gene polymorphisms in S1/42
    HLA antigen in S1/42
    human, and Heyman nephritis S1/119
    idiopathic, lipoprotein (a) and S1/109
    idiopathic, remissions and relapses S1/85
    natural history, clinical course and morphological evolution S1/35
    remissions and relapses S1/85
    role of $C_{5b\text{-}9}$ in S1/25
    statistical aspects of survival S1/53
    treatment in SLE S1/97
    treatment S1/72
  minimal-change, pathogenetic mechanisms (Abst) 668
  psoriatic, role of metabolic changes in (Abst) 692
  thin-basement-membrane, haematuria and clot colic in 1139
  thin-membrane (Abst) 546
  in IgA nephritis (Abst) 693
    permselectivity in (Abst) 697
  with asymptomatic HIV (Abst) 1067
Nephrosclerosis, hypertensive, blood pressure control and renal function in (Abst) 1159
Nephrosis, adriamycin, evidence of immunological involvement (Abst) 668
Nephrotic syndrome 357, 391, 406, 597, 1047
  and ACE inhibition (Abst) 706
  C_{1q} deposits in 391
  colchicine in (Abst) 696
  creatinine clearance in 406
  cured by renal biopsy 265

Nephrotic syndrome (*continued*)
cyclosporin A in (Abst) 688
effects of hyperlipidaemia on renal haemodynamics in (Abst) 688
effects of lovastatin on lipoprotein (Abst) 691
enalapril and (Abst) 697
erectile dysfunction in (Letter) 1073
idiopathic, immunosuppression in (Abst) 686
minimal-change, in renal insufficiency 406
puromycin-induced, Na–K–ATPase activity (Abst) 662
steroid-resistant, LDL-apheresis in (Abst) 693
treatment with CsA (Abst) 1065
Nephrotoxicity
and contrast media (Abst) 700
CsA 1124
CsA, with idiopathic uveitis (Abst) 699
gentamicin-induced (Abst) 973
growth factors in (Abst) 973
non-ionic radiological contrast and (Abst) 1064
Nephrotoxicity (Abst) 970
Nephrotoxicity, CsA, not ameliorated by nifedipine (Abst) 781
Neurological development in children with CRF (Abst) 167
Neurological disease, cause of death in ARF 230
Neuropathy, peripheral 539
Neuropsychology 1213
Neutrophil-derived reactive oxygen species (Abst) 1151
Nitric oxide synthase inhibition, effect on compensatory renal growth in rats (Abst) 555
NMR (*see* Nuclear magnetic resonance)
Non-Hodgkin lymphoma, progressive systemic sclerosis and (Letter) 1166
Noradrenaline and angiotensin II, vascular reactivity to in HD (Abst) 741
Norepinephrine (*see* Noradrenaline)
Nuclear magnetic resonance, spectroscopy, high-resolution (Abst) 545
study in chronic renal failure (Abst) 706
Nutrition, in dialysis patients (Abst) 724
Nutritional status (Abst) 462
and dialysis adequacy in CAPD (Abst) 743
in dialysis patients by bioelectric impedance and anthropometry (Abst) 740
in haemodialysis patients (Abst) 723
on haemodialysis (Abst) 731

OKT3 360
treatment modulates T ηδ cell receptor expression (Abst) 784
first-dose reactions reduced by pentoxifylline (Abst) 786
treatment of rejection with (Abst) 463
Opportunistic infection 87
Organ donors, diagnosis of cerebral death by transcranial Doppler (Abst) 1062
Osteoblast proliferation, effect of desferrioxamine on (Abst) 763
Osteoblasts in chronic renal failure 902
Osteodystrophy, renal, calcitriol in CRF patients (Abst) 761
Osteomalacia, dialysis, screening test for (Abst) 762
Osteopathy, in CRF, densitometry in diagnosis of (Abst) 1055
Oxalate balance 960
Oxalosis, causing resistance to rHuEpo (Letter) 1163
Oximeter 110
Oxygen saturation 110

P_{50} in uraemic patients on CAPD (Letter) 1071
PAF (*see* Platelet activating factor)
PAN (*see* Polyacrylonitrile)
Pancreatitis (Abst) 460
and acute renal failure (Abst) 701
Panel-reactive antibodies 422
Parathormone (*see* Parathyroid hormone)
Parathyroid ethanol injection, avoiding parathyroidectomy 412
Parathyroid function, calcitonin test in (Abst) 761
Parathyroid glands 412
ethanol injection into 412
Parathyroid hormone 8, 121, 412, 829
c-terminal 412
clearance (Abst) 166
effects of s.c. calcitriol on in CAPD (Abst) 762
immunological derangements in uraemia (Abst) 669
increased in erythropoietin treatment (Abst) 754
influence of on PAF in HD (Abst) 680
suppression of secretion by calcitriol (Abst) 763
Parathyroid hormone and $1,25(OH)_2D3$ in HD (Abst) 678
Parathyroid hormone changes and dialysis membranes in HD (Abst) 753
Parathyroidectomy, subtotal 121
procollagen type I C terminal peptide following (Abst) 756
total (Letter) 271
Pentoxifylline 1
reduces first-dose reactions following OKT3 (Abst) 786
Percutaneous fine-needle ethanol injection 412
Percutaneous transluminal angioplasty (PTA) 256, (Abst) 725
Pericatheteritis, not peritonitis (Abst) 554
Peripheral microcirculatory blood flow (Abst) 461
Peripheral neuropathy 539
Peritoneal clearance 1026
Peritoneal dialysis 50
comparative study of catheter placement techniques (Abst) 1160
fluorophores stimulated in dialysis fluid (Abst) 1160
Peritoneal dialysis bags, 1α-OHD3 adsorption to 1249
Peritoneal dialysis, nightly intermittent, mononuclear cell cytokine production and (Abst) 742
Peritoneal drainage 627
Peritoneal equilibration test (Abst) 554
Peritoneal equilibration test in children, standardization and reference values (Abst) 745
Peritoneal function in long-term CAPD (Abst) 743
Peritoneal rapid overnight dialysis (PROD) (Letter) 652
Peritoneal transport in CAPD (Abst) 169
Peritoneography, computed tomographic 1030, 1035
Peritonitis 57, 627, 967
CAPD, intraperitoneal free elastase in (Abst) 1148
dialysis-related (Abst) 166
recurrent 133
tuberculous 443
Permcath, comparative study 1111
Permeability 844
Permselectivity (Abst) 546
in thin-membrane nephropathy (Abst) 697
Phaeochromocytoma, plasma levels and cardiac release of ANP in (Abst) 680
Pharmacokinetics 848, 931
Phase-contrast microscopy in classification of urinary RBC morphology (Abst) 684
Phosphate 63
binders, calcium-based 632
excretion, regulation by dopamine in the rat (Abst) 657
Physical performance and rHuEpo 1199
Pigeons 967
PKD (*see* Polycystic kidney didease)
Plasma, magnesium 251
proteinase inhibitors in β_2-microglobulin amyloid deposits (Abst) 748
renin activity 216, 221, 306, 400
measurement in renal artery stenosis 400
Plasmapheresis, reducing proteinuria (Abst) 775
treatment of acute vasular rejection with (Abst) 774
Platelet, activating factor, influence of PTH on in HD (Abst) 680
aggregation in HD reduced with NO (Abst) 1153
exhaustion and uraemia (Abst) 705
hyperaggregability, reversal by aspirin (Abst) 461
intracellular calcium and rHuEpo (Abst) 1159
Platelets, cytometric analysis of in ESRD 707
PMN (*see* Polymorphonuclear cells)
Pneumonitis, cryptogenic 1043
interstitial 362
interstitial, azathioprine-related (Letter) 1166

Podocytes 288
Polyacrylonitrile 844
  and cuprophane dialysis, effect on erythrocyte structure (Abst) 730
Polyarteritis, microscopic 1077
Polycystic kidney disease 379, 443, 501, 563, 647
  chronic renal failure and 379
  red cell sodium transport and (Abst) 713
  with chronic renal failure 447
Polycystic kidney disease, inulin infusion technique in (Letter) 1254
  unlinked to PKD-1 locus (Abst) 667
Polycystic kidney lesion in immunodeficient mouse (Abst) 677
Polycystic mouse (Abst) 545
Polymerase chain reaction 865
Polymorphism 200
Polymorphonuclear leukocyte elastase, immunohistochemical localization (Abst) 690
Porphyria cutanea tarda, haemodialysis-related, erythropoietin treatment of 438
  iron balance in 438
Porphyria, acute, hypertension and renal impairment in 986
Porphyrins, urinary 438
Poststreptococcal glomerulonephritis 155
Post-transplant antiglomerular basement membrane disease, COL4A5 gene in (Abst) 784
Post-transplant erythrocytosis 137
  in cadaver kidney recipients (Abst) 779
Post-traumatic acute renal failure 260
Postinfectious HUS/TTP in adults (Abst) 1155
Potassium, intraerythrocytic 318
Potassium depletion 318
PRA (*see* Plasma renin activity)
Prediction of thrombotic complications in SLE (Abst) 696
Prednisone withdrawal, effect on RBC sodium (Letter) 175
Pregnancies, multiple and twin, after renal transplantation (Abst) 1063
Pregnancy 105, (Letter) 273
  albumin and retinol-binding protein excretion in (Abst) 1161
  in membranous glomerulonephritis S1/60
  renal replacement therapy and 279
Procoagulant activity of rat glomerular epithelial cells (Abst) 664
Progressive systemic sclerosis and non-Hodgkin lymphoma (Letter) 1166
Prophylaxis of CMV in transplant recipients 1230
Prostaglandin synthesis in old rats (Abst) 660
Prostaglandins and peritoneal permeability during peritonitis in CAPD (Abst) 747
Protein, 24-h excretion 450
  carboxyl methyl esterification reduced in uraemia (Abst) 665
  creatinine index 450
  excretion, urinary, in young people 487
  load, acute oral, effect on albumin excretion (Abst) 712
Protein S deficiency, erythropoietin-induced (Letter) 979
Protein structural analysis of amyloid fibrils in dialysis amyloidosis (Abst) 750
Proteinuria 87, 93, 379, 450, 597
  due to idiopathic membranous nephropathy S1/109
  heavy, vitamin D homeostasis in (Abst) 763
  in rats, caused by gentamicin (Letter) 653
  nephrotic-range 93
Proteinuria, late, histological analysis (Abst) 1060
Proteoglycans and mesangial cell proliferation (Abst) 666
Proximal tubule 225
PSGN (*see* Post-streptococcal glomerulonephritis)
Psoriasis (Abst) 457
Psoriatic nephropathy, role of metabolic changes in (Abst) 692
Psychometry 240
PTA (*see* Percutaneous transluminal angioplasty)
PTH (*see* Parathyroid hormone)
Pulmonary haemorrhage in systemic vasculitis, α_1-antiproteinase and (Abst) 693
Purpura, Henoch–Schönlein 534
Pyeloureteral stenosis, bilateral 293
Pyridoxine deficiency 960
Pyrogen 333
Pyuria, sterile, in analgesic nephropathy 384

Quality of life 811

Radioimmunoassays, comparison (Letter) 367
Radiological contrast, non-ionic, and nephrotoxicity (Abst) 1064
Ranitidine (Abst) 460
  reducing aluminium toxicity in renal failure (Abst) 555
RAS (*see* Renal artery stenosis)
RBC (*see* Red blood cells)
Recombinant human erythropoietin (*see also* Erythropoietin)
  and platelet intracellular calcium (Abst) 1159
  desferrioxamine and (Abst) 1057
  haemodynamic changes with 1199
  HbH disease and 1052
  in renal failure and HbH disease 1052
  intravenous vs subcutaneous (Abst) 1057
  oxalosis causing resistance (Letter) 1163
  physical performance and 1199
  response and administration (Abst) 1143
Recombinant human growth hormone (Abst) 975
Recurrent peritonitis 133
Red blood cell membrane-bound IgG in CAPD (Abst) 673
Red blood cell sodium, effect of prednisone withdrawal on (Letter) 175
Red cell sodium transport and ADPKD (Abst) 713
Regional citrate anticoagulation (Abst) 168
Registry Reports 279, 573, 579, 1171
Rehabilitation 573, 579
Reinfection 133
Rejection 350, 865
  acute 147, 530, 871
    antidonor-specific antibodies and (Abst) 785
    plasmapheresis and (Abst) 774
  chronic
    TNF synthesis during (Abst) 783
  circulating TNF receptor and (Abst) 780
  graft 143
  raised tumour necrosis factor in (Letter) 559
  renal allograft, cytokine gene expression in (Abst) 786
  renal vascular, comparison of ALG with OKT3 (Abst) 785
  serum neutral endopeptidase activity in (Abst) 786
Relapse 133
Renal allograft 267, 360
  rejection, treatment with OKT3 (Abst) 463
  rupture 871
Renal artery, aneurysm after percutaneous renal biopsy (Letter) 883
  embolization, renal recovery after 1047
  obstruction 211
  stenosis
    and diabetic renal disease (Abst) 684
    detection by angiography (Abst) 552
    detection by magnetic resonance angiography (Abst) 552
    diagnosis 400
    erythropoietin measurements in 400
    reduced serum erythropoietin after ACE inhibition (Abst) 767
    transplant 256
Renal biopsy 265
  database 472
  district general hospital survey (Abst) 1156
  findings in diabetes mellitus 397
  histological methods and criteria 397
  in elderly adults (Abst) 690
Renal carcinoma 265
Renal cyst formation (Abst) 545
Renal disease 563
  atheromatous, after reconstructive surgery (Abst) 711
  changing epidemiology in France (Abst) 698
  increased risk in diabetes mellitus type II (Abst) 697
  unilateral, erythropoietin concentrations in 1190

Renal dynamics of the hydrogen ion (Abst) 1064
Renal failure 8, 87, 121, 618, 817
  acute 406, 848, 879
    and endotoxaemia (Abst) 1157
    and pancreatitis (Abst) 701
    cytokines and immunoglobulins in septicaemia (Abst) 700
    in intensive care units (Abst) 699
    incidence and outcome (Abst) 701
    ischaemic, in ageing rats (Abst) 701
  chronic 623, 822, 956, 1098, (Letter) 368, (Abst) 971
    $1,25(OH)_2D3$ receptors in (Abst) 761
    ACE inhibition as antihypertensive therapy in (Abst) 1152
    adynamic bone disease in (Abst) 755
    age and thyroid abnormalities in dialysis patients (Abst) 708
    and low-protein diet, work capacity changes (Abst) 1158
    antihypertensive therapy in (Abst) 717
    blood pressure and (Abst) 710, 712
    bone reporption in (Abst) 760
    calcitriol for the treatment of renal osteodystrophy (Abst) 761
    calcium–PTH set point in (Abst) 754
    carcinoma and Waldenström's macroglobulinaemia (Letter) 1165
    cardiovascular disease in (Abst) 705
    cataract in (Letter) 1162
    comparative cardiovascular mortality (Abst) 1156
    compliance with low-protein diets (Abst) 707
    correction of metabolic acidosis (Abst) 1149
    correction of metabolic acidosis in (Abst) 1143
    diagnosis of *Helicobacter pylori* in (Abst) 709
    dietary phosphorus restriction and (Abst) 756
    dietary proteins and (Abst) 705
    ECG findings with erythropoietin (Abst) 771
    effect of parathyroidectomy (Abst) 756
    fetal antigen 2 and 902
    gestation in (Abst) 1063
    humoral immunity in (Abst) 1063
    in Asians (Abst) 553
    in rats, effects of exercise (Abst) 710
    intestinal Ca transport in rats (Abst) 761
    left ventricular function changes on IPD (Abst) 747
    neutral endopeptidase inhibition in (Abst) 1153
    plasma thrombocytopoietin in HD patients treated with erythropoietin (Abst) 774
    plasma TNF soluble receptors in (Abst) 705
    quality of life in (Abst) 707
    renal tubular protein degradation and urinary ammonia in (Abst) 1153
    volume overload (Abst) 549
    [^{31}P]NMR study in (Abst) 706
  end-stage, coronary artery disease in diabetics with (Abst) 707
    cytometric analysis of platelets in (Abst) 707
    dialysis in the elderly (Abst) 708
  experimental, lipid peroxidation in the rat (Abst) 708
  in children, low-protein diet and (Abst) 713
  progression 501
    in transgenic rats (Abst) 713
  progressive, from new X-linked hypophosphataemic rickets (Abst) 757
  ranitidine reducing aluminium toxicity in (Abst) 555, 757
  renal biopsy findings in the elderly (Abst) 689
  with sickle-cell disease, erythropoietin in (Abst) 765
Renal function 384, 1085
  deterioration after psoriasis treatment (Abst) 457
  light-chain deposition disease and (Abst) 694
  tests in analgesic nephropathy 384
  tests in glomerulonephritis 384
Renal functional reserve in renal transplant patients (Abst) 779
Renal graft biopsy 1116
Renal graft rupture, treatment by high steroid dosage (Abst) 779
Renal grafting, cardiovascular morbidity and mortality after (Abst) 774
Renal grafts, hepatitis C virus and 274
Renal growth, compensatory 1185
Renal haemodynamics 69, 216, 991
  dietary proteins, and CRF 705
  effects of protein (Abst) 712
Renal impairment, acute porphyria and 986
Renal insufficiency, erythropoietin stimulation in 1002
  reversible 406
Renal ischaemia, effect on endothelins (Abst) 1154
  injury, effects of L-arginine (Abst) 700
Renal non-modulation in Italian hypertensives (Abst) 716
Renal osteodystrophy (Letter) 369
Renal pathology, non-diabetic, in diabetes mellitus (Letter) 1258
Renal patients, recombinant human growth hormone for (Abst) 975
Renal plasma flow, and glomerular filtration rate (Abst) 710
Renal replacement therapy 479, 613
  anticardiolipin antibodies and (Abst) 709
  early deaths on 467
  early nephrological referral in 467
  for ESRF in infants 1171
  lupus anticoagulant and (Abst) 709
  mortality 467
  peripheral arterial disease and (Abst) 709
  pregnancy and 279
  rehabilitation of young adults 573–586 573
Renal reserve capacity 501
Renal tissue kallikrein 516
Renal transplantation 69, 346, 362
  and analgesic nephropathy 427
  and erythrocytosis (Abst) 1061
  late complications (Abst) 1061
  natural history (Abst) 1062
Renal tubular acidosis, type I (Letter) 365
Renal ultrasound 613
Renal vascular response in the rat 602
Renal vein thrombosis S1/105
Renin 216, 400
Renin activity, hyperfiltration, and organ damage, association in hypertension (Abst) 715
Renin–angiotensin system 400
  in kidney disease (Abst) 667
Renin–angiotensin–aldosterone axis 125
Renography 211
Renotropic activity in uninephrectomized rats 608
Renovascular disease 211
Renovascular hypertension 221
Restriction fragment length polymorphism 587
Retinoic acid, inhibiting mesangial cell division (Abst) 660
Reye's syndrome, after renal graft 158
Rhabdomyolysis and acute theophylline overdose (Letter) 883
Rheumatoid arthritis 161
rHuEpo (*see* Erythropoietin *and* Recombinant human erythropoietin)
RPF (*see* Renal plasma flow)
RRT (*see* Renal replacement therapy)

S3 segment 225
Salivary function, impaired, in dialysis (Abst) 735
Sarcoid-like granulomata in a renal transplant (Letter) 173
Schistosomiasis after kidney transplantation 858
Schooling 579
Scintigraphy, dynamic, with diphosphonate, in dialysis patients (Abst) 753
  for febrile syndrome in haemodialysis patients with non-functioning graft (Abst) 781
  renal 1085
Screening 211
Secondary hyperparathyroidism (Letter) 1070
Sensitization 422
Septicaemia, ARF, cytokines and immunoglobulins (Abst) 700

Serotonin, involved in effect of erythropoietin in uraeemia (Abst) 770
Serum aluminium in dialysis patients, retrospective study (Abst) 684
SHR (*see* Spontaneously hypertensive rats)
Sialidase, soluble, initial characterization (Abst) 666
Sicca syndrome, interstitial nephritis in (Abst) 702
Sickle-cell anaemia, homozygous, erythropoietin in 817
Sieving coefficients 844
Simvastatin, pharmacokinetics in kidney transplant recipients (Abst) 775
Single-photon emission computed tomography 1085
SLE (*see* Systemic lupus erythematosus)
Small bowel 79
Sodium 69
  conservation, impaired, in old rats (Abst) 660
  depletion 100
  excretion 493
  handling, angiotensin II and 991
Sodium–lithium countertransport (Abst) 548
  in hypertension and diabetic nephropathy (Abst) 549
Solute clearance 29
Solute transport (Abst) 554
Specificity of antimyeloperoxidase autoantibodies in vasculitis (Abst) 678
SPECT (*see* Single-photon emission computed tomography)
Spontaneously hypertensive rats 516
  11β-hydroxysteroid dehydrogenase in (Abst) 716
Spot urine samples 450
Staphylococcus aureus 627
  exit-site infections in CAPD, elimination of (Abst) 1149
  peritoneal, during CAPD (Abst) 554
Staphylococcus epidermidis, peritoneal, during CAPD (Abst) 554
  preventive vaccination against in CAPD (Abst) 742
Stenosis, bilateral pyeloureteral 293
  renal artery 1178
    detection by angiography (Abst) 552
    detection by magnetic resonance angiography (Abst) 552
    diagnosis 400
    erythropoietin measurements in 400
    transplant 256
  subclavian vein, recurrent (Letter) 270
Sterile pyuria, in analgesic nephropathy 384
Subacute bacterial endocarditis, Wegener granuloma-like lesion in (Abst) 693
Sudden death and ventricular late potentials 1013
Superoxide dismutase (Letter) 368
Survival 908
Survival in membranous nephropathy, statistical aspects S1/53
Syndrome, Alport's 1082
  Bartter's 896
  nephrotic 391
  Pseudo-Bartter's 896
  Takatsuki 373
Systemic lupus erythematosus 391, (Abst) 549
  and HUS (Abst) 1065
  anticardiolipin antibodies in 1256
  prediction of thrombotic compilications in (Abst) 696
  T cells and cyclophosphamide (Abst) 679
  transplant biopsy study 1116
  treatment of membranous nephropathy in S1/97
  with severe nephropathy, CsA in (Abst) 686

T αβ cells (Letter) 558
T ηδ cell receptor expression after OKT3 treatment (Abst) 784
T ηδ cells in human glomerulonephritis (Letter) 558
T ηδ lymphocytes, in renal transplant patients 530
T lymphocytes 530
Tachyarrhythmias in HD 1013
Takayasu's arteritis, renal amyloidosis complicating 1133
Tamm–Horsfall protein and activation of human neutrophils (Abst) 1148
TAT-III (*see* Thrombin–antithrombin III)
Technetium ^{99}m 205, 211
Tenckhoff catheter 79
Testosterone 137
Tetanus vaccination, response in haemodialysis 323
Theophylline overdose, rhabdomyolysis and (Letter) 883
Thin-membrane nephropathy (Abst) 546
Three-sample method an artefact in HD recirculation detection (Abst) 1159
Thrombin–antithrombin III complex 235
  during erythropoietin therapy (Letter) 1072
Thrombosis, renal vein S1/105
  vena cava (Letter) 979
Thrombotic thrombocytopenic purpura (Abst) 458
Thromboxane receptor antagonist (ICI 192,605) (Abst) 550
Thymoma 357
TMN (*see* Thin-membrane nephropathy)
TNF (*see* Tumour necrosis factor)
Toxicity, aluminium (Abst) 972
  reduced by ranitidine 1246
Toxicology 875
Toxins, uraemic 539
Transaminases in HD, aetiology (Abst) 1059
Transforming growth factor beta (Abst) 457
Transfusion 422
Transitional cell carcinoma 1136
Transplant recipients, hepatitis C in 1226
Transplantation 573, 579
  and analgesic nephropathy 427
  heart, in the rat 1130
  kidney (*see* Transplantation, renal)
  liver, glomerular abnormalities after (Abst) 687
  organ, detection of CMV after (Abst) 777
  postrenal 137
  renal 69, 251, 346, 350, 362, 450, 530, 613, 636, 865, 908, 944, 1039, (Letter) 651
    Alport syndrome and deletion of COL4A5 gene (Abst) 785
    ambulatory BP and LV mass in (Abst) 1154
    and analgesic nephropathy 427
    anti-B autoimmune haemolysis with group O kidney (Abst) 786
    antidonor-specific antibodies and acute rejection (Abst) 785
    B cell cytotoxic antibodies after (Abst) 783
    biopsy in SLE 1116
    C-peptide values (Abst) 775
    calcium–PTH set point after (Abst) 754
    CMV graft infection (Abst) 782
    CMV in (Abst) 776
    CsA-induced decrease in cellular potassium uptake (Abst) 777
    donor-specific blood transfusions in (Abst) 780
    epiphyseal microfractures after (Abst) 776, 976
    familial Mediterranean fever and (Abst) 782
    for amyloidosis (Abst) 780
    graft rupture, diagnosis by ultrasound 871
    growth hormone in short children after (Abst) 780
    haemodialysis-associated amyloidosis after (Abst) 779
    HCV in (Letter) 1164
    hyperimmune globulin against cytomegalovirus (Abst) 463
    iliac artery dissection after 1242
    in HCV positive patients (Abst) 778
    in-vitro TNFα and IL-6 induced by OKT3 (Abst) 778
    increased risk of malignancy with CsA (Abst) 781
    leukaemia after (Letter) 653
    multiple and twin pregnancies after (Abst) 1063
    multiple myeloma after 447
    pharmacokinetics of simvastatin (Abst) 775
    preferred treatment in diabetic end-stage renal failure 433
    pregnancy and (Letter) 273
    reactivation of EBV in (Abst) 776
    renal functional reserve after (Abst) 779
    risk factors for stone formation after (Abst) 1157
    schistosomiasis after 858

Transplantation (*continued*)
SLE in 1116
soluble CD8 and CD25 antigen after (Abst) 783
verapamil and enalapril in (Abst) 777
vessel wall elasticity (Abst) 775
Transplantation in infants 1171
Transport, convective 50
mass 50
transperitoneal 57
Transthyretin and protein intake in HD patients (Letter) 1069
Trapidil, antiproliferative effect of (Abst) 662
Trauma, hypernatraemia after 260
Trimethylamine-N-oxide, a marker of medullary damage (Abst) 1150
Trypanosomiasis 507
Tuberculous peritonitis 443
Tubular cells, proximal, isolation of pure population in rat (Abst) 667
Tubular necrosis, growth factor expression (Abst) 702
Tubular sodium handling (Abst) 456
Tumour necrosis factor, during chronic renal allograft rejection (Abst) 783
modulating nephrotoxic nephritis (Abst) 1151
not synthesized by human mesangial cells 997
raised (Letter) 559
receptor, circulating, a parameter for renal graft rejection (Abst) 780
soluble receptors in CRF (Abst) 705

Ultrafiltration 29, 306
hormonal changes in congestive heart failure 306
Ultrafiltration, transcapillary, effect on protein clearances in CAPD (Abst) 743
Ultrasonography of Tenckhoff catheter course in CAPD (Abst) 745
Ultrasonography, Doppler, colour, assessment of AV fistula shunt by (Abst) 732
Ultrasound 412
parathyroid ethanol injection and 412
Ultrasound, renal 613
Uninephrectomy 608
Uraemia 40, 246, 300, 412, (Abst) 459
acute and long-term effects of oral calcitriol pulses (Abst) 755
and diabetes (Letter) 654
calcitonin test as index of parathyroid function in (Abst) 761
cardiac alterations reversed with erythropoietin (Abst) 771
chronic, autonomic neural function in 1022
CVVHD vs CVVHF (Abst) 730
desmopressin in (Abst) 704
effect of 1,25 $(OH)_2$ D3 on glucose intolerance in 1207
effect of calcitriol on evoked potentials in HD patients (Abst) 764
effect of erythropoietin on fibrinolysis inhibitors (Abst) 772
effects of s.c. calcitriol on PTH in CAPD (Abst) 762
endothelin and blood pressure in (Letter) 176
haemodynamic effects of calcium (Abst) 764
histomorphometric bone patterns of diabetic patients on dialysis (Abst) 756
immunological derangements and PTH in (Abst) 669
inadequate ventricular hypertrophy in hyperparathyroidism (Abst) 763
inhibition of lymphocyte blast formation by furancarboxylic acid (Abst) 732
iron status with or without erythropoietin (Abst) 766
oxidative capacity of muscle fibres in (Abst) 706
platelet exhaustion and (Abst) 705
predialysis, s.c. erythropoietin in (Abst) 765
protein binding in (Abst) 971
protein carboxyl methyl esterification reduced in (Abst) 665
pulsed oral calcitriol in 829
serotonin and hypertension in (Letter) 980
serotonin involved in effect of erythropoietin in (Abst) 770
Uraemic lymphocytes, impaired myoinositol incorporation (Abst) 669
Uraemic peripheral neuropathy 539
Uraemic plasma, oxidizing component inhibited by ascorbate (Abst) 709
Uraemic pruritus, effect of erythropoietin therapy on (Abst) 767
Uraemic toxins 539
Uraemic–haemolytic syndrome and SLE (Abst) 1065
Urea kinetic model 1007
Urea kinetic modelling (Abst) 462
and high-flux dialysis (Abst) 1161
relationship to clinical parameters (Abst) 742
Urea kinetics, adequacy of HD (Abst) 1142
and direct dialysis quantification 1007
catabolism/anabolism in CAPD and (Abst) 1142
single pool, underdialysis and (Abst) 1142
Ureteric stents, transurethral removal (Abst) 463
Uric acid (Abst) 971
Urinary dysmorphism, microscopic evaluation (Abst) 686
Urinary RBC morphology, diagnostic classification (Abst) 684
Urinary tract infection, faecal loading in children (Abst) 553
Urine magnesium 251
Urolithiasis, cystine, treatment and prevention (Abst) 691
Urolithiasis, experimental, glycosaminoglycans in (Abst) 754
Uveitis, CsA nephrotoxicity and (Abst) 699

Vaccination, tetanus, response in haemodialysis 323
Vancomycin 848
Variability of protein transport (Abst) 171
Varicella, fatal, after renal graft 158
Vascular access, clotting of in HD, associated with anticardiolipin antibodies (Abst) 733
endocavitary ECG and central venous cannulation (Abst) 733
for HD (Abst) 1056
for HD with erythropoietin (Abst) 1056
Vascular access surgery
comparative study 1111
Vascular decongestants 1
Vascular disease (Abst) 462
Vascular hyperplasia in arterial hypertension (Abst) 1066
Vascular reactivity, survey of (Abst) 1067
Vascular stability, effect of buffer and Na dialysate on (Abst) 729
Vascular surgery 1242
Vasculitis (Abst) 547
animal model of (Abst) 546
disease activity and ANCA levels by ELISA (Abst) 685
myeloperoxidase–antimyeloperoxidase interactions in 1077
systemic, α_1-antiproteinase and pulmonary haemorrhage in (Abst) 693
AECA in an animal model (Abst) 675
and ANCA-associated renal disease, treatment and outcome (Abst) 1144
Vasoactive intestinal peptide and ANP, relationship in CRF (Abst) 682
Ventricular late potentials in haemodialysis patients 1013
VIP (*see* Vasoactive intestinal peptide)
Visceral leishmaniasis (Letter) 651
Vitamin D homeostasis in heavy proteinuria (Abst) 763
Von Willebrand factor, in acute cyclosporin nephrotoxicity (Abst) 551

Water loading 991
Wegener granuloma-like renal lesion and ANCA (Abst) 693
Wegener's granulomatosis, ANCA testing in (Abst) 685
time-associated (Letter) 882
Well-being, intradialytic (Abst) 733
Wilms' tumour 563, (Letter) 653
Withdrawal of treatment, cause of death in ARF 230

Zero-calcium peritoneal dialysis (Letter) 652